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 Abstract 
The identification and quantification of protein-protein interactions on large 
scale is critical to understanding biological processes at a systems level. Current 
approaches for the analysis of protein-protein interactions are generally not quantitative 
and largely limited to certain types of interactions such as binary and strong binding 
interactions. They also have high false-positive and false-negative rates. Described here 
is the development of and application of mass spectrometry-based proteomics methods 
to detect and quantify the strength of protein-protein and protein-ligand interactions in 
the context of their interaction networks. Characterization of protein-protein and other 
protein-ligand interactions can directly benefit diseased state analyses and drug 
discovery efforts.  
The methodologies and protocols developed and applied in this work are all 
related to the Stability of Unpurified Proteins from Rates of amide H/D Exchange 
(SUPREX) and Stability of Protein from Rates of Oxidation (SPROX) techniques, which 
have been previously established for the thermodynamic analysis of protein folding 
reactions and protein-ligand binding interactions. The work in this thesis is comprised of 
four parts. Part I involves the development of a histidine low H/D exchange protocol to 
facilitate SURPEX-like measurements on the proteomic scale.  The histidine slow H/D 
 
iv 
 exchange protocol is developed in the context of selected model protein systems and 
used to investigate the thermodynamic properties of proteins in a yeast cell lysate.  
In Part II an isobaric mass tagging strategy is used in combination with SPROX 
(i.e., a so-called iTRAQ-SPROX protocol) to characterize the altered protein interactions 
networks associated with lung cancer. Differential thermodynamic analyses were used 
to characterize the proteins in two different lung cancer cell lines; including ADLC-5M2 
and ADLC-5M2-C2, in which cylcophilin A (a known protein biomarker of lung cancer) 
is overexpressed and knocked down, respectively. This work identified six proteins with 
thermodynamic stability changes in the two cell-lines. 
Parts III and IV of this thesis describe the development and application of a  
SPROX protocol for proteome-wide thermodynamic analyses that involve the use of 
SILAC quantitation (i.e. Stable Isotope Labeling by Amino acid in cell Culture). A 
solution-based SILAC-SPROX protocol is described in Part III and a SILAC-SPROX 
protocol involving the use of cyanogen bromide and a gel-based fractionation step is 
described in Part IV. The SILAC-SPROX-Cyanogen bromide (SILAC-SPROX-CnBr) 
protocol is demonstrated to significantly improve the peptide and protein coverage in 
proteome-wide SPROX experiments.  Both the SILAC-SPROX and SILAC-SPROX-CnBr 
protocols were used to characterize the ATP binding properties of yeast proteins.  
Ultimately, the two protocols enabled 526 yeast proteins to be assayed for binding to 
 
v 
 AMP-PNP, an ATP mimic.  A total of 140 proteins, including 37 known ATP-binding 
proteins, were found to have ATP binding interactions.  
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 1. Introduction  
The goal of this work is to develop a mass spectrometry based proteomics 
platform for the large scale analysis of protein thermodynamic stability in complex 
biological mixtures. Thermodynamic stability of a protein is closely linked to ligand 
binding and thus can be related to its function. For instance, the thermodynamic stability 
a protein can change upon interaction with ligand (e.g., another protein or small 
molecule substrate, inhibitor or co-factor).  Therefore, such thermodynamic 
measurement of protein folding and stability are potentially useful in studying the 
altered protein interaction networks associated with diseases and drug actions.   This 
introductory chapter will focus on summarizing: (i) the basic principles underlying the 
close relationship between thermodynamic stability and protein folding/misfolding, 
mutagenesis and protein-ligand interactions, (ii) the traditional methods for 
measurement of thermodynamic stability, (iii) the conventional methods for 
characterization of protein-ligand interactions, and (iv) the principles of mass 
spectrometry-based thermodynamic stability measurements.  
1.1 Thermodynamic Stability, Protein Folding and Protein-Ligand 
Interactions 
The study of protein folding is important because proper folding is critical for the 
function of the macromolecules. Understanding the folding mechanism of proteins 
allows researchers to replicate that process and simulate the interactions that stabilize 
1 
 the native form of proteins, which directly benefits protein-drug design and discovery. 
The study of protein folding often includes: (i) structural characterization (ii) kinetic 
analyses, (iii) conformational studies, and (iv) thermodynamic analyses. 
Thermodynamics studies of protein folding and stability can involve measurements of 
the difference in free energy, in enthalpy and/or in entropy of the unfolded state with 
respect to folded state of the proteins, elucidating underlying physical forces that 
promote the folding/unfolding processes. In an effort to catalogue a large collection of all 
available thermodynamic stability information of proteins and mutants, Gromiha and 
coworkers have developed a database called “ProTherm” (Thermodynamic Database for 
Proteins and mutants). Protherm collects data including unfolding Gibbs free energy, 
enthalpy, heat capacity change, transition temperature and denaturant concentration, 
from literature and experiments. The database has a total of 14,500 entries and can be 
found at   “http://www.abren.net/protherm/protherm.php”. This database contains very 
valuable information and will facilitate the thermodynamic stability characterization of 
proteins. 
1.1.1 Thermodynamic Stability, Protein Misfolding and Mutagenesis 
Native states of proteins usually correspond to the conformations that are most 
thermodynamically stable under physiological conditions[1]. The thermodynamic 
stability of globular monomeric proteins (60 to 100 residues) often ranges from - 5 to - 15 
kcal/mol. On one hand, the thermodynamic stability of proteins is sensitive to changes in 
2 
 protein sequence by mutagenesis as changing in amino acid composition can alter the 
network of hydrophobic interactions and hydrogen bonds that stabilize the folded state 
of the proteins. Schellman and coworkers have demonstrated that substituting one 
amino acid in the primary sequence of proteins results in changes in thermodynamic 
stability of the mutants compared to the wild type[2]. This site-directed mutagenesis 
approach is useful in discovering parts of the sequence that are crucial for proper 
folding of proteins[2]. Recently, a study by Araya and coworkers using phage display 
approach has identified stabilizing mutations in a large-scale functional analysis[3]. The 
fundamental principle of this study is based on the concept that “Protein function is 
generally reduced by destabilizing mutation but can be rescued by stabilizing 
mutations”. Using this approach Araya and coworkers have identified 15 stabilizing 
mutations among 47,000 mutants of the hYAP65 WW domain, one of which had more 
stabilizing effects than any previously known mutations[3].  
On the other hand, protein misfolding can occur when a nascent chain from 
protein synthesis undergoes folding via partially unfolded states [4]. The abundance of 
these partially unfolded states and their transformation to either properly folded or 
misfolded proteins are determined by their relative thermodynamic and kinetic 
stabilities [4]. This process is tightly regulated in normal cells by various parameters 
including posttranslational modifications, small-molecule and protein-protein 
interactions. Malfunction in any steps of this folding process can lead to misfolding 
3 
 which ultimately lead to a number of degenerative diseases, e.g. Alzheimer, Parkinson, 
Prion diseases, etc. [1, 4-5] Thermodynamic stability measurements are therefore not only 
important to understand the basic mechanism of folding but also to avoid misfolding 
related to mutagenesis and diseases.  
1.1.2 Thermodynamic Stability of Proteins reflects Protein-Ligand 
Binding  
The effect of ligand binding to proteins often includes the following (i) ligand 
binds at 1 site precludes occupancy of neighboring site due to space limitation and 
overwhelming repulsion (ii) ligand binding induces conformational changes or (iii) 
ligand binding drives a reaction to one side or another. Schellman and coworkers have 
concluded that the driving effect of ligand binding on a reaction can be quantitatively 
evaluated in terms of free energy of binding of the ligand to the reactants [2, 6].  
In the simplest case, a protein-ligand binding interaction can be described by the 
following equation. 
(1) P + L  PL 
In Equation (1), P stands for Protein, L is the Ligand and PL is the Protein-Ligand 
complex. Equilibrium constant K of this reaction can be defined as 
(2) 𝐾 = [𝑃𝐿][𝑃][𝐿] 
The energy of binding ΔG can be calculated by equation (3)[2]  
(3) ∆𝐺 = −𝑅𝑇𝑙𝑛(1 + 𝐾[𝐿]) 
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 In equation (3), R is the gas constant (i.e. 1.986 x 10-3 kcal K-1 mol-1)), T is 
temperature in K and [L] is free ligand concentration (M). For a ligand that has multiple 
binding sites on the protein (n), the binding interactions can be described as below. 
(4) P + L  PL 
P + 2L  PL2 
… 
P + nL  PLn 
The binding polynomial therefore can be defined using equation (5) 
(5) ∑ ≡ 1 + 𝐾1[𝐿] + 𝐾2[𝐿]2 + ⋯+ 𝐾𝑛[𝐿]𝑛 
In equation (5) K1… Kn are the equilibrium constant of the binding reaction (4). 
The binding free energy for cases of multiple ligand binding sites is therefore 
(6) ∆𝐺 = −𝑅𝑇𝑙𝑛∑  
Using this stoichiometry model of binding, Schellman suggests that it is possible 
to measure free energy changes induced by perturbation (i.e. mutagenesis or ligand 
binding) by studying the transition between the folded and unfolded state in the 
presence and absence of the perturbing reagents (i.e. mutations or the ligand)[2]. It is also 
possible to measure this binding (perturbing) energy as a function of thermal 
denaturation. The principle of this approach is that the equilibrium between the folded 
and unfolded forms of a protein (induced by thermal denaturation) is related to the 
change in free energy of binding, the free energy of binding in turns is a simple function 
of the equilibrium constant (or the Kd). The ligand typically preferentially binds to the 
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 folded form of the proteins, hence drives the equilibrium favoring the folded states and 
therefore increasing the thermodynamic stability of proteins.  
Recently Sanchez-Ruiz has proposed a model using the partition function 
approach to predict and explain the change in thermal denaturation midpoint Tm upon 
ligand binding[7]. This study suggests if a ligand binds to the native state of a two-state 
folding protein, the thermal denaturation midpoint Tm will increase as increasing ligand 
concentration, i.e. the protein’s thermodynamic stability will increase. The ligand can 
only decrease thermodynamic stability of proteins when it binds to both native and 
unfolded states, in which case the thermal denaturation midpoint will decrease as 
increasing ligand concentrations. Waldron and Murphy also reported this trend of 
increasing Tm upon protein-ligand interactions with more complex binding models and 
have proposed a way to utilize thermal denaturation as an assay for drug screening[8].  
1.2 Traditional Methods for Thermodynamic Stability 
Measurement 
A typical protein refolds spontaneously with a rate constant of approximately 1s-
1 and unfolds under the same condition at much lower rate (10-5 s-1), which means at 
normal aqueous condition protein mainly exists in the folded states. It is harder to 
sample and measure the equilibrium between the folded and unfolded state when the 
unfolded proteins are not populated. This suggests the use of denaturant (i.e. lowering 
pH,  increasing temperature, chemical denaturant concentration, or pressure, etc.) to 
facilitate the unfolding process so as to measure the equilibrium between folded and 
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 unfolded state and ultimately to estimate the folding free energy. Any methods that can 
distinguish between the folded and unfolded states of proteins can be used to measure 
the folding equilibrium and ultimately to estimate the folding free energy of proteins. 
Summarized below are several spectroscopic and calorimetric approaches that are 
frequently used for measurement of protein thermodynamic stability.   
1.2.1 Fluorescence Spectroscopy 
Aromatic residues such as Tryptophan or Tyrosine have intrinsic fluorescence 
properties and have been exploited for monitoring the folding/unfolding equilibrium of 
proteins. The fluorescence properties of Tryptophan and Tyrosine are sensitive to 
changes in their surrounding environment occurred during the folding/unfolding 
process. For instance, these residues are usually buried in the hydrophobic core of 
proteins in which they will yield high fluorescence intensities. As the proteins unfold, 
these residues become exposed to solvent and their fluorescence intensities will 
decrease. By applying an excitation beam with wavelength of 280 nm (for both 
Tryptophan and Tyrosine) or 295 nm (for Tryptophan only) onto protein solutions at 
different conditions (i.e. different pH, temperature or chemical denaturant 
concentrations), one can measure the change in fluorescence intensities induced by 
folding/unfolding. Furthermore, the maximum emission wavelength of Tryptophan also 
changes upon changing in its surrounding chemical environment and can also be used 
to monitor protein folding/unfolding. Intrinsic fluorescence probes have been used 
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 extensively to measure thermodynamic stability of proteins but they possess several 
drawbacks. First of all, not all proteins have buried Tyrosine or Tryptophan in their 
sequences. In order to monitor the folding/unfolding of specific domains in the proteins, 
Tyrosine and Tryptophan are typically introduced to the sequence by mutagenesis. As 
described in previous section, mutagenesis can perturb protein thermodynamic stability; 
therefore the observed thermodynamic stability in this case may not represent the native 
state of the proteins. Second of all, this approach often requires large amount of purified 
proteins (typically 300 µg) which can be difficult to obtain from endogenous and clinical 
protein samples.  For these reasons the use of fluorescence spectroscopy is not suited for 
large-scale characterization of protein thermodynamic stabilities in complex mixtures. 
1.2.2 Circular Dichroism Spectroscopy 
Circular Dichroism Spectroscopy (CD) has been used extensively to study 
protein folding/unfolding as it has many advantages such as: (i) it provides secondary 
structural information, (ii) the measurement is performed in solution, and (iii) it has the 
capability to perform time-resolved measurement with millisecond resolution[9]. In the 
“far UV” CD experiment (λ ~180-260 nm), the signal represents the asymmetric 
backbone carbon atoms on either side of the amide bond, therefore reports on secondary 
structure of proteins. In the “near UV” CD experiment (λ ~ 250-350 nm), the CD signals 
come from disulfide bonds and aromatic residues such as Phenylalanine (250-270 nm), 
Tyrosine (270-290) and Tryptophan (280-300 nm). For studies of protein 
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 folding/unfolding, the samples are typically mixed with chemical denaturant and CD 
signals are monitored as a function of the denaturant concentrations. The disadvantages 
of this technique also include the requirement of large amount of purified protein 
samples (typically from 1 to 10 mg/mL protein concentration) in volumes appropriate to 
the sample holders (i.e., cuvettes) being used. 
1.2.3 Differential Scanning Calorimetry (DSC) 
In the thermal denaturation of proteins, proteins are unfolded by increasing the 
temperature. Thermal denaturation is often coupled with Differential Scanning 
Calorimetry (DSC) for measurement of protein thermodynamic stabilities [10]. This 
method measures the change in heat capacity (Cp) of proteins from the folded (low 
temperature) to unfolded (high temperature) states. This method has the ability to 
directly measure changes in enthalpy of unfolding and melting temperature of thermal 
denaturation. It can also be applied to measurement of protein thermodynamic stability 
at different pH and in presence of different mutations [11]. This approach also has the 
disadvantage of requiring large amount of purified protein samples (typically 500 µL of 
0.1 to 2 mg/mL).   
1.3 Protein-protein and Protein-Ligand Interactions 
The ability to interact and function in networks enables proteins to carry out 
various biological processes from enzyme regulation, biopolymer assembly, to 
biosynthesis pathways and signal transduction [12]. These networks of interactions 
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 include protein-protein, protein-nucleic acid and protein-small molecule (i.e. protein-
ligand) interactions. Identifying and characterizing components of these networks and 
quantifying their interactions will give a comprehensive understanding of biological 
system performance and malfunction such as in diseased conditions; and it will provide 
diagnostic and therapeutic targets for drug discovery efforts.  
1.3.1 Analyses of Protein-Protein Interactions 
Large scale analyses of protein-protein interactions is currently conducted using 
the yeast-two-hybrid assay, protein microarrays and tandem-affinity purification 
techniques coupled with mass spectrometry [12-13]. The yeast-two-hybrid assay (Y2H) [13] 
has good sensitivity but a major disadvantage is it can only detect binary interactions [14]. 
Protein micro arrays [14] and tandem-affinity purification-mass spectrometry (TAP-MS) 
[15] are also attractive strategies but are generally not quantitative and not able to detect 
binding events that result in dissociation of protein complexes. Moreover, most of these 
approaches usually have high false positive and false negative rates [16]. Hence, there 
remains an urgent need to develop alternative high throughput approaches for the 
identification and quantitation of protein-protein interactions in complex biological 
systems.  
1.3.2 Analyses of Protein - Small Molecule Interactions 
The characterization of protein-ligand interactions is crucial for understanding of 
biochemical processes and drug mode-of-action. In general the methods for Analyses 
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 Protein-Ligand interaction can be divided into 2 categories: One small molecule-multiple 
proteins and one protein-multiple small molecules strategies. A recent review by 
McFedries and Schwaid has discussed these strategies for characterization of protein-
small molecule interactions in detail [17]. The purpose of this section is to briefly mention 
these strategies and the advantages as well as disadvantages of the current approaches. 
1.3.2.1 One Small Molecule – Multiple Protein Strategy 
1.3.2.1.1 Small molecule Affinity Methods 
Affinity based methods are the most common approach used to identify protein-
small molecule interactions. Main principle of this approach relies on immobilization of 
the small molecules on a solid phase (e.g. magnetic or biotinylated beads, etc.) and 
affinity capturing of the proteins to the beads via interactions with the conjugated small 
molecules. Ong and coworkers have reported a small molecule affinity chromatography 
coupled with SILAC-based quantitative bottom-up proteomics approach to identify 
protein targets of a number of compounds[18]. In this approach, the cells are grown in 
“SILAC media” containing heavy Lysine and/or Arginine (13C6-Arginine and 13C6,15N2 
Lysine) resulting in 2 almost identical cell lines [18-19]. The only difference is that the 
proteins from SILAC labeled cell line are “heavier” than proteins from the normal cell 
lines; therefore they appear on different regions in the mass spectra and can be easily 
distinguished from their lighter counterparts. Relative abundance of the light and heavy 
species is determined by relative ratio between the light and heavy ion intensities. The 
proteins from one of the lysates (for instance the “light” one) are incubated with a 
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 soluble form of the ligands before both lysates are subject to purification by the small-
molecule coated beads. The theory is that if a protein binds to the ligand specifically, the 
excess amount of soluble ligand will out-compete the binding of the immobilized ligand 
to the proteins. Other non-interacting molecules will be washed away, non-specific 
binding proteins will bind indistinguishably between the two samples and the proteins 
with significant change in abundance in the presence and absence of excess soluble 
ligands will be identified as potential targets. The disadvantages of this strategy include 
that it requires immobilization of the ligand onto a solid support and that it is insensitive 
to indirect binding interactions. Conjugating the ligand to a solid surface may also 
perturb its native binding properties; this type of studies may not be applicable to many 
ligand classes and binding modes.  
1.3.2.1.2 Energetics-based Proteomic Analyses 
More recently, several energetics-based approaches have been developed that 
utilize the difference in thermodynamic stability between the ligand bound and un-
bound state to detect direct and indirect protein targets of small molecules. The Drug 
Affinity Responsive Target Stability (DARTS) is one such approach[20]. DARTS is based 
on the assumption that ligand-bound and folded forms of proteins are less susceptible to 
proteolysis than the un-bound forms. A side by side comparison of proteolysis 
susceptibility of the protein mixtures in the presence and absence of the ligand of 
interest will reveal proteins that have differential thermodynamic stability upon binding 
to the ligands. The results are visualized on gel electrophoresis. Retained on the gels are 
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 bands of folded and native proteins, protein bands that have differential intensities are 
identified as potential binding hits.  
A similar strategy to DARTS is the Pulse Proteolysis Energetics-based approach 
[21]. Unlike DARTS, pulse proteolysis does not rely on proteolytic susceptibility 
difference of ligand-bound and un-bound proteins; rather it is analogous to more 
conventional chemical denaturant-induced equilibrium unfolding studies of proteins.  
The proteolysis step is used to distinguish between the folded and unfolded state.  In 
pulse proteolysis, 2 aliquots of protein mixtures are equilibrated with a 3 M Urea 
solution, one of which was treated with ligand and the other was not. This Urea 
concentration is near or about the denaturant midpoint Cm of majority of proteins in the 
mixture. A short pulse of proteolysis by thermolysin was performed on both samples in 
such a way that proteolysis of folded proteins is minimal whereas most unfolded 
proteins are cleaved into small fragments. The remained proteins from both samples are 
also visualized and compared on gel electrophoresis. Folded protein bands that have 
differential intensities in the presence and absence of the ligand of interest will be 
identified as potential binding hits.  
Both of the energetics-based approaches have several advantages including: (i) 
they are general with respect to protein and ligand classes; (ii) they are general with 
respect to modes of binding; (iii) they do not require derivatization of the ligands; and 
(iv) they can be performed on proteomics scale in a targeted manner. However they do 
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 have several disadvantages including: (i) they relies on the ability of thermolysin to 
cleave the protein substrate whereas this enzyme is only active in high concentrations of 
Urea but not GdmCl (e.g., the enzyme is quickly inactivated in as low as 1.4 M GdmCl) 
[22]; (ii) in DARTS, proteins that are resistant to thermolysin cleavage cannot be assayed; 
(iii) in pulse proteolysis on the other hand proteins that are cleaved by thermolysin even 
at native condition (i.e. without Urea) are also not assayed; and (iv) both of the DARTS 
and pulse-proteolysis approaches rely on the resolving power and sensitivity of gel 
electrophoresis, which are relatively poor compared to that in LC-MS analyses. 
Therefore if a protein is not expressed in enough amounts so as to be visualized and 
successfully isolated in a spot on the gel, it cannot be assayed. 
1.3.2.1.3 Chemoproteomic Target Identification 
Another class of emerging techniques for measuring protein-ligand interaction is 
the use of chemo-reactive small molecules that can covalently attach to the active site of 
a class of enzymes via a bio-orthogonal chemical reaction [23]. Beside the active site 
reactive group, the ligand also has another reactive group that can be conjugated to an 
affinity chromatography apparatus using click chemistry. These special probes allow 
labeling of several classes of enzyme in vivo and analyses preceding cell lysis using 
proteomics approaches [17]. This technique is powerful however it is quite limited to the 
ability to synthesize such special chemical probe/substrate and not general to the protein 
classes and modes of binding studied.   
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 1.3.2.2 One Protein – Multiple Small Molecule Strategy 
There are multiple approaches for analyzing the binding of a target protein to 
multiple small molecules. One involves immobilization of the target protein onto a solid 
phase and then affinity capture of  binding ligands from a pooled mixture of small 
molecules[24]. This approach relies on the assumption that the binding properties of 
proteins are not affected by immobilization, and requires the small molecule of interest 
to have special properties such as radioactivity. The other involved measuring thermal 
stability of proteins in the presence and absence of a pool of small molecule ligands[25]. 
However these approaches cannot be applied to large scale analyses of one molecule – 
multiple proteins.  
1.4 Mass spectrometry based Proteomic Platform for 
Thermodynamic Analyses of Protein-Ligand Interactions 
1.4.1 Motivation 
As described above, the thermodynamic stability of proteins is an important 
property that is closely related to protein function.  Changes in thermodynamic stability 
of proteins can indicate mutations, misfolding and/or changes in protein-protein and 
protein-ligand interactions. The study of protein-protein and protein-ligand interactions 
is not only important for characterization of diseased states but also directly benefits the 
protein design and drug discovery effort. Large scale measurement of thermodynamic 
stability of multiple proteins is a powerful technique to evaluate protein-protein and 
protein-ligand interactions in biological samples. Traditional approaches for 
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 measurement of thermodynamic stability of proteins (i.e. fluorescence spectroscopy, CD 
spectroscopy and differential scanning calorimetry) are not suitable to large scale 
measurement of unpurified proteins. Current approaches for characterization of protein-
small molecules interactions have made some significant progresses but are still limited 
to certain classes of proteins, ligands and modes of binding and are not quantitative. 
Energetics-based approaches (i.e. thermodynamic stability based) are powerful tools for 
the identification and quantification of protein-ligand interactions because: (i) they can 
analyze large numbers of proteins for ligand binding, (ii) they do not require the time 
consuming purification process of proteins, (iii) they do not require immobilization of 
proteins or ligands, (iv) they are general with respect to assayed protein, ligand classes 
and modes of binding and, (v) they are in theory quantitative.  
The research in this dissertation is focused on the development of a proteomic 
platform for thermodynamic analysis of protein interaction networks. The 
methodologies developed in this dissertation represent a new energetics-based approach 
for the large scale analyses of protein-ligand interactions. Unlike other approaches (e.g., 
DARTS and Pulse Proteolysis), which are plagued by the low resolution and low 
sensitivity of gel electrophoresis, the new approaches described here exploit the high 
sensitivity and resolution of modern mass spectrometer systems that are commonly 
used in and quantitative bottom-up proteomic experiments. 
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 Mass spectrometry-based proteomic analyses are widely used for the 
identification of proteins in biological mixtures because of the high sensitivity and high 
throughput capabilities [26]. The development of stable isotopic labeling strategies has 
also created a fast growing field of quantitative proteomics [19, 27]. However, most mass 
spectrometry-based proteomic studies conducted to date, have centered on analyzing 
changes in protein expression levels in different biological systems [27a]. The work in this 
thesis is focused on measuring the changes in thermodynamic stability of proteins in the 
context of their interaction networks. Such measurement performed on the proteins 
expressed in normal and diseased states is expected to add a new dimension to 
understanding of disease states, disease diagnosis and drug mode-of-action.  This 
measurement will also complement the protein expression level studies that are often 
used to characterize disease states and drug mode-of-actions.  
1.4.2 Stability of Proteins from Rates of H/D Exchange – SUPREX 
SUPREX is a relatively high-throughput method for making thermodynamic 
stability measurements on proteins. The SUPREX method uses chemical induced 
folding/unfolding equilibrium of proteins in combination with amide H/D exchange and 
Matrix Assisted Laser Desorption/Ionization Mass spectrometry [28]. SUPREX 
experiments are analogous to those performed using Fluorescence or CD spectroscopy 
to study the chemical denaturation of proteins (see above).  In SUPREX, a native and 
properly folded protein solution is equilibrated in a series of denaturant and D2O 
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 containing buffers with increasing denaturant concentrations. The chemical denaturant 
can be either Urea or GdmCl. The chemical denaturant induces unfolding of proteins, 
resulting in exposure of globally protected amide protons to solvent. Once exposed, the 
amide protons can exchange with deuterons in the buffers. A general scheme for this 
folding/unfolding and H/D exchange reaction is as followed. 
 
Scheme 1: H/D exchange reaction (adapted from reference [29]) NHcl represents 
amide protons in the folded state of the protein (i.e. exchange incompetent); NHop 
represents amide protons in the unfolded state of the protein (i.e. exchange 
competent); NDop and NDcl represents deuterated form of the protein in unfolded and 
folded state, repsectively. kop represents the rate of unfolding of the protein, kcl 
represent the rate of folding of the protein and kint represents the intrinsic rate of the 
H/D exchange reaction. 
Under EX2 exchange condition, the rate of the closing reaction kcl is much faster 
than the rate of the H/D reaction kint (i.e. kcl >> kint), therefore the observed rate of H/D 
exchange kex is dependent upon the folding equilibrium between the folded and 
unfolded state by the following equation [28]. 
(7) 𝑘𝑒𝑥 = 𝑘𝑖𝑛𝑡1+𝐾𝑓𝑜𝑙𝑑 
In the chemical induced unfolding equilibrium of proteins, the equilibrium Kfold is 
related to folding free energy and denaturant concentration by the following equation 
[30]. 
(8) 𝐾𝑓𝑜𝑙𝑑 = 𝑒−(∆𝐺𝑓𝑜𝑙𝑑+𝑚[𝐷𝑒𝑛])/𝑅𝑇 
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 In equation (8), m represents the rate of change in folding free energy as 
changing denaturant concentration; R is the gas constant, T is temperature in K and 
[Den] is the denaturant concentration. Chemical induced unfolding results in increasing 
deuteration (i.e. increasing mass of the protein) that can be monitored by mass 
spectrometry as a function of denaturant concentration. The relationship between the 
mass gain (ΔMass) and denaturant concentration can be depicted as followed [28]. 
(9) ∆𝑀𝑎𝑠𝑠 =  ∆𝑀∞ + (∆𝑀𝑜 − ∆𝑀∞)𝑒−[ 𝑘𝑖𝑛𝑡𝑡1+𝐾𝑓𝑜𝑙𝑑] 
In equation (9), ΔMo is the ΔMass before the “global exchange”; ΔM∞ is the 
ΔMass after complete exchange. The dependence of the mass gain ΔMass on denaturant 
concentration of most two-state folding proteins is typically a sigmoidal curve with the 
pre-transition, transition and a post-transition region. The midpoint of this curve is 
indicative of thermodynamic stability of proteins. The midpoint of this curve, the C1/2 
value, is related to typical denaturation midpoint Cm by the following equation [28]. 
(10) 𝐶1/2 = 𝐶𝑚 − (𝑅𝑇/𝑚)ln (𝑘𝑖𝑛𝑡𝑡0.693 − 1) 
In equation (10), t is the exchange time. The shift in C1/2 values is related to 
change in folding free energy (e.g. between ligand-bound and apo-form of proteins) by 
the following equation[31]. 
(11) ∆∆𝐺𝑓𝑜𝑙𝑑 = −𝑚𝛥𝐶1/2 
Change in folding energy can thus be used to estimate the ligand binding affinity 
Kd by the following equation. 
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 (12) 𝐾𝑑 = [𝐿]
𝑒
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𝑛𝑅𝑇 �−1
 
In equation (12), n represents the number of binding sites. As these equations 
suggest, the measurable ΔGfold, ΔΔGfold, C1/2 and Kd in the SUPREX experiment can be 
tuned by using: (i) different H/D exchange time, (ii) different temperature (or pH), or 
(iii) different free ligand concentrations [L]. This allows SUPREX to measure a wide 
variety of proteins’ thermodynamic stabilities and ligand binding affinities [28]. 
SUPREX has many of the advantages of the energetics-based approaches 
described above including the ability to analyze unpurified proteins in complex 
biological samples. This is not only convenient because it eliminates the need to perform 
the protein purification step but also functionally important because native protein-
protein and protein-ligand complex may be abolished following purification. SUPREX is 
also fast and amenable to high throughput screening of large number of ligands to a 
protein of interest (i.e. the one protein-multiple small molecule strategy). Recently, this 
protocol has been employed to screen two libraries including 1280 and 9600 compounds 
for binding to Cyclophilin A (i.e. a lung cancer biomarker) [32] at a rate of 6 s/ ligand [33].  
Unfortunately, SUPREX is not amenable to the study of one ligand binding to 
multiple proteins. SUPREX requires the acquisition of protein signal in the MALDi mass 
spectrometry platform, which can be suppressed by the complexity of biological protein 
mixtures such as cell lysates. SUPREX also relies on H/D exchange reaction of amide 
protons that can be attenuated by back-exchange and thus is not amenable to large-scale 
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 bottom-up proteomics, which involves prolonged protease digestion and LC MS/MS 
Analyses.    
    
1.4.3 Stability of Proteins from Rates of Oxidation –SPROX  
SPROX is fundamentally related to SUPREX [34]. The main difference between 
SPROX and SUPREX is the use of selective oxidation of methionine residues instead of 
H/D exchange of amide protons. SPROX inherits most of the advantages possessed by 
SUPREX. It also eliminates some of the disadvantages in SUPREX experiments. That is, 
due to the stable nature of the oxidized products, SPROX generated samples can be 
subject to various types of mass spectrometry analyses. For instance, SPROX generated 
protein samples can be analyzed using the top-down proteomics approach to measure 
the change in global oxidation uptake of the protein at different denaturant 
concentrations in various conditions. SPROX generated protein samples can also be 
further digested into peptides and analyzed using bottom-up proteomic approaches. 
The ability to interface with quantitative bottom-up proteomics is unique to SPROX and 
makes it a powerful tool for the analyses of protein-ligand interactions in complex 
biological samples.  
Recently, SPROX has been coupled with isobaric mass tagging [35] for the analysis 
of proteins from a yeast cell lysate for binding to various ligands. The isobaric mass tags 
label peptides from different samples and allow combining them into a single sample 
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 that can be analyzed in a single LC-MS/MS run. This strategy, despite having high 
multiplexing capability, has several drawbacks. One drawback is that it relies on the 
identification and quantitation of the methionine containing peptides. Unfortunately, 
only 20% of the identified peptides in a typical bottom-up proteomic experiment contain 
at least 1 methionine residue in their primary sequences (i.e. a peptide-based 
quantitation) [35a]. This limits the proteome coverage of the large scale analyses in SPROX 
experiment to 1/5 of that from typical proteomic experiments. Another drawback is the 
use of MS2 quantitation in the isobaric mass tagging strategy, which can be complicated 
by the presence of chimeric mass spectra in highly complex biological samples. The MS2 
quantitation is also limited to successful selection and fragmentation of precursor ions in 
the data acquisition step, which can result in missing quantitation information from less 
abundant peptides.  
Thus, there remains a need to develop new and improved mass spectrometry-
based platforms to increase the scope of current SUPREX and SPROX analyses. The 
development of such mass spectrometry-based platforms is the main focus of this 
dissertation. One idea is to use another stable chemical modification that targets another 
residue beside methionine. This stable chemical modification should occur under 
relatively physiological condition for native folding of proteins (i.e. pH 7.4, Room 
Temperature). One such modification is the slow H/D exchange of the C2 protons on 
imidazole ring of Histidine residues [36]. The development and application of this 
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 chemical modification therefore is the focus of the first part of this work (i.e. Chapter 2 
in this dissertation).  
Another strategy is to improve the scope of existing SPROX methodology by 
increasing the number of proteins and peptides assayed. The final goal of the SPROX 
methodology is to perform large scale thermodynamic analysis of diseased state and 
drug mode-of-action in complex biological samples. To assess the validity of the current 
SPROX protocol for the analysis of diseased state proteome, a study is conducted and 
presented in Chapter 3, which involved the application of the iTRAQ-SPROX protocol to 
diseased state analysis in non-small cell lung cancer. The result from this study confirms 
the potential of SPROX in performing such large scale thermodynamic differentiation in 
diseased state analysis. However, several drawbacks of existing iTRAQ-SPROX protocol 
still remain including: (i) the high experimental errors (30-40%), (ii) the reliance on MS2 
quantitation, and most importantly (iii) the pre-requisite to identify and quantify a 
methionine containing peptides in the bottom-up proteomics readout. Therefore the last 
part of this work (i.e. Chapter 4 and 5) focuses on the development of a SILAC based 
SPROX protocol (SILAC-SPROX) to overcome some of the drawbacks associated with 
current iTRAQ-SPROX protocol (i.e. the high experimental error and the reliance on 
MS2 quantitation in Chapter 4 and the pre-requisite to identify and quantify methionine 
containing peptides in Chapter 5). 
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 2. The Development of a Histidine slow HDX protocol 
Described here is a mass spectrometry-based protocol to study the 
thermodynamic stability of proteins and protein-ligand complexes using the chemical 
denaturant dependence of the slow H/D exchange reaction of the imidazole C2 proton in 
histidine side-chain. The protocol is developed using several model protein systems 
including: ribonuclease (Rnase) A, myoglobin, bovine carbonic anhydrase (BCA) II, 
hemoglobin, and the hemoglobin-haptoglobin protein complex. Folding free energies 
consistent with those previously determined by other more conventional techniques 
were obtained for the two-state folding proteins, Rnase A and myoglobin.  The protocol 
successfully detected a previously observed partially unfolded intermediate stabilized in 
the BCA II folding/unfolding reaction; and it could be used to generate a Kd value of 0.24 
nM for the Hb-Hp complex. The compatibility of the protocol with conventional mass 
spectrometry-based proteomic sample preparation and analysis methods was also 
demonstrated in an experiment in which the protocol was used to detect the binding of 
Zn2+ to superoxide dismutase in the yeast cell lysate sample.  The yeast cell sample 
analyses also helped define the scope of the technique, which requires the presence of 
globally protected histidine residues in a protein’s three-dimensional structure for 
successful application. 
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 2.1 Introduction 
The utility of slow histidine H/D exchange as probe of protein structure has been 
demonstrated in continuous labeling experiments [11, 17, 36]. In the histidine H/D exchange 
protocol described here, the denaturant dependence of the H/D exchange reaction is 
probed in order to evaluate the more global thermodynamic parameters associated with 
the more global unfolding/refolding reactions in proteins and protein-ligand complexes. 
The protocol developed here is similar to that used in the SUPREX technique [28] (see 
Introduction), which exploits the amide H/D exchange reaction in proteins.  
The half-life of the H/D exchange reaction of an unprotected histidine residue is 
on the order of ~2 days [36],  which is considerably longer (~400,000 times longer) than 
that of the H/D exchange reaction of an unprotected amide proton [6b]. This means that 
the minimum H/D exchange time required in the histidine H/D exchange protocol is 
much longer than that in SUPREX, as both protocols require the use of H/D exchange 
times that are at least 2.5 times the half-life of the H/D exchange reaction of an 
unprotected site.  Thus, H/D exchange times of at least 5 days are required in the 
histidine H/D exchange protocol, whereas H/D exchange times on the order of minutes 
to hours can be employed in SUPREX. It also means that the extent of back-exchange 
during the mass spectral sample preparation and analysis is relatively small, even when 
conventional proteomic sample preparation and analysis methods are used.  Thus, 
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 unlike SUPREX, the histidine H/D exchange protocol developed here can be interfaced 
with standard mass spectrometry-based proteomics platforms. 
As part of this work the histidine H/D exchange protocol is developed and 
applied to a series of model protein systems including: ribonuclease (Rnase) A, 
myoglobin, bovine carbonic anhydrase (BCA) II, hemoglobin (Hb), and the hemoglobin-
haptoglobin (Hb-Hp) complex. The compatibility of the protocol with conventional mass 
spectrometry-based proteomics sample preparation and analysis methods is evaluated 
in an experiment in which the protocol is applied to the proteins in a yeast cell lysate 
sample both in the absence and in the presence of added Zn2+ in order to test the ability 
of the protocol to detect the binding of Zn2+ to unpurified superoxide dismutase.  The 
results obtained on proteins in the yeast cell lysate samples also help define the scope of 
the technique, which relies on the presence of at least one globally protected histidine 
residue in a protein’s three-dimensional structure for successful analyses.   
2.2 Experimental Procedures 
2.2.1 Materials 
The following materials were purchased from Sigma-Aldrich (St. Louis, MO): 
Rnase A from bovine pancreas (≥ 60 wt. %), myoglobin from equine skeletal muscle (≥ 95 
wt. %), BCAII from bovine erythrocytes (≥ 80 wt. %), trypsin from porcine pancreas 
(proteomic grade), deuterium oxide (D2O; 99.9 atom % D), sodium deuteroxide (35 wt. % 
in D2O, 99.9 atom % D), deuterium chloride (20 wt. % in D2O, 99.9 atom % D), 2-(N-
26 
 morpholino)ethanesulfonic acid (MES), Tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP●HCl),  and S-methyl methanethiosulfonate (MMTS). Guanidine hydrochloride 
(GdmCl) and acetone were purchased from EMD Chemicals, Inc. (Gibbstown, NJ). 
Deuterated GdmCl was prepared by dissolving the GdmCl purchased from EMD 
Chemicals, Inc. in D2O and lyophilizing the sample to dryness. Four 
dissolution/lyophilization cycles were used to maximize the deuterium content of the 
GdmCl. Immobilized porcine trypsin and immobilized bovine chymotrypsin 
(sequencing grade) were purchased from Princeton Separation (Adelphia, NJ). 
Dithiothreitol (DTT), iodoacetamide (IDA) and acetonitrile (ACN) were purchased from 
Fisher Scientific (Pittsburgh, PA). Formic acid (FA) was purchased from Thermo 
Scientific (Rockford, IL) and the Amicon Ultra-0.5 mL Centrifugal Filter units with a 
10,000 molecular weight cut-off were purchased from Millipore (Billerica, MA). 
Stroma free hemoglobin (SFH) was obtained by precipitation by ammonium 
sulfate followed by a step where the endogenous phosphates are removed and then the 
protein is purified by FPLC following a previously published method.[37] Hp, 
predominantly of the 1-1 phenotype, was purchased from Sigma-Chemical (St. Louis, 
MO) and was 99% pure. For complex formation, Hb was mixed with Hp in a 1:1 ratio 
(protein concentration). The complex was further purified using a BioSep 3000 column 
from Phenomenex (Torrence, CA) using a 50 mM potassium phosphate buffer (pH 7.4). 
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 Spectroelectrochemistry and MALDI-MS were used to verify the Hb-Hp complex 
formation as described previously [37]. 
2.2.2 Thermodynamic Analysis of Model Protein Systems 
Histidine H/D exchange analyses on Rnase A were initiated on a 1 mM stock 
solution of fully protonated protein prepared in H2O. A 10 mL aliquot of the stock 
solution was diluted into 90 mL of deuterated 20 mM sodium phosphate buffer (pD 7.4) 
containing 20 mM sodium acetate, 100 mM NaCl, and the following concentrations of 
deuterated GdmCl: 0.0, 0.6, 1.2, 1.7, 2.2, 2.5, 3.0, 3.2, 4.3, and 5.3 M.  The samples were 
incubated for 5 days at 37 oC. The H/D exchange reactions in each buffer were quenched 
by addition of 10 µL of FA before addition of 1 mL of acetone to precipitate protein in 
each denaturant-containing buffer. The protein precipitation step was allowed to 
proceed overnight at -20 oC before the samples were centrifuged at 20,000 x g for 30 min 
to pellet the insoluble protein. The resulting protein pellets were dissolved in 50 µL of 
0.1 M ammonium bicarbonate buffer (pH 8) containing 0.1% SDS. The samples were 
reduced with 10 mM DTT at 80 oC for 15 min, and alkylated with 20 mM IDA in the dark 
for 30 min. The protein was digested with a combination of 0.5 µg immobilized trypsin 
and 0.5 µg immobilized chymotrypsin for 1 hr. each at 37 oC and gentle shaking. The 
samples were centrifuged and the immobilized proteases were separated from the 
supernatant, which was adjusted to pH 2-3 with 10% TFA.  The SDS in each supernatant 
was removed using SDS removal tips (PolyLC, Columbia, MD) according to the 
28 
 manufacturer’s protocol. The resulting samples were subjected to LC-MS/MS analyses as 
described in section 2.2.4 below.  
Histidine H/D exchange analyses on myoglobin, BCAII, Hb, and the Hb-Hp 
complex were initiated on 0.5 to 1 mM stock solutions of these proteins that were 
prepared in H2O. In each case a 10 µL aliquot of stock solution was diluted into 90 µL of 
deuterated 50 mM MES buffer (pD 7.4) containing 50 mM NaCl and the following 
GdmCl concentrations: 0, 0.7, 1.2, 1.8, 2.2, 2.4, 2.7, 2.9, 3.2, 3.6 and 4.2 M (for myoglobin 
and BCAII), and 0, 1.4, 1.8, 1.9, 2.2, 2.4, 2.9, 3.4, 4.0, 4.5, 5.3 M (for Hb and Hb-Hp). The 
samples were incubated at 37 oC for either 5 or 11 days. After the specified H/D 
exchange time, a 50 µL aliquot of each H/D exchange reaction was removed and diluted 
into 350 µL H2O. Each sample was added to an Amicon Ultra-0.5 mL Centrifugal Filter 
unit and centrifuged for 15 min at 14,000 x g. Two 200 µL aliquots of 1 mM Tris buffer 
(pH 8.5) containing 8 M Urea (referred to as UA solution) were sequentially added to 
each filter unit and then centrifuged for 15 min each at 14,000 x g. Aliquots of 100 µL of 
UA containing 20 mM TCEP●HCl or 40 mM MMTS were subsequently added to reduce 
and alkylate the protein samples in the filter units for 1 hr. at RT. Three 100 µL aliquots 
of UA solution were sequentially added to the filter units and centrifuged for 15 min 
each at 14,000 x g. The protein in each filter unit was reconstituted in 120 µL of 50 mM 
ammonium bicarbonate buffer (pH 8.0) before the sample were digested in the filter unit 
with ~ 2 μg of trypsin for 12-15 hrs.; and with 1 µg of chymotrypsin for 1 hr. at room 
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 temperature. The resulting samples were each subjected to a single LC-MS/MS analysis 
as described in section 2.24 (see below).  
2.2.3 Thermodynamic Analysis of Proteins in a Yeast Cell Lysate 
2.2.3.1 Yeast Cell Lysate Preparation 
The yeast overexpression strain was grown overnight in 50 mL of a 2% raffinose 
SC-Ura solution. The cell culture was transferred into 500 mL of 2% raffinose SC-Ura to 
give an O.D.600 of 0.3 and incubated at 30 oC until log phase (O.D.600 of 0.8 ~ 1.2).  The 
overexpression of cyclophilin A was induced upon the addition of 250 mL of 6% 
galactose in 3xYP solution. After six hours of induction 125 mL fractions of the culture 
were pelleted by centrifuging at 1000 x g for 10 min at 4oC. The cells in a pellet were 
lysed in 20 mM phosphate buffer (pH 7.4) containing 1x concentration of Halt protease 
inhibitor cocktail (Thermoscientific, Rockford, IL). Cell lysis was accomplished by 
vigorously shaking the sample with glass beads (0.5 mm diameter) at RT a total of ten 
times for 20 sec each with a 1-min-incubation on ice between shakings. The resulting 
suspension was centrifuged at 14,000 x g for 10 min. The supernatant was used in the 
two yeast cell lysate experiments described below. 
2.2.3.2 Histidine HDX Analysis of Proteins from the Yeast Cell Lysate 
The yeast cell lysates, which typically contained ~10 mg/ml of total protein, were 
prepared as previously described using a cyclophilin A (YDR155C) overexpression 
strain that was purchased from Open Biosystems, Huntsville, Al, USA.[38] More detailed 
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 information about the yeast cell lysate preparation is provided in the Supporting 
Information. In the first yeast cell lysate experiment, 10 µL of the yeast cell lysate, which 
contained about 100 µg of total protein, was diluted into 90 µL of deuterated 20 mM 
phosphate buffers (pD 7.4), containing the following GdmCl concentrations: 0.5, 0.8, 1.1, 
1.6, 2.0, 2.9, 2.5, 3.6, 4.0, or 4.5 M.  The protein samples in each buffer were subject to the 
same histidine H/D exchange analysis as described above for Rnase A except that 
protease digestion step was allowed to proceed for 6 hr. and it only involved one 
protease, trypsin, with ratio of 1:20 enzyme to substrate ratio.  
In the second yeast cell lysate experiment, the yeast cell lysate was divided into 
two 135 µl fractions, with each fraction containing ~ 1350 μg of total protein. A 15 mL 
aliquot of a 1 mM ZnCl2 solution was added to one fraction and 15 ml of H2O was added 
to the second fraction.  Both fractions were incubated at room temperature for 15 min, 
before 10 mL aliquots of each fraction were diluted into 90 µL of deuterated MES buffers 
(pD 7.4) containing 50 mM NaCl and the following GdmCl concentrations: 0.0, 1.2, 1.4, 
1.9, 2.2, 2.4, 2.7, 2.9, 3.2, 4.2, and 5.3 M. The protein samples in each buffer were subject 
to the same histidine H/D exchange analysis as described above for Rnase A except that 
after the acetone precipitation, the protein pellets were dissolved in freshly prepared 50 
mM ammonium bicarbonate buffer (pH 8.0) containing 6 M urea before they were 
reduced with 10 mM DTT at 80 oC for 15 min, alkylated with 20 mM IDA for 30 min in 
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 the dark, diluted 5-fold with 50 mM ammonium bicarbonate buffer (pH 8.0), and 
digested with 1:20 trypsin for ~ 6 hrs.  
2.2.4 LC-MS/MS Data Acquisition and Analysis 
LC-MS/MS analyses were performed on an Agilent 6520 Q-TOF mass 
spectrometer equipped with a Chip Cube interface. Protease digests of the purified 
protein samples in this work were analyzed on an HPLC Chip containing a 43 mm x 75 
µm reversed-phase HPLC column with 5 µm Zorbax 300SB-C18 packing material. The 
elution gradient used for analysis of the protease digests of the purified proteins 
samples was 3 to 70% Buffer B over 7 min. Buffer A was 0.1% FA in H2O and buffer B 
was 0.1% FA in ACN. The flow rate was 0.4 µL/min. The capillary voltage was set to 
1800 V. The flow rate of the drying gas (i.e. N2) was maintained at a temperature of 350 
oC, was 6 L/min. The skimmer and fragmentor voltages were set at 65 and 175 V, 
respectively. The collision energy used in the MS/MS experiments was either 3.5V/100 
Da with a -4.8V offset (i.e., for the Rnase A experiments and for the first yeast cell lysate 
experiments), 3.6V/100 Da with a -4.8V offset (i.e., for the myoglobin, BCAII, 
hemoglobin, and hemoglobin-haptoglobin experiments), or 3.9V/100 Da with a 2.9 V 
offset (i.e., for the second yeast cell lysate experiments). The inclusion window width for 
precursor ion selection in the MS/MS experiments was 4 m/z. The scan rate in the 
MS/MS experiments was 4 precursor spectra/sec and 3 product spectra/sec.  A total of 3 
precursor ions were selected for fragmentation per cycle. 
32 
 LC-MS/MS analyses of the protease digestion products generated from the yeast 
cell lysate samples were identical to that described above for the protease digests of the 
purified protein samples with a few exceptions. One exception was that the HPLC Chip 
contained a 150 mm x 75 um HPLC column and the gradient used for the analysis was 
2% B over 5 min, 2 to 15% B over 2.5 min, 15 to 45% B over 78 min, and then 45 to 100% 
B over 10 min at 0.4 µL/min. The other exceptions were that the capillary voltage was set 
to 1875 V, the scan rate in the LC-MS/MS experiments was 3 precursor spectra/sec and 2 
product spectra/sec, and 4 precursors per cycle were selected for fragmentation.  
LC-MS/MS data were analyzed using Spectrum Mill Proteomics Workbench 
software (Rev. A03.03.084) from Agilent Technologies, Inc. (Santa Clara, CA). In 
analyses using the Spectrum Mill software, the precursor and product ion mass 
tolerance were either 20 ppm (i.e., for analysis of the Rnase A and yeast cell lysate data), 
50 ppm (i.e., for the BCA II and myoglobin data analyses) or 15 ppm (i.e., for the 
hemoglobin and hemoglobin-haptoglobin data analyses). The protease was set to trypsin 
(i.e., for the yeast cell lysate data analysis), Trypsin/Chymotrypsin (i.e., for the 
hemoglobin and hemoglobin-haptoglobin data analyses), or no enzyme (i.e., for the 
Rnase A, BCAII, and myoglobin analyses). The maximum ambiguous precursor charge 
was set to 7. The carbamidomethylation (i.e., in the Rnase A and yeast cell lysate data 
analyses) or MMTS (i.e., in the myoglobin, BCAII, Hb and Hb-Hp data analyses) 
modification of cysteine was set as a fixed modification, and oxidation of methionine 
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 was set as variable modification. The databases used for the purified protein analyses 
were comprised of the known amino acid sequences of the protein being analyzed (e.g., 
Rnase A, myoglobin, BCAII, or hemoglobin). The database used for the lysate 
experiment was the Saccharomyces cerevisiae subset from NCBinr (downloaded from 
ftp://ftp.ncbi.nlm.gov/blast/db/FASTA on June 20th 2009). 
2.2.5 Histidine HDX Data Analysis 
The deuterium content of histidine-containing peptides was determined by 
calculating the weighted average mass of the five most abundant isotopologues 
observed for each peptide in the mass spectra obtained in the LC-MS/MS analyses. This 
weighted average mass value was used to calculate a ∆Masswt,av value of a given 
histidine-containing peptide at each denaturant concentration by subtracting the 
theoretical weighted averaged mass value expected for the fully protonated peptide, 
which was also calculated using the five most abundant isotopologues expected for each 
peptide. The ∆Masswt,av values obtained in this work were determined using the 
summed ion intensities from the approximately 5 mass spectra that were collected on a 
given peptide in each LC-MS/MS analysis. The ∆Masswt,av values were plotted as a 
function of the denaturant concentration. The data in the ∆Masswt,av versus [GdmCl] 
plots were fit to a standard sigmoidal equation, equation (13), using a non-linear least-
squares analysis based on the Marquardt-Levenberg algorithm in Sigma Plot in order to 
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 evaluate the concentration of denaturant at the transition midpoint of the resulting 
sigmoidal curve (i.e., the C1/2 value). 
(13) 𝑦 = 𝑦𝑜 + 𝑎
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In equation (13), x was the [GdmCl], y was the ∆Mass value, y0 was the ∆Mass 
value in the pre-transition region, a was the amplitude of the transition, and b was 
related to the steepness of the transition. Ultimately, the C1/2 value was used to calculate 
a folding free energy according to equation (14). 
(14) ∆𝐺𝑓 = −𝑚𝐶1/2 − 𝑅𝑇 �ln� 𝑘𝜑𝑡0.693−1𝑛𝑛
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 In equation (14), which was previously been reported for the analysis of SUPREX 
data [31], ∆Gf  is the folding free energy of the protein, kϕ is first order rate constant of the 
slow H/D exchange reaction at the C2 position on an unprotected histidine imidazole 
side chain, m is 𝛿∆𝐺𝑓/𝛿[𝐺𝑑𝑚𝐶𝑙], T is the temperature, R is the ideal gas constant, t is 
the H/D exchange time, and [P] is the protein concentration expressed in n-mer 
equivalents. In all the ΔGf value calculations described here using equation (14), T was 
310 K, kϕ was set at a value of 0.288 day-1 (based on the data in reference [36]), and n was 1 
with exception of the Hb analyses in which n was 2 (as the Hb tetramer has been shown 
to dissociate into to a/b dimers in other GdmCl-induced equilibrium unfolding 
experiments [39]).  In the Rnase A and myoglobin analyses, previously determined m-
values of 3.1 [40] and 3.71 [41] kcal mol-1 M-1 (respectively) where used in equation (14) for 
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 the ΔGf calculations.  In the transition midpoint analysis method used to analyze the Hb 
and Hb-Hp data, the C1/2 values obtained at the different H/D exchange times were fit to 
equation (14) using a linear least squares analysis in which the y-intercept and slope of 
the best-fit line were taken as the ΔGf value and m-value, respectively. 
2.2.6 Kd Value Determination 
The Kd value of the Hb-Hp complex was calculated using equation (15): 
(15) 𝐾𝑑 = 4𝐿𝑡𝑜𝑡𝑎𝑙𝑒−∆∆𝐺𝑓𝑁𝑅𝑇 −4𝑃𝑡𝑜𝑡𝑎𝑙(𝑒−∆∆𝐺𝑓𝑁𝑅𝑇 −1)
�2𝑒−
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In equation (15), the derivation of which has been previously described,[34] Ltotal is 
the concentration of ligand and Ptotal is the concentration of protein, N is the number of 
independent binding sites, R is the gas constant, T is the temperature in Kelvin, and 
ΔΔGf is the binding free energy.  The binding free energy was calculated from the ΔGf 
values obtained for Hb in the absence and in the presence of Hp. 
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 2.3 Results and Discussion 
2.3.1 Histidine HDX Protocol 
 
Figure 1: Schematic representation of the slow histidine H/D exchange 
protocol developed here 
The protocol developed here (Figure 1) involves dilution of a protein sample into 
a series of deuterated buffers containing increasing concentrations of a chemical 
denaturant (e.g. GdmCl). The protein samples in each deuterated buffer are allowed to 
undergo H/D exchange at 37 oC and pD 7.4 for the same amount of time. The H/D 
exchange time (t in equation (14)) should be at least 5 days, which is equivalent to ~2.5 
half-lives of the H/D exchange reaction of a C2 proton in the imidazole side-chain of an 
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 unprotected histidine residue [36]. This is necessary to ensure that the ln-term in equation 
(14) is >>0.  It is also important that the H/D exchange time not be so long as to 
compromise the integrity of the protein sample (e.g., the protein sample can be oxidized 
and/or degraded with proteases if they are present).  However, we note that no such 
problems were observed when H/D exchange time between 5 and 11 days were used to 
analyze the model proteins in this work. 
An important consideration in the development of the histidine H/D exchange 
protocol described here was the choice of H/D exchange time.  An H/D exchange time of 
at least 5 days is required for the protocol to produce reasonably accurate ∆Gf values 
using equation (14).  This is because the kϕt term in equation (14) must be significantly 
greater than 0.693 or the accuracy of the linear extrapolation method employed in our 
data analysis is compromised (see Figure 2).  For example, the use of a 2.5 day H/D 
exchange time would lead to the calculation of an aberrantly low ∆Gf value (see Figure 
2).  In theory, data collected using longer H/D exchange times should produce the most 
accurate ∆Gf values (see Figure 2).  
38 
  
Figure 2: Theoretical plot showing the expected movement of C1/2 values as a 
function of H/D exchange time in the slow histidine H/D exchange protocol described 
here.  The data in the plot were generated using equation (14) and representative 
thermodynamic parameters of Rnase A (i.e., n =1, m-value = 3.1 kcal mol-1M-1, ∆Gf =9.2 
kcal mol-1, kϕ=0.288 day-1).  Data points at selected H/D exchange times are indicated. 
The dotted lines represent a linear extrapolation of data at 2.5 and 5 days exchange.  
The -∆Gf Apparent” term on the y-axis represents -RT[X] where “X” is the ln-term in 
equation (14).  
Unfortunately, the use of long exchange times (e.g., greater than several weeks) 
can not only be impractical but also can potentially compromise the integrity of the 
protein sample (e.g., the protein sample could be degraded and/or oxidized). Protein 
degradation may be especially problematic in unpurified protein samples (e.g., cell 
lysates) where proteases may be present.  It is possible that such problems may even 
manifest themselves when 5 and 11 day H/D exchange times are used to analyze some 
samples.  However, such complications with sample degradation are likely to be 
mitigated in protein ligand binding experiments where differential measurements are 
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 made on the same sample using the same H/D exchange time.  Moreover, potential 
problems can be identified if experiments are done using both 5 and 11 day H/D 
exchange times.  If significantly different thermodynamic parameters are determined 
using the data at the 5 and 11 day H/D exchange time, this would signal a potential 
problem.  We note that no such problems were observed using the model systems in this 
work. 
In the H/D exchange reactions all the labile hydrogens in a protein are subject to 
exchange including the relatively slow exchanging C2 protons in the imidazole side 
chain of histidine residues, the fast exchanging amide hydrogens, and the even faster 
exchanging side-chain hydrogen atoms bonded to nitrogen, oxygen and sulfur. 
Ultimately, the H/D exchange reactions are quenched by acidifying the solution and 
lowering temperature. The protein samples in the denaturant containing-buffers are 
each subjected to a desalting step in which the denaturant and the D2O are removed 
using spin columns, acetone precipitation, or TCA precipitation. 
After the desalting step, the protein samples are reduced, alkylated, and digested 
with a proteolytic enzyme (e.g., trypsin) according to standard mass spectrometry-based 
proteomic protocols. During these sample handling steps the protein samples are 
denatured and subject to alkaline pH conditions for extended periods of time (e.g., 6 to 
12 hrs.). The H/D exchange rates of unprotected amide and side-chain 
protons/deuterons under these conditions are >1 s-1 [6b]. Therefore, deuterons that were 
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 incorporated into the peptide backbone and the amino acid side chains during the initial 
H/D exchange reaction are nearly all exchanged back to protons. However, the large 
majority of deuterons that were exchanged into the C2 position of the imidazole side 
chain of histidine residues are not back-exchanged to protons because of the longer half-
life required for back-exchange. The resulting peptides are subjected to a mass 
spectrometric analysis in which the peptides are sequenced to identify histidine-
containing peptides and the mass spectral data are used to determine a ∆Masswt,av value 
for each histidine-containing peptide at each denaturant concentration in which the H/D 
exchange reaction was performed on the intact protein. Ultimately, the ∆Masswt,av values 
obtained for a given histidine-containing peptide are plotted as a function of the 
denaturant concentrations, and the data are used to calculate a protein folding free 
energy as described previously. 
2.3.2 Analysis of Two-State Folding Systems 
Rnase A, which contains four histidine residues (His-12, His-48, His-105, and 
His-119), was initially analyzed using the above protocol. Based on the results of earlier 
histidine H/D exchange studies of Rnase A in which the time course of histidine H/D 
exchange was studied [36], His-105 and His-119 in Rnase A are solvent exposed, His-12 is 
partially protected, and His-48 is buried in the hydrophobic core of Rnase A’s native 
three-dimensional structure. The slow histidine H/D exchange data obtained here for 
one of the detected His-48 containing peptides is shown in Figure 3.   
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Figure 3: Slow histidine H/D exchange data for Rnase A. Data obtained for a 
His-48-containing peptide of sequence, VHESLADVQAVCSQK, is shown in (A). The 
solid line represents the best fit of the data to equation (13), the dotted arrow indicates 
C1/2 value, the arrow labeled “1” and “2” indicates the data points for which mass 
spectral data is shown in (B) and (C), respectively  
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 As expected for a globally protected histidine residue, there was a clear 
denaturant dependence to the H/D exchange behavior of His-48 (Figure 3A). A His-12 
containing peptide showed a similar denaturant dependence to its H/D exchange 
behavior but the curve had smaller amplitude (see Figure 4 below). 
 
Figure 4: Slow histidine H/D exchange data obtained on a Rnase A peptide 
(11-25), which contained a histidine residue that was partially protected in Rnase A’s 
three-dimensional structure. The solid line is best fit of the data to equation (13) (see 
text).  Data points represented with open circles were excluded from the fit. 
Visual inspection of the isotopologues obtained here for two other Rnase A 
peptides, Rnase A (105-115) and Rnase A (106-120) covering His-105 and His-119, 
indicated that these histidine residues were each ~50% deuterated and that the extent of 
deuteration was unchanged with denaturant concentration.  Such H/D exchange 
behavior is expected for peptides containing these histidine residues, which were from 
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 solvent exposed regions of protein structure (see discussion of expected deuteration 
levels below).  
Expected Deuteration Levels. In theory, the ∆Masswt,av value for a completely 
exchanged histidine-containing peptide should be close to 0.7 Da, considering the 
deuterated buffers were 90% D2O and the H/D exchange reaction was allowed to 
proceed for 5 days (i.e., 2.5 half-lives of the H/D exchange reaction of an unprotected 
histidine residue) (i.e., 90% of 76% complete).  However, the post-transition baseline 
ΔMasswt,av values observed here were typically ~ 0.5 per histidine residue.   Presumably, 
a fraction (~30%) of the deuterons that exchanged into the C2 position of the histidine 
residues were back-exchanged with protons in protonated buffer during the mass 
spectrometry sample preparation and analysis steps of the protocol. However, it is 
important to note that as long as the extent of this back exchange reaction is similar for 
each data point that defines the curve, the C1/2 value determination is not compromised. 
In the histidine H/D exchange analysis of myoglobin, peptides covering 9 of the 
11 histidine residues in myoglobin’s amino acid sequence were identified in the mass 
spectral readout.  These 9 histidine residues included 2 that are globally protected (His-
24 and His-64), 5 that are partially protected (His-36, His-81, His-82, His-113, His-116), 
and 2 that are exposed (His-48 and His-119), based on the slow histidine H/D exchange 
behavior of the peptides in this work (see below) and on a visual inspection of 
myoglobin’s three-dimensional structure [19].  
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Figure 5: Slow histidine H/D exchange data for myoglobin using an H/D 
exchange time of 5 days. Data obtained on peptides containing globally protected 
histidine residues, His-64 and His-24 are shown in (A) and (B), respectively.  Data 
obtained on a peptide containing partially protected histidine residues, His-81 and 
His-82, is shown in (C), and data obtained on a peptide containing an exposed 
histidine residue, His-119 is shown in (D). Peptide sequences are located at the top of 
each panel. The solid lines in (A) and (B) represent the best fit of each data set to 
equation (13) in the text.  Data points represented by open circles were excluded from 
the fit. 
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 The data obtained on peptides containing the two protected histidine residues, 
His-24 and His-64, showed a clear denaturant dependence to their H/D exchange 
behavior and yielded C1/2 values that were 1.7 M and 1.6 M [GdmCl], respectively (see 
Figure 5A and 5B). The data obtained on peptides containing a partially protected 
histidine residue could also be fit to a sigmoidal curve, however, the amplitude of the 
curve was small (see Figure 5C).  Peptides containing an exposed histidine residue (e.g., 
His-119) were essentially all exchanged at each denaturant concentration (see e.g., 
Figure 5D).  
 
Figure 6: Slow histidine H/D exchange data obtained on myoglobin peptides, 
contained the globally protected histidine residues, His-64 and His-24 (respectively).  
The H/D exchange time was 11 days. The solid lines represent the best fit of the data 
to equation (13) in the text.  The data point represented with an open circle was 
excluded from the fit. 
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 The histidine H/D exchange protocol described here utilizes a peptide-readout.  
However, the C1/2 values generated for the histidine-containing peptides detected in the 
mass spectral readout are representative of the protein folding unit from which they 
derive. In the case of a two-state folding globular protein such as Rnase A and 
myoglobin, each protein molecule is considered to be a single folding unit,[41] and 
therefore the C1/2 values derived from different globally-protected histidine-containing 
peptides in these proteins are expected to be similar and to yield folding free energies 
that are comparable to those determined for the intact protein using other techniques.  
Indeed, the C1/2 value measured here for the Rnase A(47-62) peptide can be used in 
equation (14) to calculate a ∆Gf value of -6.9 kcalmol-1 for Rnase A, which is within 30% 
of that previously determined[40] for this protein (see Table 1). The similar C1/2 values 
obtained from the two different globally protected histidine-containing peptides in the 
myoglobin analysis (see Table 1) are consistent with a two state folding mechanism.  The 
∆Gf values calculated using equation (14) and these C1/2 values are also similar and 
within 20% of that previously determined [41] for myoglobin (see Table 1). 
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 Table 1: Thermodynamic parameters obtained on model proteins.  
Values in parenthesis were previously determined by others using more 
conventional experimental approaches 
Protein 
Peptide 
 
C1/2 
(M) 
m  
(kcal 
mol-1M-1) 
∆Gf  
(kcal mol-1) 
Rnase A    
VHESLADVQAVCSQKa 2.2 (2.99c)  (3.1c) -6.9 (-9.2c) 
Myoglobin    
HGTVVLTALGGILKa 1.7 (1.63d)  (3.71d) -6.4 (-6.0d) 
HGTVVLTALGGILKb 1.6 (1.63d)  (3.71d) -6.7 (-6.0d) 
VEADIAGHGQEVLa 1.7 (1.63d)  (3.71d) -6.4 (-6.0d) 
VEADIAGHGQEVLb 1.7 (1.63d)  (3.71d) -7.1 (-6.0d) 
Hb    
TPAVHASLDKFa 0.7 (0.7e) 2.43  -8.2 (-8.3f) 
TPAVHASLDKFb 0.4 (0.7e) 2.43  -8.2 (-8.3f) 
GTFATLSELHCDKa 0.7 (0.7e) 2.43  -8.2 (-8.3f) 
GTFATLSELHCDKb 0.4 (0.7e) 2.43  -8.2 (-8.3f) 
Hb - Hp    
TPAVHASLDKFa 3.1 (NA) 1.28  -10.5 (NA) 
TPAVHASLDKFb 2.5 (NA) 1.28 -10.5 (NA) 
GTFATLSELHCDKa 3.1 (NA) 1.78  -12.0 (NA) 
GTFATLSELHCDKb 
 
2.7 (NA) 1.78  -12.0 (NA) 
a5 days exchange. b11 days exchange. cValue from reference [40]. dValue from 
reference [41]. eValues from reference [39] . fValue from reference [42]. “NA” indicates 
value not available. 
2.3.3 Analysis of a Non-Two-State Folding System 
BCAII, which contains a total of 11 histidine residues in its primary amino acid 
sequence and is a known non-two-state folding protein,[43] was also analyzed using the 
protocol described above.  Peptides containing 9 of the 11 histidine residue in BCAII 
were detected in the LC-MS/MS readout, and 5 of these 9 histidine residues (i.e., His-93, 
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 His-95, His-106, His-118 and His-121) were found to be from globally protected regions 
in BCAII’s native three-dimensional structure, based on the histidine H/D exchange 
behavior of peptides containing these residues (Figure 7). Histidine-containing peptides 
containing these 5 histidine residues yielded sigmoidal curves with two clear transitions 
(Figure 7), with C1/2 values of 1.4 M and 3 M. These results are consistent with the 
presence of a folding intermediate that is stabilized in ~2 M GdmCl.  The presence of 
such an intermediate has been suggested in other chemical-denaturant induced 
equilibrium unfolding/refolding studies using intrinsic fluorescence spectroscopy [43-44] 
 
 
Figure 7: Slow histidine H/D exchange data for BCA II.  Data obtained on a 
peptide containing histidine residues, His-118 and His-121, is shown in (A) and data 
obtained for a peptide containing histidine residues, His-93, His-95 and His-96 is 
shown in (B). The dotted arrows indicate C1/2 values. The solid lines represent the best 
fit of the data to equation (13), with the data in each transition being fit separately. 
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 2.3.4 Analysis of a Protein-Protein Interaction 
An important application of the histidine H/D exchange protocol developed here 
is the detection and quantitation of protein-ligand binding interactions.  In order to test 
the ability of the protocol to detect and quantify a protein-ligand binding interaction, the 
known protein-protein interaction between Hb and Hp was analyzed.[37] A Hb sample 
and a sample of the Hb-Hp complex were each subject to the histidine H/D exchange 
protocol described here using H/D exchange times of both 5 and 11 days. In these 
analyses a total of 9 hemoglobin peptides containing 6 of the 10 histidine residues in the 
α chain of hemoglobin and 5 of the 9 histidine residues in the β chain of hemoglobin 
were identified in the LC-MS/MS readout (see Table 2).   
The ∆Masswt,av values generated for 7 of the 9 histidine-containing peptides in Hb 
were all similar (i.e., ~0.6 Da) and did not change with denaturant concentration (data 
not shown) in either the Hb or Hb-Hp analyses, suggesting that the histidine residues in 
these seven peptides (see Table 2) were solvent exposed in hemoglobin’s three-
dimensional structure.  The ∆Masswt,av values recorded for 2 of the 9 histidine-containing 
peptides detected, Hb (116-126) of sequence TPAVHASLDKF from the α chain and Hb 
(83-95) of sequence GTFATLSELHCDK from the β chain, showed a denaturant 
dependence (see Figure 8).  
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 Table 2: Summary of C1/2 values determined for the histidine-containing 
hemoglobin peptides identified in the Hb and Hb-Hp analyses described here. “ND” 
indicates that no denaturant dependence was observed for the ΔMasswt,av values 
determined for these peptides, presumably because the histidine residues in these 
peptides were derived from solvent exposed regions of the intact protein structure. 
Protein 
Peptide (amino acid #) 
C1/2 (M) 
Hemoglobin α Chain 
     VGAHAGEYGAEALER (17- 31) 
 
ND* 
TYFPHFDLSHGSAQVK (41-56) ND  
KVADALTNAVAHVDDMPNAL (61-80) ND  
LVTLAAHLPAEF (106-117) ND  
TPAVHASLDKF (116-126) 0.7(0.4*)  
Hemoglobin β Chain  
SDGLAHLDNLK (72-82) 
 
ND  
GTFATLSELHCDK (83-95) 0.7(0.4*)  
LHVDPENFR (96-105) ND  
VVAGVANALAHKYH (132-146) ND  
Hemoglobin-Haptoglobin α Chain  
VGAHAGEYGAEALER (17- 31) 
ND  
TYFPHFDLSHGSAQVK (41-56) ND 
KVADALTNAVAHVDDMPNAL (61-80) ND 
LVTLAAHLPAEF (106-117) ND 
TPAVHASLDKF (116-126) 3.1(2.5*)  
Hemoglobin-Haptoglobin β Chain  
SDGLAHLDNLK (72-82) 
 
ND  
GTFATLSELHCDK (83-95) 3.1(2.7*)  
LHVDPENFR (96-105) ND  
VVAGVANALAHKYH (132-146) ND  
* Values after 11 day exchange 
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Figure 8: Slow histidine H/D exchange data for Hb and the Hb-Hp complex. 
Data obtained on His-120 containing peptide from the α chain of Hb after 5 days (○ 
and ●) and 11 days ( and ) in the presence (○ and ) and absence (● and ) of Hp 
is shown in (A). Similar data obtained on a His-92 containing peptide from the β 
chain of Hb in the presence and absence of Hp is shown in (B). The lines represent 
best fit of each data set to equation (13). 
However, a clear pre-transition baseline was only observed in the analysis of the 
Hb-Hp complex.  Only one data point was collected in the pre-transition baseline of the 
Hb data sets because the C1/2 values obtained for Hb in the absence of Hp were small 
(i.e., < 1 M GdmCl). The peptides from α and β chains yielded similar C1/2 values at 
similar H/D exchange times (see Table 1).   These results suggest that they belong to the 
same folding unit, even though they were derived from different subunits in the 
hemoglobin complex. These data are consistent with hemoglobin’s three-dimensional 
52 
 structure, which has the histidine residues in these peptides buried in the heme 
pocket.[10]  
Hb is a tetramer in solution composed of two α chains and two β chains with 
different amino acid sequences but similar 3-D structures.[10] The GdmCl-induced 
equilibrium unfolding reaction is known to be biphasic with the Hb tetramer 
dissociating to two dimers, each containing an α and β chain, before each of the α/β 
dimers unfold at high denaturant concentration (> 5 M).[39] The C1/2 values recorded for 
the two globally protected histidine-containing peptides in our H/D exchange 
experiments on Hb are consistent with that expected for the tetramer-dimer transition 
reported earlier [39]. It is also noteworthy that there is a significant difference (i.e., ~ 0.4-
0.6 M) between the C1/2 values obtained for the Hb-Hp complex at 5 and 11 days.  A 
similar, but smaller shift of ~0.3 M was observed for Hb at 5 and 11 days for the Hb-Hp 
complex. As we have previously described for the analysis of SUPREX data,  such C1/2 
value shifts as a function of H/D exchange time can be used to evaluate ΔGf and m-
values using the transition midpoint analysis method.[31]  The ΔGf and m-values derived 
for the Hb peptides in the presence and absence of Hp using the transition midpoint 
analysis method are summarized in Table 1.  
The C1/2 values obtained for Hb in the presence and absence of Hp indicate that 
the Hb α/β dimer is stabilized in the Hb-Hp complex. If the ΔGf values obtained for the 
two peptides in the Hb analysis are averaged and the ΔGf values obtained for the two 
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 peptides in the Hb-Hp analysis are averaged, the resulting average ΔGf values, -8.2 and -
11.5 kcal/mol (respectively), can be used to quantify this increased stability (i.e., calculate 
an average binding free energy of -3.3 kcal/mol).  This binding free energy (i.e., ΔΔGf 
value) can be used in equation (15) to generate a Kd value of 0.24 nM for the Hb-Hp 
complex. This Kd value is approximately 10-fold lower than that previously reported 
using surface plasmon resonance spectroscopy (SPR).[8] The weaker binding affinity 
measured in the SPR experiment may be a result of the protein immobilization that was 
necessary in the SPR experiment.  It is also possible that the difference may be a result of 
inaccuracies in our m-value assignments, which were obtained by a linear extrapolation 
involving only 2 data points. Unfortunately, the use of more data points in the linear 
extrapolation would require the use of impractically long H/D exchange times (e.g., an 
estimated 3-6 weeks would be required to shift the C1/2 values 0.5 M lower than the 11 
day C1/2 values recorded here) (see Supporting Information).  
m-value Analysis. The ∆Gf value calculations described above for Rnase A and 
myoglobin utilized previously determined m-values.  In theory, one of the two data 
analysis methods that we previously described for the evaluation of protein folding m-
values by SUPREX (i.e., either the transition midpoint analysis method[31] or equation 
(16)[28]) could be used to evaluate m-values in the histidine H/D exchange protocol 
described here.   
(16) ∆𝑀𝑎𝑠𝑠 = ∆𝑀∞ + (∆𝑀𝑜 − ∆𝑀∞)𝑒� 𝑘𝜑𝑡1+𝑒−∆𝐺+𝑚[𝐺𝑑𝑚𝐶𝑙]𝑅𝑇 �    
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 In equation (16), ΔMo is the ΔMass before global histidine exchange, ΔM∞ is the 
ΔMass after complete histidine exchange, and the other variables are as described in the 
text. 
In practice, neither of the transition midpoint analysis method or equation (16) 
could be used effectively in our histidine H/D exchange analyses of Rnase A or 
myoglobin.  Application of the transition midpoint analysis method involves extracting 
C1/2 values from slow histidine H/D exchange data sets obtained using different H/D 
exchange times and fitting the data to equation (16).  However, the extent to which a 
protein’s C1/2 value shifts with H/D exchange time depends on the biophysical 
parameters associated with its folding/unfolding reaction (e.g., ΔGf and m-value).  Based 
on the known ΔGf and m-values of myoglobin and Rnase A, the transition midpoint 
method would have required the use of impractically long H/D exchange times (several 
months) to shift the transition midpoints of these proteins by a measurable value (e.g., > 
0.3 M).  
The ΔMass vs. [GdmCl] data obtained in SUPREX (and in theory the Histidine 
H/D exchange protocol described here) can be fit to equation (16) to obtain both a ΔGf 
and m-value.  In practice, the accuracy and precision of such ΔGf and m-value 
determinations is highly dependent on the number of data points that are recorded in 
the transition region. The lack of sufficient data points in the transition regions of the 
myoglobin and Rnase A curves (see Figure 5A, 5B and Figure 3A) did not yield reliable 
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 fits of these data sets to equation (16).  The ΔGf calculations in this work on the 
myoglobin and Rnase A thus employed equation (14) and previously determined m-
values.     
To our knowledge protein folding m-values in GdmCl-induced equilibrium 
unfolding experiments have not been reported for hemoglobin.  The C1/2 values recorded 
for the Hb peptides in this work did shift by a measurable amount using reasonable H/D 
exchange times of between 5 and 11 days in the histidine H/D exchange protocol.  
Therefore, it was possible to use the transition midpoint method to evaluate ΔGf and m-
values for this protein (see text).  We also note that if equation (16) is used to evaluate m-
values from the Hb-Hp data sets where collected using H/D exchange times of 5 and 11 
days (i.e., the two data sets for which 2 or 3 data points were actually obtained in the 
transition region), an average m-value of 1.9 kcal/(mol M) can be extracted.  This value is 
within 25% of the average value of 1.5 kcal mol-1 M-1, which can be determined from the 
Hb-Hp m-values obtained by the transition midpoint method (see Table 1).    
2.3.5 Analysis of Proteins in a Yeast Cell Lysate 
In order to investigate the scope of the histidine H/D exchange protocol 
described here, the protocol was applied to the analysis of the proteins in a yeast cell 
lysate. In this analysis a total of 780 unique peptides from 250 different proteins were 
identified in the LC-MS/MS analysis, and 93 of the 780 peptides were histidine-
containing peptides.  It was possible to extract ∆Masswt,av values for 50 of these histidine-
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 containing peptides.  In the case of the other 43 histidine-containing peptides it was 
difficult to extract meaningful ∆Mass values as the ion signals for the isotopologues 
from these peptides were relatively low and/or not well-resolved from other peptides in 
the mass spectral analyses.  
Out of the 50 histidine-containing peptides that were successfully analyzed, 10 
histidine-containing peptides from 6 different proteins had ∆Masswt,av values with a 
denaturant dependence. The C1/2 values of the peptides ranged from 0.5 to 1.5 M (see 
Table 3). The results obtained on the four histidine-containing peptides from 3-phospho-
glycerate kinase (3PGK) are noteworthy. The three histidine-containing peptides that 
came from the N-terminal domain of the protein all had a C1/2 value of 1.5 M (see Table 
3); and the one histidine-containing peptide that came from the C-terminal domain of 
the protein had a C1/2 value of 0.5 M (see Table 3). This is in good agreement with the 
results of previous protein folding studies on 3PGK that revealed this protein has two 
different functional domains that fold independently from each other [45]. 
Table 3: Summary of proteins and peptides that yielded denaturant-dependent 
histidine H/D exchange behavior 
Protein 
Peptide (amino acid #) 
Transition Midpoint 
C1/2 (M) 
3-phosphoglycerate kinase  
AHSSMVGFDLPQR (170 - 182)  1.5 
FRHELSSLADVYINDAFGTAHR (148 -169) 1.5 
HELSSLADVYINDAFGTAHR  (149-169) 1.5 
IAGVVYHPSNNELVR (78 - 92) 1.5 
ISHVSTGGGASLELLEGK (387 - 404) 0.5 
Theoredoxin peroxidase  
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 HITINDLPVGR (137-147) 1.0 
Superoxide Dismutase I  
SVVIHAGQDDLGKGDTEESLK (117-137) 1.3 
Enolase II  
NVPLYQHLADLSK (127-139) 1.0 
Glyceraldehyde-3-phosphate dehydrogenase  
VINDAFGIEEGLMTTVHSLTATQK (161-184) 1.5 
unnamed product gi3724  
VINDAFGIEEGLMTTVHSMTATQK (161-184) 1.0 
 
Superoxide Dismutase 1 (SOD-1) was one of the proteins that yielded a histidine-
containing peptide with denaturant dependent ∆Masswt,av values in the yeast cell lysate 
analysis (see Table 3). SOD-1 is a Cu-Zn binding protein. Cu2+ is known to strongly affect 
the stability of protein in vivo but much less is known about the importance of Zn2+ on 
protein stability in vivo [46]. It is noteworthy that the ∆Mass versus [GdmCl] plots 
generated here for SOD-1 yielded a C1/2 value similar to that previously reported for the 
apo form of the protein using a spectroscopic readout [47]. As part of this work we 
investigated the impact of increasing the Zn2+ concentration on the stability of this 
protein in the context of the whole cell lysate. The results show a C1/2 value shift of 
approximately 0.4 M GdmCl (Figure 9) indicating the SOD-1 was stabilized in the 
presence of the Zn metal ion in this “ex vivo” experiment. In this case the calculation of a 
Kd value is not possible because a slow histidine H/D analysis of the apo form was not 
obtained (i.e., the endogenous levels of zinc that were present in the initial cell lysate 
sample was not known).  Nonetheless, our results on SOD can be used to qualitatively 
identify SOD-1 as a Zn-binding protein. 
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Figure 9: Representative Histidine H/D exchange data obtained from a His-120 
containing peptide of superoxide dismutase 1 (SOD-1) in the presence (● and solid 
line) and absence (○ and dotted line) of added Zn2+. 
The 40 histidine-containing peptides that did not show a denaturant dependence 
to their histidine H/D exchange behavior (see Appendix A) were assumed to be from 
regions of protein structure that were not globally protected.  X-ray crystallographic 
structures have been solved for 22 of the 40 peptides in Appendix A. A visual inspection 
of the structures revealed that indeed 16 of these histidine-containing peptides are from 
solvent exposed regions of protein structure.  In the case of 4 peptides, the amino acid 
sequence region from which they were derived was not included in the solved structure.  
Only one peptide that did not show a denaturant dependence to its histidine H/D 
exchange behavior appeared to be from a protected region of structure.  However, it is 
interesting that this peptide from mitochondrial NAD+-dependent isocitrate 
dehydrogenase was at a subunit interface in the crystal structure.  It is possible that the 
subunits of this protein may not have been assembled at the protein concentrations used 
in our experiment.   
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 2.4 Conclusions 
The slow histidine H/D exchange protocol outlined here is complementary to 
other chemical modification and mass spectrometry-based protocols that have been 
recently described for use in LC-MS/MS based bottom-up proteomics platforms [38, 48] as 
it provides a new amino acid probe for characterizing the global and subglobal 
unfolding reactions of proteins and protein-ligand complexes in these experiments.  
While the results of our cell lysate analysis suggest that a large fraction of the histidine 
residues in proteins are solvent exposed and not useful for the described protocol, it is 
noteworthy that many metalloproteins [49] (such as the myoglobin, BCA II, Hb, and SOD-
1 proteins analyzed in this work) do indeed have buried histidine residues that are 
useful for the described protocol. This is because histidine is a common metal ligand in 
proteins. Thus, the described methodology is likely to be broadly useful for the analysis 
of ligand binding interactions involving metalloproteins and enzymes.  
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 3. Application of iTRAQ-SPROX protocol to diseased 
state analysis in Non-Small Cell Lung Cancer  
Described in this Chapter is the application of the current iTRAQ-SPROX 
protocol to the analysis of diseased state in Non-Small Cell Lung cancer. In this study, 
an iTRAQ-SPROX analysis is performed to compare the thermodynamic stability profile 
of proteins from a Cyclophilin-A overexpressing lung cancer cell line (ADLC-5M2) and 
proteins from a Cyclophilin-A knockdown lung cancer cell line (ADLC-5M2-C2). 
3.1 Introduction 
3.1.1 Cyclophilin A and Lung cancer 
Lung cancer is one of the leading causes of cancer death in the US [32]. Despite a 
lot of efforts in finding biomarkers to lung cancer in particular and to cancer in general, 
most of the current biomarkers are not predictive [50]. There are a number of cases when 
biomarkers are just detected at advanced stage [32, 50] and no longer useful to prevent the 
onset of the disease. Therefore, it is always necessary to discover multiple biomarkers or 
even a system of biomarkers for more accurate diagnosis and stratification of diseases. A 
high-throughput approach such as the well-established iTRAQ-SPROX protocol will be 
well-suited for these studies. The ability to measure thermodynamic stability of 
hundreds of proteins in one experiment and to quantify the more functional difference 
between normal vs. diseased state will facilitate the discovery of biomarkers and 
networks of biomarkers for not only diagnostic but also therapeutic purposes.  
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 The iTRAQ-SPROX protocol is applied for the analysis of two different Lung 
Cancer Cell lines, one of which has Cyclophilin A overexpressed (ADLC-5M2) and the 
other has Cyclophilin A knockdown (ADLC-5M2-C2). Cyclophilin A (Cyp-A) is a 
protein that has been reported to be up-regulated in many different types of cancer such 
as non-small cell lung cancer [51], breast cancer, pancreatic cancer, colorectal cancer, etc. 
[52]. However, role of Cyclophilin A cancer is still unclear [52]. To a rough estimation, a 
Cyp-A overexpressed (Cyp-A (+)) and Cyp-A knockdown (Cyp-A (-)) cell line will 
resemble the diseased vs. the normal state in which Cyp-A (+) represents the diseased 
state and Cyp-A (-) represents the normal one. The use of Cyp-A knockdown is more 
convenient than the use of primary lung cell line for couple reasons. Firstly, this 
experiment ensures that the majority of the thermodynamic stability difference between 
the “diseased” and “normal” state will come from the change in Cyp-A expression level. 
Secondly, the knockdown cell line Cyp-A (-) is also a cancer cell line that doubles almost 
infinitely as opposed to only 50±10 populations in the primary lung cell line WI-38. This 
is convenient for the purpose of this preliminary study because of the unlimited 
resource of biological samples for replicates. A longer term goal of this work is to apply 
the methodology to more clinical related samples when the protocol is optimized.   
3.1.2 The iTRAQ-SPROX protocol 
The Isobaric mass tagging in combination with SPROX protocol (see 
Introduction) has proved to be amenable to large scale analysis of thermodynamic 
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 stability and protein-ligand binding interactions [35]. In a recent study combining SPROX 
with TMT (Tandem Mass Tag, Thermoscientific), SPROX was able to simultaneously 
assay 327 proteins in a yeast cell lysate for binding to an immunosuppressive drug 
Cyclosporine A (CsA) [35a]. This study identified a total of 10 protein targets of CsA 
including both direct and presumably indirect interaction. A known direct interaction 
was Cyclophilin A, a specific protein target of CsA with previously determined Kd value 
of 70nM; the known indirect interaction detected was between CsA and UDP-glucose-4-
epimerase. An improvement of the large-scale SPROX methodology by implementing 
iTRAQ (isobaric Tag for Relative and Absolute Quantitation) and a Methionine 
enrichment step was recently reported [35b, c]. This protocol involved the use of a 
commercially available resin to chemo-selectively isolate the un-oxidized methionine 
containing peptides in the large-scale SPROX experiment. The protocol was applied to 
evaluate the interactions of proteins from a yeast cell lysate with a well-known enzyme 
cofactor β-nicotinamide adenine nucleotide (NAD+) and a less well-understood 
biologically active ligand, Resveratrol. A total of 232 peptides corresponding to 122 
proteins were effectively assayed in the NAD+ binding study and 410 peptides 
corresponding to 243 proteins were assayed in the Resveratrol binding study. The 
implementation of a chemo-selection step for Methionine peptides increased the peptide 
and protein coverage by 1.5 and 2 fold respectively. Also reported in these studies was 
an estimate of the false positive rate, which was determined to be on the order of 2-4%. 
63 
 For this is a rather well-established protocol for thermodynamic stability profiling of 
large protein mixture, the iTRAQ-SPROX protocol was employed for the study of Cyp-A 
(+) versus Cyp-A (-) reported here. 
The underlying hypothesis in conducting this study is that the proteome from 
diseased cells have different thermodynamic stability profiles compared to those of the 
proteins in normal cells. This altered thermodynamic stability can be the result of any 
one of many factors including, for example: (i) a change in protein expression level; (ii) a 
change in protein-protein or protein-ligand interactions; or (iii) a change in 
posttranslational modifications (i.e. phosphorylation, glycosylation, etc.). The main 
difference between the Cyp-A (+) and Cyp-A (-) cell lines used in this study was the 
expression level of Cyp-A. Overexpression of Cyp-A can introduce changes in protein 
thermodynamic stability resembling the diseased state, e.g. (i) a change in expression 
levels of other proteins that are genetically regulated by the abundance of Cyp-A (ii) a 
change in protein-protein interactions between other proteins and Cyp-A or (iii) a 
change in posttranslational modifications resulting from downstream effect of Cyp-A 
overexpression. This study is expected to produce a better molecular level 
understanding of the functional consequences of Cyp-A overexpression in lung cancer.  
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 3.2 Experimental Procedures 
3.2.1 Cell line maintenance 
The ADLC 5M2 parental cell line and 5M2-C2 Cyp-A knockdown cell line were 
originally generated by Howard and coworkers in the laboratory of Dr Edward F. Patz 
Jr and were given as a kind gift [53]. Both cell lines were maintained in R10+ media that 
contains the following: RPMI-1640, 10% FBS, 1mM Na-pyruvate, 10mM HEPES, 0.25 
(w/v) glucose and 100 Units/mL penicillin and 100 µg/mL streptomycin in a total of 500 
mL. The cells in a frozen stock of ADLC 5M2 and ADLC 5M2-C2 were separately 
inoculated into pre-warmed 10 mL of R10+ media and subsequently passaged to the T-
150 flask and grown to almost 100% confluency. Cells were harvested with HQTase, 
centrifuged at 1,000xg for 10 min at 4oC before being washed with PBS buffer and kept 
frozen at -20oC until subsequent SPROX analysis.  
3.2.2 Western Blot 
1 pellet of each cell line was obtained and 500 µL of Lysis buffer (20 mM pH 7.4 
and 1 X Halt inhibitor cocktail) was added to each pellet. The cells were lysed by 10 
cycles of disruption with 1 mm glass silicon beads (biospec) for 20 sec and incubation on 
ice for 1 min. Protein concentrations were measured by Bradford assay to be 13.2 mg/mL 
for ADLC 5M2-C2 and 12.8 mg/mL for ADLC 5M2. The lysates were kept at -20oC 
overnight before subject to gel electrophoresis. A 5 µL of undiluted Lysate was 
combined with 95 µL of Sample buffer. Sample buffer contains 1X NuPAGE sample 
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 buffer, 50mM DTT and H2O. The lysate was subsequently diluted 2, 4 and 8 fold and a 
20µL was loaded to the NuPAGE precast polyacrylamide gel for 1-D SDS PAGE. The 
loading order (from right in Figure 10) was as followed: 8 fold diluted 5M2-C2, 8 fold 
diluted 5M2, 4 fold diluted 5M2-C2, 4 fold diluted 5M2, 2 fold diluted 5M2-C2, 2 fold 
diluted 5M2, 1X 5M2-C2 lysate, 1X 5M2 lysate, positive control (5 ng Cyp-A), blank and 
Marker. The gel was allowed to run for 30 min at 200 V. Proteins were transferred to 
PVDG membrane for an hour. Resulting transferred proteins were confirmed with 
Ponceau Dye, wet with Methanol, washed with diH2O and blocked with 5% milk/PBST 
(1X PBS, Tween-20 and H2O). The protein blot was incubated with 1st Antibody (rabbit 
anti-Cyp-A igG) with 1:1000 fold dilutions to 5% milk/PBST for approximately 1 hr. The 
protein blot was rinsed with twice PBST before binding to the 2nd Antibody; anti-rabbit 
igG (1:10,000 fold dilutions). The protein blot was rinsed twice with PBST again before 
incubation with the West Pico mixture and exposed for 1 sec, 3 sec… 3 min. The result 
shown in figure 10 is from 1 sec exposure. 
3.2.3 SPROX Analysis 
The Cyp-A (+) and Cyp-A (-) lysates were prepared from 2 comparable cell 
pellets each. Each pellet had a number of cells equivalent to a monolayer on 2 T-150 cell 
culture flasks. The pellets were lysed using the procedure reported in Chapter 2-
Histidine HDX. The total protein concentration in each lysate was determined using a 
Bradford assay.  The concentrations were 9 mg/mL and 7.5 mg/mL for the Cyp-A (+) and 
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 Cyp-A (-) lysates respectively. The total protein concentration in each lysate was 
adjusted to 7 mg/mL. 
SPROX analysis was initiated by dilution of 25 µL of each lysate (i.e. Cyp-A (+) 
and Cyp-A (-)) to a series of eight 20 µL aliquots of denaturant containing buffers. Each 
of the two series contained the following GdmCl concentrations: 1.2, 2.5, 3.1, 4.3, 5, 6.2, 
7.1 and 8.3 M. The lysates were allowed to equilibrate in denaturant containing buffers 
for approximately 30 min before oxidation was initiated by adding 5 µL of 30% (w/v) 
H2O2 (approximately 10 M). The final GdmCl concentration at the time of the oxidation 
reaction was: 0.5, 1, 1.3, 1.7, 2.0, 2.5, 2.8, 3.3 M.   
Oxidation reaction was allowed to proceed for 3 min, which is 3 half-lives of the 
oxidation reaction for an un-protected methionine residue, before the reaction was 
quenched with 1 mL of saturated solution of L-Methionine (300 mM). An aliquot of 
100% (w/v) TCA solution was added to each SPROX sample to a final concentration of 
10% and incubated overnight to precipitate proteins. The resulting protein pellets were 
washed with 300 µL Ethanol three times and digested with trypsin; resulting peptide 
digest were labeled with iTRAQ reagent according to protocol that has been reported 
elsewhere[35c].  
3.2.4 Methionine Enrichment 
An 80 µL aliquots of each iTRAQ labeled samples was subject to a Methionine 
Enrichment step using Pi3-Methionine Resin according to the reported protocol [35c] with 
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 the following exceptions (i) the 80 µL samples were speed-vac down to approximately 
30 µL and diluted with 60 µL of Acetic Acid (ii) the peptide solution was incubated with 
the methionine capturing resin for 2.5 hours instead of 1.5 hours.  
3.2.5 LC-MS/MS Analysis and Data Analysis 
A 50 µL aliquot of each iTRAQ labeled sample was combined resulting in 
approximately 400 µL. A 100 µL aliquot of this combined sample was subject to a C18 
desalting step, the desalted peptides were eluted to a total of 150 µL of 70% Acetonitrile. 
These desalted peptide solutions were speed-vac down to dryness, brought back to 10 
µL of 100% acetonitrile and diluted with 240 µL of buffer A. A 40 µL aliquot was subject 
to LC MS/MS analysis on the Agilent QTOF in a similar manner to the previously 
reported protocol[35c]. A total of 5 LC MS/MS runs were performed for each sample. The 
Data Analysis is performed in similar manner to previously reported protocol with the 
following exception: the matched peptides are directly visually inspected for C1/2 shift 
instead of subjecting to difference analysis.         
3.3 Results and Discussion 
3.3.1 Western Blot data confirms Cyp-A knockdown 
Three replicate Western Blot experiments were performed to confirm 
knockdown of Cyp-A in the Cyp-A (-) cell line. Presented in Figure 10 is representative 
the Western Blot result from the third replicate. The result shows an approximate 3 fold 
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 decrease of the expression level of Cyp-A in Cyp-A (-) with respect to Cyp-A level in 
Cyp-A (+) cell line.  
 
Figure 10: Representative Western Blot Result of proteins from Cyp-A parental 
(+) and Cyp-A knockdown (-) cell line. Upper panel is an image of the ponceau 
stained PVDG blot preceding tranfering showing decreasing total protein amount 
loaded on to each lane. Lower panel is the western blot result showing decreased 
expression level of Cyp-A in the knockdown Cyp-A (-) cell line. 
3.3.2 General Strategy 
The iTRAQ-SPROX protocol used in this study is shown in Figure 11. Initially, equal 
amounts of proteins from Cyp-A (+) and Cyp-A (-) cell lysate were subject to 
simultaneous SPROX analyses as reported elsewhere [35b, c]. Once the oxidation reaction 
was quenched, the resulting proteins in each SPROX sample were subject to TCA 
precipitation, re-dissolvation, reduction, alkylation and protease digestion. The resulting 
peptide digests were labeled with each of the iTRAQ 8-plex reagents in such a way that 
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 the lowest denaturant concentration corresponded to the lowest isobaric tag (113) and 
the highest denaturant concentration corresponded to highest isobaric tag (121). After 
labeling with isobaric mass tags, the peptide samples were combined into a single 
sample, resulting in one sample from the Cyp-A (+) and one sample from the Cyp-A (-) 
cell lines. 
 
Figure 11: General strategy for the iTRAQ-SPROX protocol 
Once combined, the peptide solutions were subject to LC MS/MS analyses either 
directly or after a Methionine enrichment step. The role of the methionine enrichment 
step is to chemically select the un-oxidized methionine- allowing the oxidized 
methionine- and non-methionine- containing peptides to flow through. The data 
obtained on the direct submission of iTRAQ labeled samples (i.e. without methionine 
enrichment) is called the control data set. This data contained identification and 
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 quantitation information for (i) non-methionine- (ii) oxidized methionine- and (iii) un-
oxidized methionine- containing peptides. The data obtained on the non-methionine- 
containing peptides are expected to be unaltered by the oxidation reaction and/or 
denaturant concentration. Therefore any changes observed for the non-methionine- 
containing peptides can be results from experimental errors (i.e. random iTRAQ 
quantitation error, differential precipitation and re-dissolvation in the TCA precipitation 
step, mixing error, etc.). As a result the data from the non-methionine containing 
peptides in the “control” runs can be used to generate “normalization factors” to correct 
for the experimental errors may be introduced to sample preparation steps. After 
applying normalization on methionine- containing peptides from both the control and 
the methionine- enrichment runs, the peptides from the Cyp-A (+) samples are matched 
against the Cyp-A (-) samples. The iTRAQ-SPROX data obtained on common peptides 
in the Cyp-A (+) and Cyp-A (-) samples are compared and peptides with significant C1/2 
shift (i.e. ≥0.5 M GdmCl) are identified as hits (See Data Analysis section and 
reference[35c]). 
3.3.3 Proteomic Coverage 
Presented in Table 4 is a summary of the proteomic coverage for this iTRAQ-
SPROX experiment. The results are typical of those generated in shotgun proteomics 
experiments conducted on the Agilent QTOF platform used in this work. The number of 
methionine containing peptides in the control runs represents 20% of the total peptide 
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 identifications (IDs) and approximately 30% of the total protein IDs. Successful 
methionine enrichment added an extra 186 methionine-containing peptides and 82 
methionine-containing proteins to the analysis of the Cyp-A (-) samples corresponding 
to a 3-fold increase in the number of peptides and 2-fold increase in the number of 
proteins observed. Methionine enrichment of the Cyp-A (+) samples on the other hand 
only added an extra 86 peptides (1.5 fold the number of peptides) and 3 extra proteins to 
the analysis.  A total of 282 peptides (164 proteins) from the Cyp-A (-) and 216 peptides 
(114 proteins) from the Cyp-A (+) samples were matched, and the resulting 120 matched 
peptides (57 proteins) were further analyzed for C1/2 shift greater than or equal to 0.5 M 
GdmCl.   
Table 4: Proteomic coverage of the iTRAQ-SPROX Cyp-A (+) vs Cyp-A (-) 
experiment 
Runs Criteria  CypA (-) CypA (+) 
Control (5 
runs) 
Peptide identifications 1329 1669 
Unique Peptide IDs 
(proteins) 
464 (304) 543 (345) 
Unique Met-Peptides 
(proteins) 
96 (82) (67 oxidized) 130 (111) (99 oxidized) 
Met- 
enrichment 
runs 
Peptide identifications 385 437 
Unique Peptide IDs 
(proteins) 
148 (96) 157 (108) 
Unique oxidized-Met- 
peptides (proteins) 
29 (21) 32(22) 
Matched peptides (proteins) 120 (57) 
 
The methionine-enrichment results from the Cyp-A (-) samples are comparable 
to that of the recently reported NAD+ binding study[35b]. Due to less successful 
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 methionine enrichment in the Cyp-A (+) samples, the amount of matched peptides (and 
proteins) are half as much of the NAD+ binding study. Nevertheless, this result is 
comparable to that of previously reported iTRAQ-SPROX data sets and considered fairly 
standard outcome.   
3.3.4 iTRAQ-SPROX Analysis 
Experimental errors that can arise from (i) iTRAQ reporter ion intensity 
difference from peptides to peptides and (ii) different iTRAQ reporter ion intensity of 1 
peptide from tags to tags.  Therefore, two normalization steps were performed on the 
each raw iTRAQ reporter ion intensities of a peptide. The first normalization (N1 
normalization) takes into account the difference in iTRAQ reporter ion intensity from 
tags to tags. That is, all intensity across different reporter ions (i.e. iTRAQ tags) was 
averaged for 1 particular peptide sequence. This averaged intensity is then used to 
normalize all intensity from each tag (i.e. by dividing the raw intensity from each tag by 
the averaged intensity). This N1 normalization accounts for the random error of the 
iTRAQ reporter ion intensities (from tags to tags). The second normalization factor (N2 
normalization factor) was determined by averaging all intensity of different peptides 
from the same tag (from peptides to peptides). For instance, each peptide sequence 
contains a specific 113 reporter ion intensity. The averaged value of all N1 normalized 
113 reporter ion intensities of all peptides will give the N2 normalization factor for the 
113 tag. The variation of the N1 normalized 113 reporter ion intensities is considered the 
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 variation of the iTRAQ quantitation in this experiment. This normalization step accounts 
for systematic difference of the total peptides amount generated from each SPROX 
samples (i.e. each denaturant concentration). This difference can arise from TCA 
precipitation, protease digestion and iTRAQ labeling. The N2 normalization factor is 
summarized in Table 5.  
Table 5: Normalization factors of the 8 iTRAQ reporter ions in the iTRAQ-
SPROX experiment 
 113 114 115 116 117 118 119 121 
N2 
Factor 
0.96 0.88 0.89 1.09 1.05 0.997 0.99 1.03 
STDEV 0.47 0.37 0.36 0.41 0.38 0.40 0.397 0.43 
 
As can be seen from table 5, most of the averaged values of the N1 normalized 
reporter ion intensities (i.e. the N2 normalization factors) centered around 1 representing 
reproducible sample preparation from samples to samples (i.e. different denaturant 
concentrations). The standard deviations are relatively similar with range from 36 to 
47%, which also represents typical iTRAQ quantitation error in the iTRAQ-SPROX 
analysis on the Agilent QTOF platform. The N2 normalization factors and standard 
deviations are not affected by the identification scores, therefore were used to generate 
N2 normalized iTRAQ intensities for subsequent data analysis. 
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Figure 12: Distribution of the iTRAQ intensities of the 113 and 121 reporter 
ions for un-oxidized methionine containing peptides from Cyp-A (+) on left and Cyp-
A (-) samples on right. Black arrows indicate intersection of the 2 distributions (113 vs. 
121). Distribution of the 114 and 119 tags are also included for comparison. 
Presented in Figure 12 is the distribution of iTRAQ intensities for all the un-
oxidized methionine containing peptides for the lowest isobaric tag (113) and highest 
isobaric tag (121) representing the lowest and the highest denaturant concentration, 
respectively. In the SPROX experiment, most proteins remain folded at low denaturant 
concentration protecting the buried methionine residues from being oxidized by H2O2. 
Increasing denaturant concentration increases the unfolded protein population hence 
increasing extent of oxidation at the globally protected methionine residues. Therefore 
the un-oxidized methionine containing peptides will appear predominantly at low 
denaturant concentration, i.e. the 113 tag will have higher normalized iTRAQ intensity 
and the 121 tag will have lower normalized iTRAQ intensity. This is indeed the case for 
un-oxidized methionine containing peptides from both Cyp-A (-) and Cyp-A (+) 
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 samples. The intensities of the 113 tag distribution centered around 0.4 and the 
intensities of the 121 tag distribution centered around 1.8-2.2. The intersection of the 2 
distributions (i.e. 113 tag intensity and 121 tag intensity) is considered the averaged 
transition midpoint and is utilized herein as a “cut-off” line between the pre- and post- 
transition baseline. That is, the iTRAQ intensity above this line (of 1) is considered “pre-
transition” and below this line is considered “post-transition”. Any iTRAQ intensity 
within 10% of the transition baseline is considered “at the transition mid-point” and the 
corresponding denaturant concentration is defined as the C1/2 value.  Using these 
criteria, a total of 6 of hit proteins were identified with altered thermodynamic stability 
in the presence and absence of Cyp-A overexpression (see below). 
3.4 Hit Proteins Identified 
Table 6: Protein hits that show changes in thermodynamic stability in the 
presence and absence of Cyp-A overexpression. 
Protein Peptide ΔC
1/2 (M) 
Fructose-bisphosphate Aldolase A isoform-1 (K)FSHEEIAMATVTALR(R) 0.8 
Phosphoglycerate kinase-1 (K)ALMDEVVK(A) -0.7 
Alpha-Enolase isoform-1 (K)LMIEM(ox)DGTENK(S) 0.7 
Argininosuccinate synthase (R)MPEFYNR(F) 0.6 
Beta-tubulin (K)MAVTFIGNSTAIQELFK(R) 0.9 
Eukaryotic Translation Initiation Factor 5A-2 (K)IVEMSTSK(T) 0.5 
 
Summarized in Table 6 are the proteins (and peptide) hits identified in this 
iTRAQ-SPROX experiment and their corresponding C1/2 shifts (all are significant shifts ≥ 
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 0.5 M GdmCl). Interestingly, β-tubulin was identified to be overexpressed in non-small 
cell lung cancer by Okuzawa and coworkers using 2-Dimensional gel electrophoresis 
and nonenzymatic sample preparation[54]. Chen and coworkers also reported the 
overexpression of eIF-5A in lung cancer using 2-DE analysis with identification using 
mass spectrometry and 2-Dimensional Immunoblots [55]. Both of these proteins are 
stabilized by overexpression of Cyp-A in the parental cell lines ADLC-5M2 suggesting 
possible interactions of these proteins with Cyp-A in the development of lung cancer. 
Presented in Figure 13 is representative iTRAQ-SPROX data from β-tubulin and 
Eukaryotic Translation Initiation Factor 5A-2.  
It is important to note that the false discovery rate of a typical iTRAQ-SPROX 
experiment can be as high as 5%[35b] which make the possible number of falsely 
identified peptide hits in this assay to be ~6 (i.e,5% of 120 times), which is equivalent to 
the to the number of hits identified. Also, it can be seen from Table 6 that all proteins are 
identified with 1 peptide hit.  Thus, it is possible that these peptide hits are falsely 
discovered, and they do not have any biological significance. However, based on the 
results of previous biomarker studies in lung cancer, there may be some real biological 
significance to at least some of these hits.     
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Figure 13: Representative iTRAQ-SPROX results from β-tubulin (A) and iEF5A 
(B). Bar graphs on the left represent peptides generated in Cyp-A(+) sample and bar 
graphs on the right represent peptides generated in Cyp-A (-) sample. Black arrow 
indicates estimated C1/2 value and dotted line represents the “cut-off” line (see text) 
3.5 Conclusions 
The iTRAQ-SPROX protocol presented here has been applied to the 
thermodynamic stability differentiation analyses of the proteins from a Cyp-A 
overexpressing lung cancer cell line versus proteins from a Cyp-A knockdown lung 
cancer cell line. The protocol has assayed a total of 57 proteins and identified 6 potential 
protein hits whose thermodynamic stability changes in the presence and absence of 
Cyp-A overexpression; two of which are known lung cancer biomarker discovered in 
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 previous proteomics studies (i.e. β-tubulin and eIF5A). More biological replicates are 
needed to confirm the reproducibility of these potential hits. The current iTRAQ-SPROX 
protocol utilized here is amenable to this type diseased state of analyses, however the 
proteome coverage is largely limited to the identified and quantified methionine 
containing peptides in the bottom-up proteomics readout. To obtain more 
comprehensive analyses in the human proteome such that in the Lung cancer cell lines, 
proteomics coverage of this experiment needs to be improved. 
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 4. Development of a SILAC-SPROX protocol and 
application to ATP binding discovery 
4.1 Introduction 
4.1.1 Motivation 
As described in previous chapter, current iTRAQ-SPROX methodology has 
several drawbacks. One drawback is that in the iTRAQ-SPROX protocol (see Figure 11), 
the (+) and (-) ligand samples at different denaturant concentrations are prepared 
separately and are not labeled with iTRAQ reagents until the end of the protocol. This 
means that technical errors associated with various sample handling steps, e.g. TCA 
precipitation, re-dissolvation and protease digestion, can arise. The inherent technical 
error associated with iTRAQ quantitation (i.e., the error associated with the LC MS/MS 
readout) is approximately ± 10%[56]. However, due to the aforementioned issues related 
to sample handling in the SPROX experiment; the variation in iTRAQ-SPROX 
experiments can reach 30-40%. This error is acceptable for measurement of large changes 
in iTRAQ intensities. However, a typical iTRAQ-SPROX curve has relatively few points 
(i.e., 8 points) and relatively small amplitude (~1 normalized iTRAQ intensity unit). This 
ultimately makes the C1/2 assignment challenging.    
Another drawback is that iTRAQ quantitation is based on the data collected in 
product ion mass spectra, in which complications can arise from the analysis of chimeric 
peptides in which two precursor ions with similar m/z are simultaneously subject to CID 
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 and sequenced. This has been demonstrated to be a significant source of error in the 
isobaric mass tag quantitation strategy[57].  
A third and major drawback to the iTRAQ-SPROX methodology developed to 
date is that it requires the detection and quantitation of methionine-containing peptides 
to report on the thermodynamic stability of the proteins to which they map.  While the 
frequency of methionine residues in proteins is relatively low (~2.5%), the large majority 
of proteins have at least 1 methionine[58]. Thus, the scope of SPROX is not fundamentally 
limited by the relatively low frequency of methionine residues in proteins.  Rather, the 
protein coverage in proteome-wide SPROX experiments is limited by the practical 
considerations associated with the comprehensive detection of methionine-containing 
peptides in the bottom-up shotgun proteomics experiment. In the iTRAQ-SPROX 
experiment quantitative data is only generated in product ion mass spectra.  Therefore, 
if a methionine containing peptide is not selected for fragmentation (i.e., a product ion 
mass spectra is not collected), the quantitation information for that peptide will be 
missing.  
The stable isotope labeling with amino acids in cell culture (SILAC) approach has 
been widely used in mass spectrometry-based proteomic studies of gene expression 
levels[19].  Proteome-based expression profiling studies using SILAC and other 
quantitative proteomics technologies are now commonly used to characterize drug-
mode-of-action and to understand the basic physiological processes and biological 
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 pathways involved with aging and disease[26].  The use of SILAC quantitation in SPROX 
experiments has the potential to overcome some of the drawbacks of iTRAQ 
quantitation described above.  
Firstly, the (+) and (-) ligand samples are labeled by amino acid in cell culture at 
the protein level allowing combining the (+) and (-) ligand samples with matching 
denaturant concentration right after the SPROX reaction and before proteomics sample 
preparation. Ultimately, the ratio between (+) and (-) ligand samples are measured 
within each denaturant concentration, allowing direct comparison of the extent of 
oxidation of proteins in presence and absence of ligand. This means that the (+) and (-) 
ligand samples are prepared simultaneously for each denaturant concentration, 
reducing errors from sample handling steps. Secondly, SILAC quantitation relies on 
data collected in the first stage of mass spectrometry in LC MS/MS experiments, so, the 
problem with chimeric peptides in product ion mass spectra (i.e., the second stage of 
mass spectrometry in the LC-MS/MS experiment) should only affect identification but 
not quantitation of a certain peptide. A third advantage of SILAC-SPROX experiments is 
that since SILAC is based on MS1 quantitation, a methionine containing peptide must 
only be identified in at least on LC-MS/MS analysis for successful analysis. For 
methionine peptides that ionize but are not actually selected for sequencing in all 
samples, the identification can be translated based on m/z and retention time from 
previous LC MS/MS analysis. This allows measurement of (+) to (-) ligand ratio even 
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 when the peptide is not actually sequenced. Lastly, a major advantage of the SILAC-
SPROX protocol is that it can be used in combination with a cyanogen bromide cleavage 
reaction and gel-based fractionation protocol to significantly expand the scope of SPROX 
experiments, as described in Chapter 5.  
4.1.2 Discovery of ATP-binding proteins 
To access the validity, scope and sensitivity of the SILAC-SPROX protocol 
described in this chapter, an ATP-binding experiment was performed using proteins 
from a yeast cell lysate. ATP (Adenosine-5’-triphosphate) is a common enzyme cofactor 
that binds to a variety of different protein classes with a wide range of binding affinities. 
However little is known about binding properties of ATP to proteins in large scale. Two 
large scale analyses of ATP-binding have been reported, to date. One ATP-binding 
study involved the use of an energetics based approached called “pulse proteolysis” to 
detect ATP-binding in proteins from an E. coli cell lysate [21a, b]. The other involved the 
use of an active site reactive immobilized ATP probe (desthiobiotin-conjugated ATP) 
and affinity pull-down strategy to identify ATP-binding in proteins from a 
Mycobacterium tuberculosis cell lysate [59].  
In the pulsed-proteolysis study, two main strategies were employed to 
fractionate and simplify the E. coli proteome. The first strategy, which involved the use 
of 2-D SDS-PAGE, claimed to observe approximately 500 proteins and identified 10 
ATP-binding targets [21a]. 7 out of 10 ATP binding hits found in this experiment were 
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 previously annotated with ATP-binding GO-term (GO:0005524) from the EcoCyc 
database. The three ATP-binding hits that were not previously annotated with GO-term 
ATP-binding were: dihydrolipoamide dehydrogenase (E3), Glyceraldehyde 3-phosphate 
dehydrogenase A (GAPDH), and periplasmic-binding protein (mlaC). Subsequent 
validating experiments revealed 1 possible false positive hit (mlaC), which brings the 
false positive rate to approximately 10%. The second “simplified” strategy involved up-
front fractionation of the E. coli proteome by ion exchange chromatography and pulse 
proteolysis incorporated with 1-D SDS-PAGE[21b]. In this study, a total of 30 ATP-binding 
hits were identified, 21 of which were known to bind ATP (70%). A total of 6 out of the 9 
remaining proteins (66%) were not known to bind ATP, but do bind ligands that are 
similar to ATP (e.g., the nucleoside (uridine), the nucleotide (GTP), or cofactors with 
adenosine moiety (NAD+ and FAD)). One of the previously unknown ATP binding 
proteins identified in this E. Coli study, phosphoglycerate mutase (PGM), was further 
validated in additional experiments.   
In the Mycobacterium tuberculosis cell lysate study, a total of 176 ATP-binding 
proteins were identified, 122 of which (also approximately 70%) are associated with 13 
protein families that were annotated with the GO-term ATP-binding[59]. The remaining 
54 proteins are presumably proteins that are associated with the ATP-binding hits. 
Interestingly, a GO-term analysis of the 176 proteins identified to bind ATP reveals 
84 
 diverse functions associated with small molecule binding (34%), with transferase activity 
(17%), with oxidoreductase activity (16%), and with DNA binding (9%), etc.  
In both of the above studies, there were no estimations of Kd values. However it 
was noted in the pulse proteolysis study that based on literature search of previously 
determined Kd from 5 known ATP-binding binding proteins, Kd values are from 0.025 
µM to 600 µM. The global analysis of ATP-binding proteins in yeast proteins has not 
been previously reported.  The availability of ATP-binding GO-term and the previous 
analysis of selected ATP-binding proteins in other organisms help validate the results 
reported in this chapter and create a means to evaluate the validity, scope and sensitivity 
of the assay. 
4.2 Experimental Procedures 
4.2.1 Yeast Cell Lysate preparation 
A glycerol stock of the yeast deletion strain BY4739 (Open Biosystems, Lafayette, 
CO), an auxotroph for lysine, was streaked on a petri-dish containing synthetic complete 
(SC) media and 30 mg/mL of Light L-Lysine.   The SC-media was comprised of 1.7 g of 
Yeast Nitrogen Base, 5 g of Ammonium Sulfate, 20 g of Bacto-agar, 2 g Glucose, 1.92 g of 
Synthetic Drop out mix without Lysine (Sunrise Science Product, San Diego, CA). After 
a 3 day incubation at 30oC, one colony was selected and inoculated into 10 mL of SC-
media containing 30 mg/mL of Light L-lysine (Sigma Aldrich) before an overnight 
incubation at 30oC. A 5 µL portion of this cell culture was transferred into 50 mL (or 100 
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 mL) of SC-media containing Light L-lysine (Sigma Aldrich) at a final concentration of 
30mg/mL; while another 5 µL portion of the culture was transferred into 50 mL (or 100 
mL) of SC-media containing same concentration of Heavy Lysine (13C6 15N2.Cl).  The two 
cell culture were incubated at 30oC overnight, and a 5 µL portion of each culture was 
transferred to 50 mL (or 100 mL) of corresponding Light and Heavy media twice before 
they were ultimately transferred to 1 L of the corresponding Light and Heavy media and 
grown overnight at 30oC. Portions of the 1 L overnight culture, 60-80 mL each, were 
centrifuged at 1,000 g at 4 °C for 10 min to generate about 16 cell pellets of the light 
lysine labeled yeast cells and 12 pellets of the heavy lysine labeled yeast cells. 
 The Light and Heavy lysine labeled cell lysates (referred to as Light and Heavy 
lysates) were prepared by combining 400 to 600 µL of lysis buffer to each of cell pellets 
depending on their size in order to have final protein concentration in the range of 10-20 
mg/mL. Lysis buffer was composed of 0.1M Tris•HCl (pH 7.4) and a protease inhibitor 
cocktail containing 1 mM AEBSF, 500 µM Bestatin, 15mM E-64, 20 µM Leupeptin and 10 
µM Pepstatin A.  The cells were lysed by mechanical disruption using a disruptor genie 
(scientific industries) and 400-600 µm diameter glass beads.   A total of 15 cycles 
consisting of mechanical disruption for 30 s and cooling on ice for 1 min were used to 
lyse the cells in each cell pellet. Ultimately, the lysed cells were centrifuged at 14,000 x g 
for 10 min at 4 °C, and the supernatant was collected for use in SILAC-SPROX analyses.  
The concentrations of proteins in the Light and Heavy lysate were determined by 
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 Bradford assay. If the protein concentrations were unequal between the Light and 
Heavy lysate, both protein samples were normalized to the lower concentration before 
proceeding to the SPROX analysis.  
4.2.2 SILAC-SPROX Analysis 
In Solution based experiment 1A/B, 1 volume of 100 mM MgCl2 was added to 8 
volumes of both the Light and Heavy lysate; 1 volume of aqueous 828 mM AMP-PNP 
was subsequently added to the Heavy lysate and 1 volume of Lysis buffer was added to 
the Light lysate in order to generate the (+) and (-) ligand samples (respectively). Both (+) 
and (-) ligand samples (i.e. Heavy and Light lysates) were incubated on ice for 30 
minutes before a 20 µl aliquot of each sample was combined with 75 µl of each 
denaturant-containing buffer stock solution, which was prepared in   0.1 M Tris•HCl 
buffer (pH 7.4) with urea concentrations that ranged from 0 to 8 M. The exact 
concentration of urea in each denaturant-containing stock solution was determined from 
a refractive index measurement of the buffer as described previously [60]. The final urea 
concentration in the 8 denaturant-containing buffers used for these solution based 
SILAC-SPROX experiments were 0, 1, 2, 2.7, 3.3, 4, 4.8, and 6 M.  The samples were 
equilibrated for 30 min in the denaturant containing buffers before initiating the 
methionine oxidation reaction in SPROX, which involved the addition of 5 µl of 9.8 M 
hydrogen peroxide to the protein and protein-ligand samples in each denaturant-
containing buffer. The oxidation reactions were each allowed to proceed for 6 min before 
87 
 they were quenched with 760 µl of a 375 mM solution of L-methionine. The (+) and (-) 
ligand samples (i.e. Heavy and Light lysate) from the same denaturant containing 
buffers were combined and 191 µL of 100% TCA (w/v) was added to each combined 
sample to precipitate the proteins. The samples were incubated overnight at 4°C, and 
centrifuged at 8,000 x g for 30 minutes at 4 °C, the resulting protein pellets were washed 
3 times with 1 mL of Ethanol and 2 times with Acetone and air-dried for 5 min in 
chemical fume hood before subjected to conventional bottom up proteomics in solution.  
The Solution-based ATP-binding experiment 2 was performed as described 
above for experiment 1 with the following exceptions: (i) the initial MgCl2 concentration 
was 1M instead of 100mM, (ii) the (-) and (+) ligand samples were incubated on ice for 1 
hour and in denaturant containing buffers for 1 hour instead of 30 and 30 min 
respectively, (iii) the protein samples were distributed into 10 different denaturant 
containing buffers instead of 8 different buffers with Urea concentration ranged from 0 
to 8M; the final Urea concentration in each buffers was: 0.0, 1.0, 1.5, 2.0, 2.5, 2.8, 3.3, 4, 
4.9, and 6.0 M, and (iv) the oxidation reaction was allowed to proceed for 24 min instead 
of 6 min. 
4.2.3 Proteomics Sample Preparation 
The combined (-) and (+) ligand samples (i.e. Light and Heavy lysates) were 
subjected to a conventional proteomic analysis.  In this proteomic analysis the dried 
pellets were re-dissolved in 60 µL of 0.1M Tris buffer, pH 8.0, containing 8 M urea; 
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 heated at 37 oC for 5 min; vortexed for 10 min; and heated again at 37 oC for 5 min. A 6 
µL aliquot of 50 mM TCEP●HCl and 3 µL aliquot of 2% SDS solution were added to 
each re-dissolved pellet and the samples were incubated for 1 hr. at 37 oC before 6 µL of 
a 100 mM solution of MMTS was added to each protein sample.  After 10 minute 
incubation at room temperature, approximately 99 µL of Tris buffer (pH 8.0) containing 
4 µg of Lys-C was added to each sample and the proteins were digested overnight at 37 
oC. Each sample was centrifuged at 15,000 g for 5 min to precipitate undigested protein. 
The supernatant from the protein digest was desalted with C18 resin and ultimately 
eluted in 150 µL of 70% Acetonitrile in 0.1% Formic Acid. A 50 µL aliquot of each 
peptide solution was dried in a speed-vac (accounted for 1/3 of the cleaned samples), re-
dissolved in 50 µL of Buffer A (0.1% Formic acid) and approximately 2 µL of each 
sample, which contained an estimated 2 µg of peptide, was subjected to LC-MS/MS 
analyses. 
4.2.4 LC MS/MS Analyses 
LC-MS/MS analyses were performed using an LTQ Orbitrap XL mass 
spectrometer (Thermo-Scientific, Inc.). The LC system was configured in a vented 
format[61] and consisted of a fused-silica nanospray needle packed in-house with Magic 
C18 AQ 100A reverse-phase media (Michrom Bioresources Inc.) (25cm) and a trapping 
column containing Magic C18 AQ 200A reverse-phase media (2cm). The peptide 
samples were loaded onto the column and chromatographic separation was performed 
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 using a two-mobile-phase solvent system consisting of 0.1% formic acid in water (A) and 
0.1% acetic acid in acetonitrile (B). The mass spectrometer operated in a data-dependent 
MS/MS mode over the m/z range of 400-1800.  For each cycle, the five most abundant 
ions from each MS scan were selected for MS/MS analysis using 35% normalized 
collision energy.  Selected ions were dynamically excluded for 45 seconds.   
 Raw MS/MS data were submitted to the Maxquant data analysis platform[62] and 
searched using the Yeast Proteome Database downloaded on 01/09/2013 from 
ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/proteomes/. 
The following modifications were considered: methyl methanethiosulfonate (MMTS) at 
cysteine as a fixed modification; SILAC labeling of lysine (+8), and oxidation of 
methionine and deamidation of asparagine and glutamine (N and Q). The enzyme was 
set to Lys-C, and up to 2 missed cleavages were permitted. The false discovery rate was 
set to 1%. Ultimately, the search output containing the modified peptide sequence, 
protein name, normalized H/L ratios, score, retention time and raw file name was 
exported to Excel for further data analysis. 
4.2.5 Data Analysis 
The protein and peptide identifications obtained from the LC-MS/MS data 
searches were filtered to contain only H/L ratios ≥ 0. In cases where multiple H/L ratios 
were obtained for a given peptide sequence and charge state at a specific denaturant 
concentration (e.g., both the Light and Heavy version of a peptide and charge state were 
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 identified in the LC-MS/MS analysis; and/or a given peptide sequence with a particular 
charge state was identified in multiple scans); the multiple H/L ratios were averaged to 
give a single L/H ratio for the peptide with a particular charge state at that specific 
denaturant concentration. Ultimately, these average H/L ratios were used to generate 
SILAC-SPROX data sets. Depending on the quality of the data (i.e. the reproducibility of 
LC-MS/MS runs) and the number of samples with different denaturant containing 
buffers, a threshold of 4-8 times was used to filter for peptides that appear reproducibly 
across different denaturant concentration. For instance, the data in the Solution-based 
ATP-binding experiment 1A was obtained on the Agilent QTOF instrument was filtered 
to contain peptides identified in 4 or more denaturant concentrations. Whereas the data 
in the Solution-based ATP-binding experiment 1B, which was obtained on the faster and 
more sensitive Orbitrap instrument, was filtered to contain peptides appearing in 6 or 
more denaturant concentrations. The data in the solution based ATP-binding 
experiment 2 was obtained on the Orbitrap and has 2 more denaturant points was hence 
filtered to contain peptides appearing in 8 or more denaturant concentrations.  
A peptide “hit” was defined as a peptide that has two or more H/L ratios 
differing by ≥ 1.7 fold with respect to the minimum H/L across the 4 (or 6, 8) denaturant 
concentrations. An excel formula was used to automatically filter the data sets for 
peptides that meet those criteria. Ultimately, this list of filtered “hits” was visually 
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 inspected to confirm that their plots of SILAC-SPROX H/L ratios versus denaturant 
concentrations resemble the structure of the SILAC-SPROX curves depicted in Figure 14. 
 
Figure 14: Expected results from SILAC-SPROX solution-based experiments. 
(A) is an oxidized methionine peptide from a protein that has no interaction with the 
ligand; (B) is an oxidized methionine peptide from a protein that is stabilized by 
binding to the ligand; and (C) is a corresponding un-oxidized peptide of that 
stabilized protein. Open circles represent data points (denaturant concentrations) that 
have no change in H/L ratio, closed circles represent data points that have significant 
H/L ratio difference. 
 
4.3 Results and Discussion 
4.3.1 General Strategy 
The SILAC-SPROX protocol developed in this work is outlined in Figure 15. 
Initially, “Light” and “Heavy” cell lysates are prepared and the test ligand is spiked into 
one of the cell lysates. In this case, the ATP analog was spiked into the Heavy lysate. The 
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 two cell lysate samples are subjected to simultaneous SPROX analyses in which aliquots 
of each cell lysate are distributed into a series of denaturant-containing buffers and 
reacted with hydrogen peroxide under conditions that we have previously established 
for the selective oxidation of exposed methionine residues in SPROX analyses (e.g., 0.5 
M H2O2 for 6 min).37 The oxidation reactions are quenched (e.g., with the addition of 
excess L-methionine) and the appropriate Light and Heavy samples with matching 
denaturant concentrations are combined (see Step 4 in Figure 15).  At this point the 
protein samples can be directly submitted to a conventional bottom-up proteomics 
analysis in solution (hereafter referred to as the “solution-based” approach). 
The SILAC-SPROX strategy described here is analogous to the PrSUIT 
experiment that has previously been reported[63].  The PrSUIT experiment relied on the 
use of heavy and light H2O2 (i.e., H218O2 and H216O2) to define the (-) and (+) ligand 
samples in SPROX.  One disadvantage to PrSUIT is that the differential labeling only 
incorporates a small mass shift, which complicates the data analysis. The SILAC-SPROX 
experiment described here has the advantages that the light and heavy samples are 
separated by at least 8 mass units and the LC-MS/MS data is easily analyzed using well-
established SILAC methods.  The PrSUIT experiment is also not amenable to the gel-
based readout in SILAC-SPROX that ultimately enables the potential binding properties 
of a protein to be determined using the L/H ratios obtained from any peptides.  
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Figure 15: The solution-based SILAC-SPROX protocol 
 
4.3.2 ATP-binding Result Summary 
4.3.2.1 Proteome Coverage 
The ATP binding properties of the proteins in a yeast cell lysate were analyzed 
using the SILAC-SPROX protocol developed here (Figure 15). The ligand in the ATP 
binding study was adenosine 5’-(β,γ-imido)triphosphate (AMP-PNP), a non-
hydrolysable ATP mimic that is spiked into the “Heavy” lysate. A total of 2 Solution-
based ATP-binding experiments were performed.  Other important experimental 
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 parameters (e.g., ATP concentration, equilibration time, oxidation reaction time, and MS 
instrument platform) used in these experiments are highlighted Table 7.  
Table 7: Experiment parameters utilized in ATP-binding solution-based 
experiments 1A/B and 2 
Experiment 
Name 
MS 
platform [Ligand] 
Equilibration 
Time (min) 
Oxidation 
Time (min) 
Number of 
Denaturant 
concentration 
Solution based 
Exp1A 
QTOF 
 
1mM 30 and 30 6 8 
Solution based 
Exp1B 
Orbitrap 1mM 30 and 30 6 8 
Solution based 
Exp2 Orbitrap 7mM 60 and 60 24 10 
 
The main difference between experiments 1A/B and 2 was the effective ligand 
concentrations, equilibration time and oxidation time. As explained in Chapter 1, section 
1.4, the sensitivity of this protocol can be tuned by (i) increasing free Ligand 
concentrations [L] (ii) increasing the incubation time between proteins and ligand for 
more complete equilibrium and (iii) increasing oxidation time to maximize the linear 
dependence of C1/2 values to changes in folding free energy of the proteins upon binding 
to ligands. Thus, all the changes made in the solution-based experiment 2 were expected 
to make the ATP-binding assay in this experiment more sensitive.  
It is important to note that the effective ligand concentration is the stoichiometric 
concentration of the Mg-ATP complex, which is 1 mM in the solution based experiments 
1A and B and 7mM in solution based experiment 2. SILAC-SPROX samples from 
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 solution based experiment 1 A and B were subjected to mass spectral analyses using 
both QTOF and Orbitrap, platforms, respectively, in order  to compare the proteome 
coverage in the two platforms. 
Table 8: Proteome coverage and potential protein hits from ATP-binding 
solution-based experiments 1A/B and 2. 
 
Experiment 
Total Peptides 
(Proteins) Assayed 
for Binding 
Hit Peptides 
(Proteins) 
Known ATP 
Binding Proteins 
Assayed (Hits) 
Solution-Based Exp. 1A 93 (38) 5 (3) 6 (0) 
Solution-Based Exp. 1B 526 (209) 55 (27) 56 (4) 
Solution-Based Exp. 2 353 (216) 138 (99) 61 (29) 
Total 689 (302) 180 (112) 82 (33) 
 
Summarized in Table 8 are the proteomic results obtained for the above solution-
based ATP-binding experiments. On average, when using the Orbitrap mass 
spectrometry platform, approximately 200 proteins are assayed. The protein included in 
the assay were those that had at least 1 methionine containing peptide being successfully 
identified and quantified in at least 6 (or 8) denaturant concentrations. On the other 
hand, the same samples subjected to LC-MS/MS analyses on the Q-TOF platform 
resulted in only 38 proteins assayed. These are proteins that also have at least 1 
methionine containing peptide being successfully identified and quantified in at least 4 
or more denaturant concentrations. This result suggests the use of Orbitrap mass 
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 spectrometry platform gives approximately 5 fold increase in proteomic coverage with 
respect to the Agilent QTOF platform utilized in these experiments. In total there are 689 
peptides corresponding to 302 proteins are assayed across all the solution-based 
experiments.  
The proteomic coverage obtained on the QTOF platform is slightly lower than 
that obtained on the iTRAQ-SPROX data set reported recently in which approximately 
103 peptides corresponding to 70 proteins are effectively assayed[35b]. This is likely due to 
multiple injections implemented in the LC MS/MS Analyses of the iTRAQ-SPROX 
samples as oppose to single injection in the SILAC-SPROX samples. When these iTRAQ-
SPROX samples were subject to a methionine enrichment step, the proteome coverage 
increased by approximately 2 fold to 122 proteins assayed.  A similar methionine 
enrichment strategy could be used in SILAC-SPROX; however, it was not done in this 
work due to the expense associated with performing 8-10 different methionine 
enrichments on the SILAC-SPROX generated samples.  
Presented in Figure 16 are the distributions of the H/L ratios measured for the 
lysine- and non-methionine-containing peptides identified in the solution-based ATP 
binding experiment 1B and 2.  As shown below in Figure 16, the majority of log2 
(normalized H/L ratio) values in both experiments lie within the range of -0.5 to 0.5.  As 
expected the log2 values also center around 0 indicating that the large majority of 
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 peptides showed no difference in their relative abundance in the (+) and (-) ligand 
samples.   
 
Figure 16: Distribution of the log2 of the normalized H/L ratios in (A) solution-
based experiment 1B and in (B) solution-based experiment 2. Dotted lines represents 
distribution of all peptide sequences, dash-and-dotted line represents distribution of 
peptides that do not contain methionine in their primary sequences and solid line 
represents distribution of methionine containing peptides. Inset are zoom-in image of 
the methionine containing peptide distributions 
A global analysis of the raw H/L ratios’ distribution reveals approximately 98% 
of the SILAC-SPROX ratios lies within 0 to 10. These distributions show that the 
standard deviations (σ) of all peptides with H/L ratios from 0-10 lies within 0.32 -0.36. 
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 Therefore, a significant H/L difference is defined as outside of [1 ± 2 σ] (equals to 
confidence intervals of 95%). That is, if one divides the altered H/L ratio at a particular 
denaturant concentration by the average H/L ratio across multiple denaturant 
concentrations for a given peptide, the result will be 1.7 fold or higher. This 1.7 fold 
difference is herein used as a threshold to filter for significant difference in the 
aforementioned data analysis routine.   
In total, 302 proteins in the yeast cell lysate were effectively assayed for binding 
to the ATP analogue utilized in this study, and 180 peptide hits from 112 different 
proteins were identified. Increasing proteome coverage resulting from switching 
between QTOF and Orbitrap platforms results in significant increase of known ATP-
binding proteins assayed in these solution-based experiments. Known ATP-binding 
proteins are defined as protein annotated with the GO-term ATP-binding (GO:0005524) 
from the Yeast Genome Database (SGD). A search for the GO-term “ATP-binding” in the 
Yeast Genome Database results in 666 genes, accounting for 13% of the yeast verified 
open reading frames (ORFs). A total of 82 of these 666 genes were effectively assayed in 
these solution-based experiments, and 33 of these known ATP binding proteins were 
detected as hits. The large majority of these hits were identified in experiment 2 where 
the higher concentration of the ATP ligand made the assay more sensitive. 
99 
 4.3.2.2 Representative SILAC-SPROX data from Phosphoglycerate mutase 
 
Figure 17: Representative SILAC-SPROX data from phosphoglycerate mutase 
(PGM-1) in (A) Solution-based experiment 1B, and (B) Solution-based experiment 2. 
Diamond shape represents data points from the un-oxidized methionine containing 
peptide (TVMIAAHGNSLRGLVK); square shape represents data points from the 
oxidized methionine containing peptide (TVM(ox)IAAHGNSLRGLVK) and triangle 
shape represents data points from a selected non-methionine containing peptide 
(LSRAIQTANIALEK) 
Shown in Figure 17 is SILAC-SPROX data obtained on Phosphoglycerate mutase 
1 (PGM-1). PGM-1 homolog was identified as a tentative ATP-binding protein in 
previous study using the energetics based pulse proteolysis approach in E. coli (See 
Introduction- ATP binding discovery). PGM-1 was not annotated with the GO-term 
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 ATP-binding and was not previously known to binding ATP. In the previous ATP-
binding in E. coli, the PGM-1 homolog was cloned, purified and validated to bind ATP. 
In this ATP-binding study using the solution-based SILAC-SPROX described 
here, PGM-1 was identified as hits in both experiments. The data from both oxidized 
and un-oxidized Methionine containing peptides in solution-based experiment 1B 
resembles the structure of SILAC-SPROX curves predicted in Figure 14 (Data Analysis).  
Note that the SILAC-SPROX curve from the un-oxidized (TVMIAAHGNSLRGLVK) is a 
mirror image of the oxidized (TVM(ox)IAAHGNSLRGLVK) methionine containing 
peptide about the x axis. The straight line represents SILAC-SPROX data from a typical 
non-methionine containing peptide which is not affected by the oxidation reaction and is 
expected to center around 0.  PGM-1 is also identified as one of the 3 hits detected in 
solution based experiment 1A on the QTOF platform and showed the same behavior as 
that in Figure 14 (data now shown). 
 This data is also in agreement with previous data obtained on the E. coli 
homolog, in which the Cm value of PGM increased from 1.4 M to 1.8 M Urea upon ATP-
binding. Reconstruction of SPROX curves from both of these solution-based SILAC-
SPROX data using a procedure reported elsewhere[63] indicates a C1/2 shift of 1 M Urea 
from 1.8 to 2.8 M Urea (see Table 11 and Appendix B). Endogenous PGM-1 is a dimer in 
solution, and thus the thermodynamic stability is dependent on protein concentration.  
Thus, small discrepancy in relative apparent Cm shifts is to be expected due to changes 
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 in protein concentrations. Interestingly, the results reported here for yeast PGM indicate 
that the protein folding and ATP-binding properties of this protein are very similar to 
that of E. coli PGM.  This is despite that fact that the primary amino acid sequences of the 
two proteins are only 54% conserved.   
4.3.2.3 Representative SILAC-SPROX data from GAPDH 
As noted above in the Introduction to this Chapter, GAPDH was previously 
found to be destabilized in the presence of ATP [21a, b]. In theory, if a ligand binds to the 
native state of a protein, the protein is expected to be stabilized in the presence of the 
ligand [6a, 7-8]. Park and coworkers performed a number of biophysical studies on GAPDH 
binding to ATP and concluded that ATP binds and stabilizes a partially unfolded 
intermediate of GAPDH rather than native GAPDH resulting in an apparent 
destabilization[64]. For example, using tryptophan fluorescence emission spectroscopy, 
GAPDH showed a shift in apparent Cm by 0.2M Urea from 2.0 to 2.2 and decrease in m 
value from 3.2 to 1.7 (by half). Monitoring the tryptophan fluorescence intensity on the 
other hand showed two transitions in the unfolding behavior of GAPDH in the presence 
of ATP; with one transition at about 1.6 M and the other about 2.4 M Urea. Using ANS, a 
compound that tends to bind to nonpolar surface exposed in partially unfolded proteins 
and fluorescence, the Park group found the presence of an intermediate at 
approximately 2 M Urea in the presence but not in the absence of 1 mM ATP. In addition 
using size exclusion gel filtration, Park and coworkers found that GAPDH was 
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 predominantly tetrameric at 2M Urea in the absence of ATP and mostly dimeric at 2M 
Urea in the presence of ATP. Park and coworkers also showed that ATP does not bind to 
native form of E. coli GAPDH but a seemingly dimeric partially unfolded intermediate 
with an estimated Kd of 150 µM. The effect of ATP binding to GAPDH is increasing both 
the folding and unfolding rate of the protein. They also went on and determined the 
effect of other nucleotides binding to GAPDH and saw the same results with ADP and 
AMP.   
More recently, a book discussing the biological properties of GAPDH in detail 
was published and also indicated the binding of ATP to the dimer form of yeast 
GAPDH, which results in promoting the tetramer to dimer dissociation reactions[65]. This 
study also showed that binding of ATP to GAPDH at low temperature (i.e. 0oC) results 
in almost complete loss of activity after 5 hours. The estimated Kd from this study in 
yeast (450 µM) was slightly higher than that in the E. coli study (150 µM). Also according 
to yeast GAPDH study, the ATP binding site lies in the N term region with sequence 
“GXGXXG” for a number of organisms. Yeast GAPDH exists in 3 isoforms with very 
high sequence identity (more than 90%) and share 70% conserved sequence with their E. 
coli counterpart. An alignment of the E. coli GAPDH sequence with the Yeast GAPDH-3 
sequence gives rise to a highly conserved region on the N-term “INGFGRIGR”, which 
resembles the typical ATP-binding motif.  
103 
  
Figure 18: SILAC-SPROX data for multiple peptides from GAPDH in 
Solution-based experiment 1B (A) and Solution-based experiment 2 (B). Circles are 
peptides with sequence NVEVVALNDPFISNDYSAYMFK; triangles are VINDAFGI-
EEGLMTTVHSLTATQK; diamonds are LTGMAFRVPTVDVSVVDLTVK; and 
squares are (K)VVITAPSSTAPMFVMGVNEEK. Closed symbols represent un-
oxidized and open symbols represent oxidized methionine containing peptides. 
Dotted line represents SILAC-SPROX data from a non-methionine containing peptide 
(VLPELQGK). 
The SILAC-SPROX results reported here on yeast GAPDH are consistent with 
the results previously reported by Parks and coworker on E. coli GAPDH (see Figure 18 
below). Interestingly, multiple peptides from GAPDH in both solution-based SILAC-
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 SPROX experiments indicate the same change in thermodynamic stability of the protein 
upon binding to ATP, namely apparent destabilization.  
These results altogether suggest the following (i) ATP (AMP or ADP) binds to a 
partially unfolded dimeric form of GAPDH (ii) this binding results in dissociation of 
tetrameric GAPDH (iii) The folding and ATP-binding properties of the yeast GAPDH 
isoforms are similar to each other and to their E. coli homolog and (iv) the ATP-binding 
site seem to be localized in the N-term region but also have remote effect on other 
domains of the protein. This result is very intriguing because it demonstrates the 
strength of these energetics based approach to identify not only binding that results in 
association but also dissociation of a protein complex, which would not be possible, for 
example, for ligand affinity and chemoproteomic target identifications (see 
Introduction).  
4.3.3 False Positive/Negative Rate 
4.3.3.1 False Positive Rate 
In these solution-based ATP binding studies using SILAC-SPROX, it is possible 
to ascertain the false positive rate by examining the data obtained on non-methionine 
containing peptides (i.e. peptides that contains no Methionine in their primary 
sequence), which should not be affected by the oxidation reaction performed in SPROX 
analysis. Thus, the H/L ratios of these non-methionine containing peptides should be 
close to 1 and should not change regardless of which denaturant containing buffer they 
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 come from. However, it is important to note that due to small differences in protein 
expression level between the Light and Heavy lysates, the non-Methionine containing 
peptide H/L ratios can fluctuate lower or higher than 1 depending on particular 
proteins. In theory, if the non-Methionine-containing data set is subject to the same data 
analysis routine adopted for the Methionine containing peptides, there should be no 
emerging peptide hits. Any protein hits found in such an analysis will be an indication 
of the false discovery rate of the data analysis. When the 1898 non-methionine 
containing peptides from solution-based experiment 1B were subjected to the same data 
analysis routine described in experimental procedures; a total of 24 non-methionine 
containing peptides satisfied the requirement to be a potential hit. In solution-based 
experiment 2, 1739 non-methionine containing peptides are assayed (i.e. have H/L ratio 
≥0, appear in 8 denaturant concentrations or more), 24 peptides were also identified as 
hits. These analyses suggest a false-positive rate of protein target identification of 1.3% 
of the number of peptides assayed.  
It is important to note that misidentification of peptides in the LC-MS/MS 
analysis step of SILAC-SPROX experiments can lead to the presence of false positives in 
the SILAC-SPROX experiment. In this regard, the false discovery rate of protein-ligand 
targets in the SILAC-SPROX experiment should not be lower than the FDR of the 
database search result, which was set to ≤1% because there is a 1% chance that a 
particular sequence is a mis-identified one.   
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 4.3.3.2 False Negative Rate 
The false negative rate associated with SILAC-SPROX experiments is more 
difficult to determine and it is likely to depend on the system under study.  There are 
several caveats to the use of SILAC-SPROX in protein-ligand binding experiments.  One 
caveat is that the ligand binding event must shift the SPROX transition midpoint by a 
measurable amount.  The magnitude of a SPROX transition midpoint shift is related to 
the free ligand concentration, binding affinity, and protein folding m-value.  The 
hydrogen peroxide concentration and reaction time can also impact the magnitude of 
the shift. The use of more aggressive oxidation reaction conditions (e.g., longer reaction 
times and/or higher concentrations of hydrogen peroxide) can make the assay more 
sensitive to the detection of weaker binding interactions (see discussion in Chapter 2 and 
Figure 2).  It is also important that the protein (or protein domain) contains a buried 
methionine residue. Furthermore, oxidation of the methionine residue can abrogate 
ligand binding. 
4.4 Conclusions 
In conclusions, the SILAC-SPROX protocol reported here has been applied to the 
study of ATP-binding proteins in yeast. The protocol has eliminated several drawbacks 
associated with the current iTRAQ-SPROX such as (i) the high experimental error 
associated with separate sample handling prior to multiplexing by iTRAQ reagent (ii) 
the reliance on MS2 quantitation. First, the SPROX generated protein samples from 
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 SILAC-based protocol reported here involved upfront labeling of the (-) and (+) ligand 
samples at protein level allowing combination of the two samples, eliminating 
discrepancy arising from sample handling procedure prior to LC MS/MS analysis. 
Second, the use of SILAC-based quantitation allows confirmation of the peptide 
(protein) hits by consulting the raw MS1 spectra. As a result, the SILAC-SPROX protocol 
described here has an improved false discovery rate of the SPROX analysis from 2-4 % to 
1.3%. The protocol has successfully assayed 302 proteins and found 112 potential ATP-
binding targets; of which 33 are previously annotated with GO-term ATP-binding in the 
Yeast Genome Database. The preliminary results are consistent with ATP-binding 
studies in E. coli. The proteome coverage is also close to that reported in the E. coli study 
using the pulse proteolysis approach.  The proteomic coverage is also similar to that 
observed in a previously reported iTRAQ-SPROX experiment in which 327 yeast 
proteins were effectively assayed for binding to Cyclosporine A[35a]. This is not 
surprising because the solution-based SILAC-SPROX protocol described here and the 
iTRAQ-SPROX protocol both rely on the identification and quantitation of the 
methionine containing peptides. However, this reliance on methionine-containing 
peptides in the solution-based SILAC-SPROX protocol can be eliminated using a gel-
based SILAC-SPROX protocol as described below. 
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 5. Development of a SILAC-SPROX-Cyanogen Bromide 
protocol and application to ATP binding discovery 
5.1 Motivation 
The SILAC-SPROX-Cyanogen Bromide protocol described in this chapter is an 
extension of the SILAC-SPROX protocol described in chapter 4. The SILAC-SPROX 
protocol described in Chapter 4 eliminated some of the drawbacks associated with the 
iTRAQ-SPROX protocol. For example, it allows the (+) and (-) ligand samples to be 
combined early in the protocol (i.e., immediately after SPROX analysis), rather than late 
in the protocol (i.e.., after the proteolytic digestion step). However, the SILAC-SPROX 
protocol described in Chapter 4 still requires the detection and quantification of 
Methionine containing peptides. As methionine peptides only account for 20% of 
identified peptides in a typical proteomics experiment, the proteome coverage in the 
SILAC-SPROX experiments is roughly 1/5 of that observed in conventional bottom-up 
proteomic analyses. In theory, enrichment of Methionine containing peptides can be 
used to improve the proteome coverage in SILAC-SPROX experiments. However, it is 
time consuming and costly to perform 8-10 different Methionine enrichments before 
subjecting SILAC-SPROX samples to LC MS/MS Analysis.  
Described in this chapter is a SILAC-SPROX-Cyanogen Bromide (SILAC-SPROX-
CnBr) strategy that is designed to expand the protein coverage in proteome-wide 
SPROX experiments.  The SILAC-SPROX-CnBr strategy enables any peptide (i.e., 
methionine-containing or not) that is identified and quantified in a bottom-up shotgun 
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 proteomics experiment to report on the stability of the protein to which it maps. As part 
of the work described here an ATP-binding study is performed using the same two 
conditions employed in the solution-based experiments described in Chapter 4. The 
results obtained from this study including the increased proteome coverage observed 
and the ATP binding properties of selected yeast proteins will be discussed.  
5.2 Experimental Procedures 
5.2.1 SILAC-SPROX Analyses 
Table 9: Experimental parameters utilized in ATP-binding gel-based 
experiment 1 and 2 
Experiment 
Name 
MS 
platform 
[Ligand] Equilibration 
Time (min) 
Oxidation 
Time 
(min) 
Number of 
Denaturant 
concentration 
Gel based 
Exp1 
Orbitrap 1mM 30 and 30 6 8 
Gel based 
Exp2 
QTOF 7mM 60 and 60 24 10 
 
Two SILAC-SPROX-CnBr experiments were performed. Summarized in Table 9 
are key experimental conditions employed for these experiments (i.e. the Gel-based 
experiment 1 and 2). Note that Gel-based Experiment 1 employed the same ATP-binding 
and SILAC-SPROX Analysis as the Solution-based Experiment 1 A/B described in 
Chapter 4. Gel-based Experiment 2 also employed the same ATP-binding and SILAC-
SPROX Analysis as the Solution-based Experiment 2 in Chapter 4.  
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 5.2.2 Cyanogen Bromide Digestion 
In Gel-based experiment 1, the combined (-) and (+) ligand protein pellets were 
re-dissolved in 70% (v/v) aqueous solution of formic acid (TCI America, Portland, OR) 
containing 1 mg of crystalline CnBr (Sigma Aldrich) and incubated with frequent 
shaking at room temperature for 4 hours. This was equivalent to an estimated CnBr: 
Methionine ratio of ~ 67:1 (mole/mole). The unreacted CnBr was evaporated by heating 
samples with open caps at 50oC for 5 min in chemical fume hood. The protein samples 
were neutralized by 200 µL of 1.7 M of 4-ethylmorpholine (NEM) (Sigma Aldrich) and 
diluted with 1.5 mL of diH2O and 200 µL of 100% (w/v) TCA was added to each sample. 
The samples were mixed and incubated at 4oC overnight. Precipitated proteins were 
pelleted by centrifuging at 13,000 g for 30 min, and washed according to similar 
procedures described in the SILAC-SPROX protocol in Chapter 4.  
The CnBr digestion in Gel-based Experiment 2 was performed in a similar 
manner as that described above for Gel-based Experiment 1 with the following 
exceptions (i) a 5 M solution of CnBr in Acetonitrile (Sigma Aldrich) was used instead of 
crystalline CnBr, and (ii) the final estimated CnBr: Methionine Ratio was ~ 138:1 instead 
of 67:1. 
Important precautions! Cyanogen Bromide is a severely irritating chemical that 
has high acute toxicity. The lethal concentration of CnBr by inhalation for human is 92 
ppm (398 mg/m3 for 10 min) [66]. The amount of CnBr utilized in this work is 
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 approximately 20-30 mg per SPROX experiment, therefore can be safely handled under a 
functional chemical fume hood. When weighing crystalline CnBr, be sure to use a closed 
container (e.g. a closed cap eppendorf tube); and never handle CnBr outside of the 
chemical fume hood. CnBr containing waste can be collected into a 1 L glass container 
with cap prefilled with 300 mL of household bleach and placed into a secondary 
container (e.g. a bucket). Make careful precautions when handling the waste; be sure to 
seal the cap, label the content of the waste container and have it picked up by authorized 
waste managers. Protective equipment such as lab coats, goggles and impermeable 
gloves should be worn at all time while working with CnBr.   
5.2.3 1-D SDS PAGE and In-gel Digestion  
A total of 8 samples for SDS-PAGE analysis were generated in Gel-based 
experiment 1 after combining (-) and (+) ligand samples (i.e. Light and Heavy lysates).  
Each of the 8 TCA precipitated protein pellets, which contained both the (-) and (+) 
ligand samples (i.e. Light and Heavy lysates), were re-dissolved in 40 µL of freshly 
made 8M Urea and 20 μL of 6X Laemmli sample buffer containing 375 mM Tris•HCl pH 
6.8, 6% SDS, 50% Glycerol and 0.045% Bromophenol (Boston Bioproduct). A 3 µL aliquot 
of β Mercaptoethanol (BME) was added to each sample before heating at 95oC for 5 min 
to reduce the disulfide bonds. A 20 µL aliquot of each protein sample was loaded on a 
mini polyacrylamide gel 10 x 8.5 cm (NUsep). The gel was fixed with fixing solution 
containing 25% isopropanol, 10% acetic acid in 65% distilled H2O for 20 min. The fixed 
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 gel was stained overnight with staining solution containing 0.01% R-250 in 10% Acetic 
acid (Bio-Rad), and de-stained with 10% acetic acid repeatedly until the gel image was 
clear. A portion of the gel corresponding to a molecular weight range of 20 – 30 KDa was 
excised resulting in 8 different gel bands, which were subject to a standard in-gel 
digestion protocol[67]. Gel-based experiment 2 was performed in a similar manner with 
the following exceptions (i) there were 10 samples after combining (-) and (+) ligand 
samples instead of 8; (ii) each samples was re-dissolved in 40 µL of freshly made 10M 
Urea instead of 8M Urea; (iii) 15 µL of each protein sample was loaded onto a midsize 
polyacrylamide gel (Bio-Rad Criterion); and (iv) the gel was cut into 14 different 
molecular weight (MW) fractions that correspond to the following MW ranges: 0-6, 6-12, 
12-15, 15-18, 18-19, 19-20, 20-24, 24-30, 30-37, 37-50, 50-75, 75-100, 100-250 and larger than 
250 KDa. The resulting 140 gel pieces were each subject to a standard in gel digestion as 
described elsewhere [67]. The Gel-cutting strategy for Gel-based experiments is depicted 
in Figure 19. 
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Figure 19: Gel-cutting strategy for (A) Gel-based experiment 1 and (B) Gel-
based experiment 2. Black boxes represent relative sizes of the gel bands. Arrows 
indicates the estimated molecular weight ranges for each gel band. 
 
5.2.4 LC MS/MS Analyses 
The extracted peptide mixture from each in-gel digestion was evaporated down 
in a speed-van to approximately 100 µL, diluted with 500-1000 µL of buffer A and 
desalted using C18 resin.   Peptides were eluted in 150 µL of 70% Acetonitrile in 0.1% 
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 TFA before being speed-van down to dryness and re-dissolved in 20-50 µL of Buffer A 
(0.1% formic acid). Approximately 2-4 µL of each sample was combined with 19-20 µL 
of buffer A and subjected to LC-MS/MS analyses. The 8 SILAC-SPROX-CnBr samples 
from Gel-based Experiment 1 were subject to LC MS/MS Analysis on the Orbitrap 
platform in the same manner as the Solution-based experiment 1B and 2 described in 
Chapter 4.  
The 10 SILAC-SPROX-CnBr samples in the Gel-based experiment 2 were 
subjected to an LC-MC/MS analysis using an Agilent 6520 Q-TOF mass spectrometer 
equipped with a Chip Cube interface. The HPLC column was a short chip with a 40 nL 
enrichment column and a 73 x 43 mm analytical column packed with Zorbax 80SB-C18 
5µm material. Peptides were eluted using a linear gradient: 3-5% buffer B over 2 min, 5-
15% over 2 min, 15-50% over 18 min 60-90% over 3 min, 100% over 2 min and 5% over 3 
min.  The flow rate was set to be 0.4 µL/min. The capillary voltage ranged from 1800 to 
1850 V.  The flow rate of the drying gas was set at 6 L/min at 350°C.  The skimmer and 
fragmentor were set at 65 and 175 V, respectively. The collision energy was as 
determined by the equation 3.5 V/100 Da with a -4.8 V offset. The inclusion window 
width for precursor ions was 4 m/z. The scan rate was three scans per second in the mass 
spectra and two scans per second in the product ion spectra. In every cycle, four 
precursors were selected for fragmentation. All spectra were collected in profile mode.  
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 5.3 Results and Discussion 
5.3.1 General Strategy 
 
Figure 20: The SILAC-SPROX-Cyanogen Bromide Protocol 
The SILAC-SPROX-CnBr protocol developed in this chapter is outlined in Figure 
20. The first 4 steps of the protocol are identical to the solution-based SILAC-SPROX 
protocol outlined in Chapter 4. The CnBr reaction in step 5 of the SILAC-SPROX-CnBr 
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 protocol is used to cleave the polypeptide chain of proteins after un-oxidized 
methionine residues (i.e., methionine residues that were not oxidized in the SPROX 
experiment).  Methionine residues that were oxidized in the SPROX experiment are 
protected from CnBr cleavage.  As proteins are unfolded in the presence of the 
increasing concentrations of chemical denaturant used in the SPROX experiment, the 
“buried” methionine residues in a protein’s three-dimensional structure are exposed to 
solvent, get oxidized, and become protected from cyanogen bromide cleavage. Thus, as 
depicted in Figure 20, full-length and fully oxidized proteins (i.e. whose all Methionine 
residues in primary sequence are quantitatively oxidized) will appear predominantly in 
SPROX samples with higher concentrations of denaturant, and the corresponding CnBr 
fragments of proteins will appear predominantly in SPROX samples with lower 
concentrations denaturant. Therefore, a fractionation step by 1-D SDS-PAGE is used to 
separate full-length proteins from their corresponding CnBr fragments. Subsequently, 
rows of gel-bands corresponding to specific molecular weight ranges are excised, and 
subjected to conventional bottom up proteomics to quantify, in each gel-band, the 
relative amount of Full-length protein (or corresponding CnBr fragments) from the (-) 
and (+) ligand samples.   
The CnBr digestion and subsequent gel-based separation of the full-length 
proteins from their respective CnBr fragments is important in the gel-based approach 
because it enables every peptide that is successfully identified and quantified in the 
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 bottom-up proteomics readout (not just the methionine-containing peptides) to report 
on the ligand binding properties of the protein from which it was derived. However, the 
SILAC-SPROX behavior of full-length proteins and their respective CnBr fragments will 
be opposite of each other.  The amount of a full-length protein will increase as a function 
of denaturant concentration; whereas, the amount of CnBr fragments of a protein will 
decrease as a function of denaturant (see Figure 20).  Therefore, it is important that the 
gel be excised in molecular weight ranges that effectively separate intact proteins from 
their CnBr fragments. 
Ultimately the H/L (or L/H) ratios of the identified peptides are evaluated as a 
function of the denaturant concentration at which the protein oxidation reaction was 
performed. Unique to the gel-based experiment is that the denaturant dependence of the 
H/L ratios obtained from non-methionine-containing peptides can also be used to 
identify protein hits.  As with the methionine-containing peptides from protein hits in 
the solution-based experiment, the non-methionine-containing peptides from protein 
hits in the gel-based experiment will have high (or low) H/L ratios at intermediate 
denaturant concentrations (see Figure 21). 
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Figure 21: Expected SILAC-SPROX-CnBr results from the gel-based 
experiments; (A) is an oxidized methionine peptide of a protein that has no 
interaction with the ligand; (B) is any peptides from the full-length protein that is 
stabilized by binding to the ligand; and (C) is any peptides from the corresponding 
CnBr fragments of stabilized proteins. Open circles represent data points (denaturant 
concentrations) that have no change in H/L ratio, closed circles represent data points 
that have significant H/L ratio difference. 
More specifically, any peptides that originate from the full-length proteins 
(regardless of whether or not they contain a methionine residue) will have similar 
SILAC-SPROX behavior as the oxidized methionine residues that the protein bears.  
Conversely, any peptides which originate from the CnBr fragments will have similar 
SILAC-SPROX behavior as the un-oxidized methionine residue that was cleaved by 
CnBr. Hence the so-called “full-length” originated peptides will have the reverse SILAC-
SPROX curve as oppose to the “CnBr-fragment” originated peptides. 
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 5.3.2 Proteome Coverage 
Table 10: Proteome coverage from all ATP-binding experiments including 
solution-based 1A/B and 2; gel-based 1 and 2. 
 
Experiment 
Total Peptides 
(Proteins) Assayed 
for Binding 
Hit Peptides 
(Proteins) 
Known ATP 
Binding Proteins 
Assayed (Hits) 
Solution-Based Exp. 1A 93 (38) 5 (3) 6 (0) 
Solution-Based Exp. 1B 526 (209) 55 (27) 56 (4) 
Gel-Based Exp. 1 1346 (354) 45 (12) 73 (1) 
Solution-Based Exp. 2 353 (216) 138 (99) 61 (29) 
Gel-Based Exp. 2 431 (171) 148 (46) 27 (8) 
Total 2035 (526) 325 (140) 109  (37) 
 
Presented in Table 10 is the proteomics coverage from all SILAC-SPROX-CnBr 
ATP-binding experiments performed in this work. Results from the 2 solution-based 
SILAC-SPROX experiments described in Chapter 4 are also included in the table for 
comparison. In Gel-based experiment 1, only bands from the 20 to 30 KDa molecular 
weight range of the gel were excised, digested and the resulting peptides subjected to an 
LC MS/MS Analysis. Even just considering the peptide and protein identifications from 
this 20-30 KDa molecular weight range, 2.5 times as many peptides and 1.7 times as 
many proteins are assayed compared to the Solution-based experiment 1B (i.e. 1346 vs. 
526 and 354 vs. 209). This improvement is due to (i) removal of the requirement that a 
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 methionine containing peptide must be identified and quantified in order for the 
proteins to be assayed and (ii) use of the 1-D gel fractionation strategy to reduce the 
complexity of the lysate samples prior to LC MS/MS Analysis.  
The 140 SILAC-SPROX-CnBr samples generated in Gel-based experiment 2 were 
analyzed on an Agilent Q-TOF mass spectrometry platform. Due to the relatively low 
complexity of the in-gel digested samples, each SILAC-SPROX-CnBr generated samples 
were subject to a short (i.e. 30 min) LC MS/MS analysis using a short (75 µm x 43mm) 
HPLC column. A direct comparison can be drawn between the solution-based 
experiment 1A and the gel-based experiment 2 in terms of peptide and protein coverage. 
The results suggest that SILAC-SPROX-CnBr increased the proteome coverage by 5 fold 
compared to the SILAC-SPROX protocol (i.e. from 38 proteins to 171 proteins). 
The analytical capabilities (e.g., speed and sensitivity) of the mass spectrometry 
instrument used in the SILAC-SPROX experiment clearly impact the proteome coverage.  
The total number peptides (and proteins) assayed using the Orbitrap instrument in 
Solution-Based Experiment 1B, 526 peptides (and 209 proteins), was about 5-fold greater 
than that obtained using the Q-TOF instrument in solution-based experiment 1A, 93 
peptide (and 38 proteins). A comparison of the protein coverage in Gel-Based 
Experiment 1 (1346 peptides and 354 proteins) to the protein coverage obtained in the 20 
to 30 KDa molecular weight range of the gel in Gel-Based Experiment 2 (237 peptides 
and 102 proteins) also revealed a similar 3 to 5-fold increase in peptide and protein 
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 coverage when the Orbitrap instrument was used in the gel-based protocol.  The 
proteome coverage obtained in the large-scale gel-based experiment using the Q-TOF 
(i.e., 431 peptides and 171 proteins in Gel-Based Experiment 2) was also ~5-fold larger 
than that of the solution-phase experiment using the Q-TOF (i.e., 93 peptides and 38 
proteins in Solution-Phase Experiment 1A).  If a similar 5-fold improvement were 
realized using the Orbitrap instrument, a large-scale gel-based experiment using the 
Orbitrap would be expected to assay about 1800 to 2500 peptides and about 1000 
proteins, which is five times the number of peptide and proteins assayed in Solution-
Based experiments 1B and 2.  This is approximately 3-5-fold more peptide and protein 
coverage than that previously reported in SPROX experiments using an isobaric mass 
tagging strategy[35b]. 
One important feature of the gel-based SILAC-SPROX protocol is that it increases 
the number of peptide probes per protein.  In the two gel-based SILAC-SPROX 
experiments in this work there were 3.2 and 3.8 peptide probes per protein, whereas in 
the solution-based experiments described in Chapter 4, the number of peptide probes 
per protein was between 1.6 and 2.5. Moreover, the protein hits in the gel-based 
experiments were identified with more peptide probes.  For example, the protein hits in 
the two gel-based experiments were identified with an average of 3.2 and 3.8 peptides 
each, whereas the protein hits in the solution-based experiments were only identified 
with an average of between 1.4 to 2 peptides each.  
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  It is also noteworthy that the solution- and gel-based protocols are 
complementary in their peptide and protein coverage.  Shown in Figure 22 is a 
comparison of the peptide and proteins assayed and ATP binding hits detected in all of 
the gel- and solution-based experiments described here.    
 
Figure 22: A comparison of the (A) proteome coverage (i.e. assayed proteins) 
from gel-based and solution-based experiments and (B) potential protein hits from 
gel-based and solution-based experiment 
In total, 526 proteins in the yeast cell lysate were effectively assayed for binding 
to the ATP analogue covering a total of 109 proteins annotated with “ATP-binding” GO-
term. A total of 325 peptide hits from 140 different proteins were identified (see 
Appendix B), and 37 of these known ATP binding proteins were identified as hits.  
These 37 proteins constituted 25% of the protein hits in this study. Many of the other 
protein hits in this study are also known to bind other nucleotides (e.g., NAD, GTP), 
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 DNA, RNA and a number of ribosomal proteins were identified as hit proteins in this 
study (see Figure 23). It is also noteworthy that 6 of the newly discovered ATP binding 
proteins in this study are homologues to E. coli proteins that were recently reported to 
have ATP binding interactions based on results of a pulse proteolysis study[21b] (Data not 
shown). 
 
Figure 23: Distribution of known ligands for the hit proteins in this study 
 
5.3.3 Representative SILAC-SPROX-CnBr data from PGM-1 
In the SILAC-SPROX-CnBr experiment, the gel bands must be cut in molecular 
weight ranges such that the full-length protein and the cyanogen bromide fragments are 
not in the same set of gel-bands. This is demonstrated clearly in the case of PGM-1. 
PGM-1 is a small globular protein with 247 amino acids in its primary sequence 
(approximately 27 KDa in MW). It is known from previous solution-based SILAC-
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 SPROX experiments that the yeast PGM-1 binds to ATP and ATP-binding stabilizes the 
protein (See Chapter 4).  
 
 
Figure 24: The sequence coverage of PGM-1 in the 2 gel-based experiments. 
Each arrow represents a peptide identified in the LC MS/MS. Solid arrows represent 
peptides identified the gel-based experiment 1. Dash arrows represent peptides 
identified in the gel-based experiment 2 and correspond to the full-length protein. 
Dotted arrows represent peptides identified in the gel-based experiment 2 and 
correspond to the CnBr-fragment.  
PGM-1 has 2 Methionine residues, one is the initial methionine and the other is at 
position 180. CnBr cleavage at Met-180 results in two fragments; including one which is 
21 KDa and one which is 6KDa. This makes PGM-1 an excellent model for this ATP-
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 binding Study. In the gel-based experiments, PGM-1 serves as a positive control for the 
ATP binding reaction, SPROX Analysis and also gel cutting strategy.  
Presented in Figure 24 is the sequence coverage obtained for PGM-1 in both Gel-
based experiment 1 and 2. In the Gel-based experiment 1, the gel was excised between 20 
and approximately 30 KDa (See Figure 19, experimental procedures). This gel band thus 
contains both the fragment (21KDa) and the full-length protein (27KDa). As expected the 
sequence coverage of PGM-1 this first gel-based experiment showed: (i) peptides that 
are common between the 21 KDa fragment and the full-length protein; and (ii) peptides 
that are unique to the full-length protein (TVM(ox)IAAHGNSLRGLVK and 
HLEGISDADIAK). Peptides from the full-length protein are expected to have the 
opposite SILAC-SPROX curve as peptides from the 21 KDa CnBr fragment. Thus, 
peptides that are common to both the full length protein and the 21 KDa CnBr fragment 
(see Figure 24) will have SILAC-SPROX curves that are the sum of the two behaviors, 
resulting in H/L ratios close to 1 regardless of the denaturant concentration (see Figure 
21 – Expected Results). Peptides that are unique to the full-length protein should have 
SILAC-SPROX curves resemble that shown in Figure 21, in which the H/L ratios 
displayed a significant dip in the transition region. This was indeed the case for all 
PGM-1 peptides obtained in the gel based experiment 1 (see SILAC-SPROX curves of a 
selected non-methionine containing peptide with sequence LSRAIQTANIALEK in 
Figure 25A).  
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Figure 25: Representative SILAC-SPROX-CnBr data from PGM-1 in (A) gel-
based experiment 1 and (B) gel-based experiment 2. Closed circles represents data 
points from peptide TVMIAAHGNSLRGLVK, open circles represents data from 
TVM(ox)IAAHGNSLRGLVK; closed triangles represents data points from a selected 
non-methionine containing peptide LSRAIQTANIALEK in the CnBr Fragment; open 
triangles are data points from LSRAIQTANIALEK in the Full-length protein. Solid 
line represents peptides from gel-based exp. 1; dotted line represents peptide from 
gel-based exp. 2 and the CnBr fragment; dashed line represents peptides from gel-
based exp. 2 and the Full-length protein (see Figure 24). 
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 Ultimately, because of the cutting strategy employed in gel-based experiment 1 
(see Figure 19), the only peptide hits identified were (TVM(ox)IAAHGNSLRGLVK) and 
(TVMIAAHGNSLRGLVK) (See Figure 25A). Interestingly, the presence of 
TVMIAAHGNSLRGLVK in the peptide readout suggests incomplete cleavage of CnBr; 
this is probably the reason why the (HLEGISDADIAK), a peptide unique to the full-
length protein did not show up as a hit in Gel-based experiment 1(Data not shown).  
In Gel-based experiment 2, a more aggressive CnBr digestion was employed 
along with an improved cutting strategy (See Figure 19, experiment procedures). The 
cutting strategy in this region (also one of the most intensely coomassie-stained region) 
involved generating 2 sets of gel-bands; one set in the 20-24 KDa and the other in the 24-
30 KDa MW range. This allowed the full-length 27KDa protein to be effectively 
separated from its corresponding CnBr Fragment (21 KDa).  
The sequence coverage obtained in this second gel-based experiment (see Figure 
24) showed no evidence of the un-oxidized methionine containing peptide, which is 
consistent with more complete cleavage by CnBr. In this case, all peptides from the full-
length protein regardless of whether or not they are common or unique are expected to 
show a “dip” in the H/L ratios from the transition region (i.e. around 2 M Urea) (see 
Figure 21 - Expected Results). Conversely, all peptides from the CnBr fragment are 
expected to show a “peak” in the H/L ratios from the transition region (see Figure 21 – 
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 Expected Results). This was indeed the case for all peptides obtained for PGM-1 in the 
gel-based experiment 2 (see Figure 25B and 26).  
 
Figure 26: SILAC-SPROX-CnBr data of PGM-1 in gel-based experiment 2. (A) 
are all non-methionine containing peptides identified in Full-length protein and (B) 
are those identified in the 21 KDa CnBr Fragment. Dashed line and open symbols 
represents peptide originates from Full-length protein; dotted line and closed 
symbols represents peptides originates from 21 KDa CnBr Fragment.  
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 Interestingly, the change in H/L ratios seems to be more dramatic for methionine 
containing peptide than that of non-methionine containing peptides (see Figure 25B). 
Also, the peptide that is unique to the 27KDa Full-length protein (HLEGISDADIAK) was 
also identified in the gel band with MW range of 20-24 KDa in the gel-based experiment 
2 and showed opposite SILAC-SPROX curves from peptides that originate from the 
CnBr fragment (see Figure 26 below). These suggest that the cutting strategy may not 
separate all full-length protein from the CnBr-fragment.  Nevertheless, the cutting used 
in this case did not affect the ability of the non-methionine containing peptides to report 
on the binding properties of the protein to ATP. This suggests that the cutting strategy in 
the SILAC-SPROX-CnBr experiments does not have to be perfect. An imperfect cutting 
strategy can be tolerated at least in some cases. 
The cutting strategy clearly has an impact on the false negative rate in the Gel-
based experiment 1. Although as many as 354 proteins are assayed (including 73 known 
ATP-binding proteins), only 12 proteins are identified as hits, including only one of the 
known ATP-binding proteins. It is also important to stress that the 20-30 KDa region is 
the most crowded region that contains a large fraction of the proteins/fragments on the 
gel; cutting this region into smaller gel pieces clearly seems to be beneficial.  When 
performing such a 1-D fractionation strategy, it might be advantageous to choose 
alternative gels to better resolve the fragments in this 20-30 KDa region. Also impacting 
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 the false negative rate in gel based experiment 1 is the use of less aggressive oxidation 
reaction conditions. 
5.3.4 Representative SILAC-SPROX-CnBr data from 
Phosphoglycerate Kinase (3-PGK) 
Phosphoglycerate kinase (3-PGK) is another ATP-binding protein identified in 
the gel-based experiments described here. As discussed in the histidine HDX study in 
Chapter 2, 3-PGK has 2 functional domains that fold independently from each other. The 
N-terminal domain has a C1/2 determined from histidine HDX of 1.5 M GdmCl and the 
C-terminal domain has a C1/2 value of 0.5 M GdmCl. These C1/2 values can be roughly 
translated to 3 M and 1 M Urea, respectively. The ATP-binding region is presumably 
located in the C-terminal domain between residues 205-220 (PFLAILGGAKVADKIQ)[68]. 
In Solution-based experiment 1 and 2, one methionine containing peptide was 
identified, (229)-VDSIIIGGGMAFTFK-(243). However this peptide was not effectively 
assayed in either case because it only appears in 5 SILAC-SPROX generated samples in 
Solution-based experiment 1 and 6 SILAC-SPROX generated samples in Solution-based 
experiment 2. As a result, 3-PGK was not identified as a hit in the solution-based 
experiments. 
A visual inspection of the 3-D Structure of this protein (PDB: 1QPG) suggests this 
methionine (Met 238) is protected and in close proximity to the ATP-binding region. 
However the SILAC-SPROX results showed no change in the H/L ratios as a function of 
Urea concentrations in the range of 2.5 to 6 M indicating no interaction. Although it is 
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 interesting to note that, the peptide was not identified in SILAC-SPROX samples with 
Urea concentration < 2.5 M. According to the data generated in the Histidine slow H/D 
exchange experiments (see table 3), the mid-point of this C-term domain is 0.5 M 
GdmCl, which is consistent with previous results in reference[69]. This C1/2 value is 
approximately 1 M Urea and is outside of the 2.5 M to 6 M Urea range that was probed 
in the solution-based SILAC-SPROX experiment. It is noteworthy that 3-PGK is 
identified to be a ATP-binding hit in Gel-based experiment 2 in which non-methionine 
containing peptides can be used to report on the thermodynamic stability of proteins. In 
fact, all 14 peptides that were identified from 3-PGK in the 37-50 KDa MW range of the 
gel-band in Gel-based experiment 2 had a denaturant dependence to their H/L ratios, 
which consistently indicates that 3-PGK is an ATP binding protein (see Figure 27).  
3-PGK has 3 methionine residues; including one that is located on the N-terminal 
domain (i.e. Met-174), and 2 that are located on the C-terminal domain (i.e. Met-238 and 
Met-267). The CnBr digestion of un-oxidized yeast 3-PGK[70] results in 4 CnBr fragments 
with molecular weight ranges from 4.4 to 22 KDa (see Figure 28). The oxidation behavior 
of Met-238 and Met-267 are expected to be similar and to report on the thermodynamic 
stability of the C-terminal domain; whereas the oxidation behavior of Met-174 should 
report on thermodynamic stability of the N-terminal domain. Unfolding of the C-
terminal domain at lower Urea concentrations (≤ 1M) results in protection against CnBr 
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 cleavage at Met-238 and 267 resulting in a CnBr fragment that has the size of fragment B, 
C and D combined (i.e. 23.4 KDa). 
 
Figure 27: Representative SILAC-SPROX-CnBr data from 3-PGK in gel-based 
experiment 2. 
Unfolding of the N-terminal domain at higher Urea concentrations results in 
protection against CnBr cleavage at Met-174 and in the appearance of the Full-length 
protein. The SILAC-SPROX data was collected in the 37-50 KDa molecular weight range. 
Therefore a gel band excised in this molecular weight range should contain only full-
length 3-PGK. The SILAC-SPROX data from all 14 peptides generated from this gel band 
showed a very reproducible curve with a peak initiating at 2M and continuing on to 
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 more than 6 M Urea. The transition at 2 M urea in this case suggests an averaged C1/2 
value of both the C-terminal and N-terminal domains. This data also indicates a 
destabilization. This 3-PGK example demonstrates the power of the gel-based (i.e. the 
SILAC-SPROX-CnBr) strategy to detect protein-ligand binding that may have been 
missed in the solution-based SPROX experiments. 
 
Figure 28: CnBr digestion pattern of the yeast Phosphoglycerate Kinase 1 (3-
PGK). Arrows indicate CnBr cleavage sites, upper numbers indicate molecular weight 
of corresponding CnBr fragments.  
 
5.3.5 ATP binding Properties of Yeast Proteins 
5.3.5.1 ATP binding is promiscuous 
The solution and gel-based SILAC-SPROX experiments described here and in 
Chapter 4 identified a total of 140 protein targets of ATP.   A fraction of the ATP binding 
proteins identified in this work, 28%, were previously annotated with GO-term “ATP 
binding.” A large fraction (21%) of the ATP-binding hits identified in this work that 
were not previously annotated with GO-term “ATP binding”, are proteins known to 
bind nucleoside or nucleotides (e.g.,  uridine, or GTP) or to bind cofactors with the 
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 adenosine moiety (NAD+, FAD). The similarity of these ligands to ATP suggests that 
there is some promiscuity to nucleotide binding proteins.  
ATP binding consists of two parts: the phosphate moiety and the adenine based 
recognition motifs[71]. Among the phosphate binding motifs is the P-loop, a Glycine-rich 
sequence followed by a conserved Lysine (K) and a Serine (S) or Threonine (T). 
Interestingly, some GTP-binding proteins such as Elongation factors (i.e. EF-Tu, EF-1α, 
EF-2 and EF-G) also contain the P-loop[68]. This may explain why many GTP-binding 
proteins are identified as hits in the ATP-binding experiments. EF-Tu and EF-G are 
found to be ATP-binding hits in a previous energetics-based study using pulse 
proteolysis in E. coli[21b]. The corresponding yeast homologs of these proteins, EF-1α and 
EF-2, were also identified as hits in this SILAC-SPROX ATP-binding study (i.e. in Gel-
based experiment 2 and Solution-based experiment 2, respectively). Other GTPase 
Elongation factors such as EF-1β, EF-3A are also identified as hits (i.e. in Solution-based 
experiment 2 and Gel-based experiment 2, respectively).  
The mode of protein-adenine recognition for ATP is similar to that of other 
adenine containing cofactors including coenzyme A (CoA) and NAD+/NADP 
(Nicotinamide Adenine Dinucleotide Phosphate) [71]. The experimental data from this 
ATP-binding study also suggests there is a common motif between ATP and NAD+ as 
well as FAD binding proteins. These results are also in good agreement with results 
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 obtained from previous ATP-binding study in E. coli and Mycobacterium tuberculosis 
(Mtb) [21a, b, 59]. 
5.3.5.2 ATP-binding comprises of both weak and tight bindings 
In this ATP-binding study, a total of 109 known ATP-binding proteins are 
effectively assayed (i.e. proteins annotated with GO-term “ATP binding” in the Yeast 
Genome Database). A total of 37 ATP-binding proteins are detected in this ATP-binding 
study, which accounts for 30% of the assayed ATP-binding proteins. The other 70% of 
the assayed ATP-binding proteins presumably have low affinity toward ATP and thus 
escape from this analysis. This result agrees well with the ATP-binding properties found 
in Mycobacterium tuberculosis (Mtb)[59]. In this study the proteins from Mtb lysate were 
incubated with a chemical probe (desthiobiotin-conjugated ATP) in the presence and 
absence of an ATP inhibitor (ATPγS). If ATP-binding is tight and competitive, the 
presence of excess ATPγS will out-compete the binding of the chemical probe (i.e. the 
desthiobiotin-conjugated ATP). In this study, 2 different sets of proteins were identified: 
those that bind weakly (no difference in presence/absence of ATPγS) and those that bind 
tightly (significant reduced binding to desthiobiotin-conjugated ATP in presence of 
ATPγS)[59]. The results from this study suggest a 50:50 ratio between the tight- and weak- 
ATP binding proteins.  
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 5.3.5.3 Many of ATP-binding Hits Show a Destabilization 
Of the 140 ATP-binding hits identified in this study, only 7 proteins show 
stabilization upon binding to ATP; and 4 of these 7 proteins had some peptide probes 
showing a destabilization and some peptide probes showing stabilization (see Table 11). 
The large majority of the ATP-binding hits found in this study showed only a decrease 
in the thermodynamic stability of proteins upon binding to ATP (see Appendix B). 
The findings are consistent with the ATP-binding study in E. coli using the pulse 
proteolysis approach (see discussion in Chapter 4). In this study, several proteins were 
found to be destabilized by ATP-binding, e.g. GAPDH, GroEL and Uridine 
phosphorylase. Interestingly, the GroEL complex was reportedly destabilized by ADP 
and AMP-PNP; AMP-PNP destabilizes the complex to a lesser extent than ADP (i.e. 
approximately 10.5 kcal/mol vs. 14.1 kcal/mol)[72]. Apparent destabilization of GroEL by 
ADP/AMP-PNP, similar to the case of GAPDH, results from dissociation of the 14 mer 
complex in the presence of these ligands. However, it is noteworthy that the destabilized 
proteins represented a much smaller fraction of the hits (i.e. 3 out of 30) than in this 
yeast study. 
Many of the destabilized proteins identified in the SILAC-SPROX ATP-binding 
study are also multimeric proteins. For example, Alcohol dehydrogenase and GAPDH 
are tetramers; Pyruvate kinase is a dimer, and Aminoacyl tRNA synthetase class II are 
usually dimers and multi-domain proteins, etc. Apparent destabilization resulting from 
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 dissociation of multimeric proteins may be because of the ligands binding to partially 
unfolded intermediates and may not report on the change in global thermodynamic 
stability between the folded and unfolded state of the proteins. 
Table 11: Estimated Kd of proteins that have peptides showing stabilization 
upon binding to ATP. The Kd can only be estimated for peptides that show 
stabilization and if there are enough data points in the transition regions for re-
construction of SPROX curves from SILAC-SPROX data. N/A means there is no 
calculated Kd available. 
Peptides Accessio
n # 
Proteins ΔC1/2 Calculated 
Kd (µM) 
Experiment 
AGM(ox)TTIVRDLDRPGS
K 
P14126 60S 
ribosomal 
protein L3 
Stabilize N/A Solution 
based 1B 
TITPM(ox)GGFVHYGEIK P14126 60S 
ribosomal 
protein L3 
Destabiliz
e 
N/A Solution 
based 1B 
TITPMGGFVHYGEIK P14126 60S 
ribosomal 
protein L3 
Destabiliz
e 
N/A Solution 
based 1B 
(ac)SSSESIRM(ox)VLIGPPG
AGK 
P07170 Adenylate 
kinase 1 
1.5 204.7 Solution 
based 1B 
(ac)SSSESIRMVLIGPPGAG
K 
P07170 Adenylate 
kinase 1 
1.2 343.4 Solution 
based 1B 
GTQAPNLQERFHAAHLA
TGDM(ox)LRSQIAK 
P07170 Adenylate 
kinase 1 
1 484.7 Solution 
based 1B 
GTQAPNLQERFHAAHLA
TGDMLRSQIAK 
P07170 Adenylate 
kinase 1 
1 484.7 Solution 
based 1B 
DLLLLDVAPLSLGVGM(ox
)QGDM(ox)FGIVVPRNTTV
PTIK 
P11484 Heat shock 
protein SSB1 
Destabiliz
e 
N/A Solution 
based 2 
M(ox)VNQAEEFK P40150 Heat shock 
protein SSB1 
1.5 570.1 Solution 
based 2 
NIPM(ox)M(ox)PAGEPVLE
AIFEVDANGILK 
P40150 Heat shock 
protein SSB1 
-1.75 N/A Solution 
based 2 
ESEPM(ox)EVDEDDSK P15705 Heat shock 
protein STI1 
1.5 570.1 Solution 
based 2 
LM(ox)SFPEAIADCNK P15705 Heat shock 
protein STI1 
Destabiliz
e 
N/A Solution 
based 2 
GVVDSEDLPLNLSREM(ox P15108 HSP82 -2.25 N/A Solution-
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 )LQQNK based 2 
GVVDSEDLPLNLSREMLQ
QNK 
P15108 HSP82 Destabiliz
e 
N/A Solution-
based 2 
LLDAPAAIRTGQFGWSA
NM(ox)ERIM(ox)K 
P15108 HSP82 -2 N/A Solution-
based 2 
VLEIRDSGIGMTK P15108 HSP82 Stabilize N/A Solution-
based 2 
TVM(ox)IAAHGNSLRGLV
K 
P00950 Phosphoglyc
erate mutase 
1 
Stabilize N/A Solution_b
ased 1A 
TVM(ox)IAAHGNSLRGLV
K 
P00950 Phosphoglyc
erate mutase 
1 
1.75 133.0 Solution_b
ased 1B 
TVM(ox)IAAHGNSLRGLV
K 
P00950 Phosphoglyc
erate mutase 
1 
1 1519.2 Solution-
based 2 
TVMIAAHGNSLRGLVK P00950 Phosphoglyc
erate mutase 
1 
Stabilize N/A Solution_b
ased 1A 
TVMIAAHGNSLRGLVK P00950 Phosphoglyc
erate mutase 
1 
1.75 133.0 Solution_b
ased 1B 
 
5.3.6 Sensitivity of the SILAC-SPROX protocol  
An average protein contains approximately 300 residues and a typical folding 
domain often contains 60 – 100 residues. An average m value of proteins unfolding in 
Urea is approximately 0.013 per residue[73], thus an average m value for an average 
folding domain should be from 0.78 to 1.3 kcal mol-1 M-1. Assuming this average m 
values, a detectable ΔC1/2 of 1 M Urea and the free Ligand concentration of 1 mM, the 
expected Kd in this first ATP-binding experiment should be approximately in the range 
of 90 – 400 µM (See equation (12), chapter 1). 1 mM ATP is the effective free ligand 
concentration utilized in the first ATP-binding experiments (i.e. Solution-based 
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 experiment 1A/B, Gel-based experiment 1). Therefore, ATP binding hits detected in 
these first experiments are fewer and tighter ATP-binding proteins. For instance, 
GAPDH, ATP is estimated to bind to an E. coli homolog of this protein as tight as 150 
µM[64]. Another reported Kd values of dimeric GAPDH to ATP is 450 µM (See discussion 
in Chapter 4).  
One reason for the inability to detect the binding of ATP to nearly 70% of 
previously annotated ATP binding proteins may be that this fraction of ATP binding 
proteins have binding affinities that are relatively weak and below the threshold of these 
analyses. Therefore, in ATP-binding experiment 2 (i.e. solution-based experiment 2 and 
gel-based experiment 2), the ATP-binding condition and SPROX reaction were adjusted 
to improve the sensitivity of this assay. First increasing oxidation time maximizes the 
C1/2 shift (See discussion in Histidine HDX chapter 2). In the second ATP-binding 
experiment, the measurable C1/2 shift is in the range of 0.75 M to 2 M Urea. Increasing 
effective free ligand concentration increases the measurable Kd (i.e. calculated using 
equation (12)) from 90-400 µM to approximately 600-2700 µM. As a result, the number of 
ATP-binding hits identified in this second ATP-binding experiment increase from 27 to 
99. The number of known ATP-binding proteins increases from 4 to 29. Nevertheless, 
this fraction only accounts for approximately 30% of known ATP-binding proteins 
assayed; we hypothesize that the binding of the other known ATP-binding proteins have 
Kd higher than 2.7 mM. The fraction of detected known ATP-binding proteins in this 
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 work is about half of that in the in E. coli and Mtb studies (both are approximately 
70%)[21a, b, 59]. 
It is noteworthy that the ATP-binding study in E. coli and Mtb utilized a slightly 
different ATP-analog than that employed in the SILAC-SPROX experiments (i.e. ATPγS 
vs. AMP-PNP).  ATPγS significantly reduces the rate of ATP hydrolysis in ATP-binding 
proteins whereas AMP-PNP is completely non-hydrolysable. Because ATP-binding 
systems vary greatly in their specificity so what acts as a good analog in one case may be 
very poor in another[74]. For instance, in a recent study regarding Clamp/Clamp loader 
proteins in Archaeoglobus fulgidus (afRFC), the ability of different ATP analogs (i.e. 
ATPγS and AMP-PNP) to induce native interaction between afRFC and afPCNA 
(Proliferating Cell Nuclear Antigen homologue) was compared with ATP[75]. In this 
system, the binding of ATP but not the hydrolysis of the nucleotide is enough to induce 
the afRFC-afPCNA interaction. The amount of afPCNA recruited to afRFC by ATP is 
considered 100%. Whereas 1mM ATPγS was able recruit comparable amount of afPCNA 
to afRFC, 1mM AMP-PNP only recruits 1/3 of that by ATP. Increasing this AMP-PNP 
concentration from 1mM to 10mM increases the amount of afPCNA recruited to afRFC to 
comparable to that by ATP. It is unknown why 2 seemingly similar ATP analogs have 
different effect on ATP dependent protein activity and this can be the reasons for 
discrepancy between the SILAC-SPROX ATP-binding study and other ATP-binding 
studies in E. coli and Mtb. 
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 5.4 Conclusions and Future Directions 
The SILAC-SPROX strategy (including both solution-based and gel-based 
approaches) successfully assayed 526 proteins in the yeast proteome for ATP binding. A 
total of 109 of the assayed proteins were known to bind ATP based on GO-term “ATP 
binding” annotated in the Yeast Genome database. A total of 140 proteins hits were 
identified as potential ATP-binding targets in yeast, 37 of which have known ATP-
binding interactions. An additional 8 proteins detected in these yeast studies have 
homologs that have been found to interact with ATP in E. coli.  
The SILAC-SPROX-CnBr approach eliminated the pre-requisite to identify and 
quantify methionine containing peptides and improved the proteome coverage of 
solution-based approach by 5-fold. The SILAC-SPROX-CnBr approach not only 
increases the number of peptides (proteins) assayed in general but it also increased the 
number of peptide probes per protein. This improvement changes the fundamental basis 
of current SPROX protocol from a peptide-based quantitation to a protein-based 
quantitation. However, there are benefits of performing both gel-based and solution-
based SILAC-SPROX experiments as the results from both experiments are 
complementary. Altogether the SILAC-SPROX protocol described here has the potential 
to assay 1,000 yeast proteins simultaneously for thermodynamic stability changes and 
protein-ligand interactions. 
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 One unique feature of this SILAC-SPROX analysis is the ability to tune its 
sensitivity toward the ligand of interest by (i) changing free ligand concentration (ii) 
changing equilibration time and (iii) changing oxidation time. This flexibility allows the 
SILAC-SPROX protocol to be applied on a wide variety of ligand classes with wide 
range of binding affinity (i.e. up to 2-3 mM). This is demonstrated in the ATP-binding 
study described here, changes in aforementioned conditions in second ATP-binding 
experiment in solution increased the number of identified protein hits by approximately 
5 fold.  
The SILAC-SPROX-CnBr approach is also amenable to different gel-based 
fractionation and quantification protocol. One of which is Difference gel electrophoresis 
(DIGE)[76]. In this approach, two different biological samples can be labeled with two 
different fluorescent dyes. This allows combination of the 2 samples and simultaneous 
comparative analysis between the two on 2-Dimensional gel electrophoresis. In the 
SILAC-SPROX-CnBr experiment, one can subject the (-) and (+) ligand samples to 
labeling by 2 different fluorescent dyes preceding digestion by CnBr. The (-) and (+) 
ligand sample can then be combined and analyzed simultaneously on 2-D gel 
electrophoresis. In this experiment, each SILAC-SPROX samples from one denaturant 
concentration is analyzed on a 2-D gel. As described previously, the full-length proteins 
will appear as the corresponding CnBr fragments appear. The rate of appearance will be 
different between the (-) and (+) ligand samples resulting in distinguish fluorescence 
143 
 color at a certain spot on the 2-D gel. Identification of proteins with actual altered H/L 
ratios from this gel spot will suggest potential binding targets. This approach promises 
to change the basis of current SPROX protocol from a shotgun proteomic measurement 
to a targeted approach.  
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 Appendix A 
Start 
AA 
sequence Accession # Protein Name Comments 
98 (K)ISDDILSVLDSHLIPS
ATTGESK(V) 
6320304 14-3-3 protein, minor isoform, Bmh2p No structure 
170 (R)AHSSMVGFDLPQRA
AGFLLEKELKYFGK(A) 
10383781 3-phosphoglycerate kinase,  Pgk1p 3pGK, exposed 
225 (K)GYLADDIDADSLED
IYTSAHEAIR(A) 
133003 60S ribosomal protein L5, L1a 3O5H, not enough density to determine orientation 
of the His 
86 (R)YGITHGLTNWAAA
YATGLLIAR(R) 
133003 60S ribosomal protein L5, L1a 3O5H,Not enough density to determine 
orientation, part of the loop 
179 (K)DLTHVEPPKDLDVI
LVAPK(G) 
6323387 Acetohydroxyacid 
reductoisomerasemitochondrial DNA and 
found in mitochondrial nucleoids 
No structure 
96 (R)VAPEEHPVLLTEAP
MNPK(S) 
3328 actin 1YVN,1VAG,Exposed 
148 (R)TTGIVLDSGDGVTH
VVPIYAGFSLPHAILR(L
) 
3328 actin 1YVN,part of beta sheet facing to contact with 
loops regions, seems to be either exposed or 
partially protected 
235 (K)ATDGGAHGVINVS
VSEAAIEASTR(Y) 
1168350 Alcohol dehydrogenase 1, YADH-1 2HCY, exposed 
234 (R)LVNHFIQEFK(R) 6323004 ATP binding protein involved in protein 
folding and vacuolar import of proteins 
No structure 
249 (R)IYAFHAEGVRLLK(I) 6320703 Component of CORVET tethering complex, 
Vps3p 
No structure 
124 (K)HVVFGEVVDGYDIV
K(K) 
6320359 Cytoplasmic peptidyl-prolyl cis-trans 
isomerase (cyclophilin),Cpr1p 
1IST, exposed, loop region 
481 (R)EMGEEVYHAYTEVK
(A) 
6325196 Cytosolic aldehyde dehydrogenase No structure 
63 (K)TVDESNVDPDELLF
DTELADEDLLTHDAR(
6321724 Cytosolic ribosome-associated chaperone, 
Zuo1p 
No structure 
145 
145 
 D) 
786 (R)QATGGQAFPQMVF
DHWSTLGSDPLDPTSK(
A) 
6320593 Elongation factor 2 (EF-2) 1N0V 
33 (R)SIVPSGASTGVHEAL
EMR(D) 
119336 Enolase 1 3ENL, exposed 
289 (K)RYPIVSIEDPFAEDD
WEAWSHFFK(T) 
119336 Enolase 1 3ENL, exposed 
498 (K)ATHILDFGPGGASG
LGVLTHR(N) 
3694 fatty acid synthetase subunit beta 2PFF, loop, exposed 
11 (K)TGVIVGEDVHNLFT
YAK(E) 
6322790 Fructose 1,6-bisphosphate aldolase No structure 
133 (K)QSDLVHIVNSWQAL
TDDLSR(E) 
6319492 Galactose-1-phosphate uridyl transferase No structure 
376 (R)GNVFTDYSTGSILFG
EPATNAQHSFFQLVHQ
GTK(L) 
6319673 Glycolytic enzyme phosphoglucose 
isomerase, Pgi1p 
No structure 
11 (R)GTLEGHNGWVTSL
ATSAGQPNLLLSASR(D
) 
6323763 G-protein beta subunit, Asc1p 3RFG, 3RFH,seems exposed part of the loop but 
facing inward 
456 (R)THLMSPAMAAAAG
IAGHFVDIR(E) 
6321429 Isopropylmalate isomerase No structure 
571 (R)HFVELPR(L) 20428568 major coat protein,  Pdc1p 1M1C Exposed 
244 (R)HALTVQDADEWIE
GDRTDDQFRPPSSK(V) 
20428568 major coat protein,Pdc1p 1M1C, exposed 
244 (R)HALTVQDADEWIE
GDR(T) 
20428568 major coat protein,Pdc1p 1M1C, exposed  
485 (K)AQYNEIQGWDHLS
LLPTFGAK(D) 
6323073 Major of three pyruvate decarboxylase 
isozymes 
1PYD,On the loop oriented inward 
110 (K)QLLLHHTLGNGDFT
VFHR(M) 
6321524 Minor isoform of pyruvate decarboxylase,  
Pdc6p 
No structure 
299 (K)IHPIGELSSEEEEML
QK(C) 
6322765 Mitochondrial malate dehydrogenase No structure 
146 
146 
 112 (R)IAEWADITNAHGVV
GPGIVSGLK(Q) 
6320814 Orotidine-5'-phosphate (OMP) 
decarboxylase,  Ura3p 
1DQW,kinda partially protected, part of beta sheet 
but facing outward to the pocket and maybe in 
contact with the alpha chains 
272 (K)VGYTLPSHIISTSDVT
R(I) 
6320215 Protein component of the large (60S) 
ribosomal subunit 
1S1I,2WWA, sequence in structure didn't cover this 
His 
143 (R)VDFKNPHDIIEGINA
GEIEIPEN(-) 
6320625 Protein component of the large (60S) 
ribosomal subunit 
3O5H,Not included in the structure 
57 (K)ALAIFVPVPSLAGFH
K(V) 
6324670 Protein component of the small (40S) 
ribosomal subunit 
No structure 
90 (R)SVAVPVDILDHDNN
YELK(V) 
6319546 Small heat shock protein (sHSP) with 
chaperone activity 
No structure 
141 (R)ENTEGEFSGLEHESV
PGVVESLK(V) 
6324291 Subunit of mitochondrial NAD(+)-
dependent isocitrate dehydrogenase 
3BLX, seems to be protected, low intensity 
157 (K)ETNPGTDVTVSSVES
VLAHL(-) 
6323138 Thiol-specific peroxiredoxin, Ahp1p No structure 
405 (R)NTAAWHPVIENLV
GTVDDDSLVSIYKPYTE
ESE(-) 
6324804 Transcriptional repressor involved in 
regulation of meiosis and silencing,Wtm1p 
and Rnr4p 
No structure 
145 (K)AIEMEGLTWGAHQ
FIPIGFGIK(K) 
6319315 Translation elongation factor 1 beta 1F60, exposed 
89 (R)KEGGLGPINIPLLAD
TNHSLSR(D) 
6323613 Ubiquitous housekeeping thioredoxin 
peroxidase 
No structure 
71 (R)AIPSALSYVGEDEYH
GGQALQQLIR(N) 
487960 Yhr064cp No structure 
147 
147 
  
Appendix B 
Peptide sequence Accession # Protein name Experiment Known Ligand 
M(ox)TDYFACGDDDVK P22146 1,3-beta-glucanosyltransferase GAS1 Solution-based Exp.2 N/A 
LAM(ox)VVPGSGLVK P07264 3-isopropylmalate dehydratase Gel-based Exp. 2 
4Fe-4S, Fe, Fe-S, 
Metal ion 
LAM(ox)VVPGSGLVK P07264 3-isopropylmalate dehydratase Solution-based Exp.2 
4Fe-4S, Fe, Fe-S, 
Metal ion 
LLEM(ox)STEDFVK Q01855 40S ribosomal protein S15 Gel-based Exp. 2 Ribosomal Protein 
LLEM(ox)STEDFVK Q01855 40S ribosomal protein S15 Solution-based Exp.1B Ribosomal Protein 
LLEM(ox)STEDFVK Q01855 40S ribosomal protein S15 Solution-based Exp.2 Ribosomal Protein 
     
RAGELTQEELERIVQIM(ox)QNPTHYK P0CX55 
40S ribosomal protein S18-A;40S 
ribosomal protein S18-B Solution-based Exp.1B RNA 
IGIVEISPK P07280 40S ribosomal protein S19-A Gel-based Exp. 2 Ribosomal Protein 
LEVPGYVDIVK P07280 40S ribosomal protein S19-A Gel-based Exp. 2 Ribosomal Protein 
TSSGNEM(ox)PPQDAEGWFYK P07281 
40S ribosomal protein S19-A;40S 
ribosomal protein S19-B Solution-based Exp.1B Ribosomal Protein 
TSSGNEM(ox)PPQDAEGWFYK P07280 
40S ribosomal protein S19-A;40S 
ribosomal protein S19-B Solution-based Exp.2 Ribosomal Protein 
EVQGSTLAQLTSK P33442 40S ribosomal protein S1-A Gel-based Exp. 2 Ribosomal Protein 
FDVGALM(ox)ALHGEGSGEEK P33442 40S ribosomal protein S1-A Gel-based Exp. 2 Ribosomal Protein 
LIPEVINK P33442 40S ribosomal protein S1-A Gel-based Exp. 2 Ribosomal Protein 
NLLTNFHGM(ox)DFTTDK P33442 40S ribosomal protein S1-A Gel-based Exp. 2 Ribosomal Protein 
VTGFKDEVLETV P33442 40S ribosomal protein S1-A Gel-based Exp. 2 Ribosomal Protein 
VSGFKDEVLETV P23248 40S ribosomal protein S1-B Gel-based Exp. 2 Ribosomal Protein 
148 
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 FDVGALM(ox)ALHGEGSGEEK P23248 
40S ribosomal protein S1-B;40S 
ribosomal protein S1-A Solution-based Exp.2 Ribosomal Protein 
NLLTNFHGM(ox)DFTTDK P23248 
40S ribosomal protein S1-B;40S 
ribosomal protein S1-A Solution-based Exp.2 Ribosomal Protein 
NLLTNFHGMDFTTDK P23248 
40S ribosomal protein S1-B;40S 
ribosomal protein S1-A Solution-based Exp.2 Ribosomal Protein 
EFQIIDTLLPGLQDEVM(ox)NIKPVQK P25443 40S ribosomal protein S2 Solution-based Exp.2 Ribosomal Protein 
ITTIEEIFLHSLPVK P25443 40S ribosomal protein S2 Gel-based Exp. 2 Ribosomal Protein 
IVVQLNGRLNK P0C0W1 40S ribosomal protein S22-A Gel-based Exp. 2 Ribosomal Protein 
    
 
ALPDAVTIIEPK P05750 40S ribosomal protein S3 Gel-based Exp. 1 RNA 
ALPDAVTIIEPK P05750 40S ribosomal protein S3 Gel-based Exp. 2 RNA 
ALPDAVTIIEPK P05750 40S ribosomal protein S3 Gel-based Exp. 2 RNA 
ALPDAVTIIEPKEEEPILAPSVK P05750 40S ribosomal protein S3 Gel-based Exp. 2 RNA 
EEEPILAPSVK P05750 40S ribosomal protein S3 Gel-based Exp. 1 RNA 
EEEPILAPSVK P05750 40S ribosomal protein S3 Gel-based Exp. 2 RNA 
EEEPILAPSVK P05750 40S ribosomal protein S3 Gel-based Exp. 2 RNA 
YAPGTIVLYAERVQDRGLSAVAQAES
M(ox)K P05750 40S ribosomal protein S3 Solution-based Exp.2 RNA 
TIAETLAEELINAAK P26783 40S ribosomal protein S5 Gel-based Exp. 1 RNA 
WSFEEVEVK P26783 40S ribosomal protein S5 Gel-based Exp. 1 RNA 
VLEDM(ox)VFPTEIVGK P48164 40S ribosomal protein S7-B Gel-based Exp. 1 Ribosomal Protein 
VLEDMVFPTEIVGK P48164 40S ribosomal protein S7-B Solution-based Exp.1B Ribosomal Protein 
QIVNIPSFM(ox)VRLDSEK P05755 
40S ribosomal protein S9-A;40S 
ribosomal protein S9-B Solution-based Exp.2 RNA 
AYTYFGEQSNLPK P05694 
5-
methyltetrahydropteroyltriglutamat
e--homocysteine met Gel-based Exp. 2 Metal, Zinc 
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 FINSEIEK P05694 
5-
methyltetrahydropteroyltriglutamat
e--homocysteine met Gel-based Exp. 2 Metal, Zinc 
GTISAEEYEK P05694 
5-
methyltetrahydropteroyltriglutamat
e--homocysteine met Gel-based Exp. 2 Metal, Zinc 
LASAGATEVQIDEPVLVLDLPANAQA
AIK P05694 
5-
methyltetrahydropteroyltriglutamat
e--homocysteine met Gel-based Exp. 2 Metal, Zinc 
LDEVVVITK P05694 
5-
methyltetrahydropteroyltriglutamat
e--homocysteine met Gel-based Exp. 1 Metal, Zinc 
LDEVVVITK P05694 
5-
methyltetrahydropteroyltriglutamat
e--homocysteine met Gel-based Exp. 2 Metal, Zinc 
M(ox)STRAAPFEQRLPEQQK P05694 
5-
methyltetrahydropteroyltriglutamat
e--homocysteine met Gel-based Exp. 2 Metal, Zinc 
NVSGQDVAAALEANAK P05694 
5-
methyltetrahydropteroyltriglutamat
e--homocysteine met Gel-based Exp. 2 Metal, Zinc 
VFNLPLFPTTTIGSFPQTK P05694 
5-
methyltetrahydropteroyltriglutamat
e--homocysteine met Gel-based Exp. 2 Metal, Zinc 
ELRGRAVVLM(ox)GK P05317 60S acidic ribosomal protein P0 Solution-based Exp.1B Ribosomal Protein 
LREYLEEYK P05317 60S acidic ribosomal protein P0 Gel-based Exp. 1 Ribosomal Protein 
NTM(ox)VRRAIRGFLSDLPDFEK P05317 60S acidic ribosomal protein P0 Solution-based Exp.1B Ribosomal Protein 
NVIVSNRVAAPARAGAVAPEDIWVRA
VNTGM(ox)EPGK P05317 60S acidic ribosomal protein P0 Solution-based Exp.1B Ribosomal Protein 
NVIVSNRVAAPARAGAVAPEDIWVRA
VNTGMEPGK P05317 60S acidic ribosomal protein P0 Solution-based Exp.1B Ribosomal Protein 
SLFVVGVDNVSSQQM(ox)HEVRK P05317 60S acidic ribosomal protein P0 Gel-based Exp. 1 Ribosomal Protein 
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 SLFVVGVDNVSSQQM(ox)HEVRK P05317 60S acidic ribosomal protein P0 Solution-based Exp.1B Ribosomal Protein 
SLFVVGVDNVSSQQMHEVRK P05317 60S acidic ribosomal protein P0 Solution-based Exp.1B Ribosomal Protein 
RNFLETVELQVGLK P53030 60S ribosomal protein L1 Gel-based Exp. 2 Ribosomal Protein 
     
IGPLGLSPK P17079 60S ribosomal protein L12 Gel-based Exp. 2 RNA 
HSGNIQLDEIIEIARQM(ox)RDK P0CX53 
60S ribosomal protein L12-A;60S 
ribosomal protein L12-B Solution-based Exp.1B RNA 
HSGNIQLDEIIEIARQMRDK P0CX53 
60S ribosomal protein L12-A;60S 
ribosomal protein L12-B Solution-based Exp.1B RNA 
IVVVRAEALNISGEFFRNK P26785 60S ribosomal protein L16-B Gel-based Exp. 1 RNA 
SCGVDAM(ox)SVDDLK P0CX43 
60S ribosomal protein L1-A;60S 
ribosomal protein L1-B Solution-based Exp.2 Ribosomal Protein 
EYQVIGRRLPTESVPEPK P0C2I0 60S ribosomal protein L20 Gel-based Exp. 2 Ribosomal Protein 
AQGVAVQLK Q02753 60S ribosomal protein L21-A Gel-based Exp. 2 Ribosomal Protein 
SSVGVIINK Q02753 60S ribosomal protein L21-A Gel-based Exp. 2 Ribosomal Protein 
TGVVYNVTK Q02753 60S ribosomal protein L21-A Gel-based Exp. 2 Ribosomal Protein 
GSGSRLNRLPAASLGDM(ox)VM(ox)AT
VK P0CX41 
60S ribosomal protein L23-A;60S 
ribosomal protein L23-B Solution-based Exp.2 Ribosomal Protein 
M(ox)KVEVDSFSGAK P24000 60S ribosomal protein L24-B Solution-based Exp.1B RNA 
KVEDGNILVFQVSM(ox)K P04456 60S ribosomal protein L25 Solution-based Exp.1B RNA 
VIEQPITSETAMK P04456 60S ribosomal protein L25 Solution-based Exp.2 RNA 
ETAPVIDTLAAGYGK P02406 60S ribosomal protein L28 Gel-based Exp. 2 Ribosomal Protein 
     
LWTLIPEDK P02406 60S ribosomal protein L28 Gel-based Exp. 2 Ribosomal Protein 
AGM(ox)TTIVRDLDRPGSK P14126 60S ribosomal protein L3 Gel-based Exp. 2 Ribosomal Protein 
AGM(ox)TTIVRDLDRPGSK P14126 60S ribosomal protein L3 Solution-based Exp.1B Ribosomal Protein 
AHLAEIQLNGGSISEK P14126 60S ribosomal protein L3 Gel-based Exp. 2 Ribosomal Protein 
ALEEVSLK P14126 60S ribosomal protein L3 Gel-based Exp. 2 Ribosomal Protein 
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 DDRSKPVALTSFLGYK P14126 60S ribosomal protein L3 Gel-based Exp. 2 Ribosomal Protein 
IYRVGKGDDEANGATSFDRTK P14126 60S ribosomal protein L3 Gel-based Exp. 2 Ribosomal Protein 
TITPM(ox)GGFVHYGEIK P14126 60S ribosomal protein L3 Gel-based Exp. 2 Ribosomal Protein 
TITPM(ox)GGFVHYGEIK P14126 60S ribosomal protein L3 Solution-based Exp.1B Ribosomal Protein 
TITPM(ox)GGFVHYGEIK P14126 60S ribosomal protein L3 Solution-based Exp.2 Ribosomal Protein 
TITPMGGFVHYGEIK P14126 60S ribosomal protein L3 Solution-based Exp.1B Ribosomal Protein 
TVAVDSVFEQNEM(ox)IDAIAVTK P14126 60S ribosomal protein L3 Gel-based Exp. 2 Ribosomal Protein 
VDWAREHFEK P14126 60S ribosomal protein L3 Gel-based Exp. 2 Ribosomal Protein 
LIIIAANTPVLRK P14120 60S ribosomal protein L30 Gel-based Exp. 2 Ribosomal Protein 
LHM(ox)GTDDVRLAPELNQAIWK P0C2H8 60S ribosomal protein L31-A Solution-based Exp.1B Ribosomal Protein 
LHM(ox)GTDDVRLAPELNQAIWK P0C2H8 60S ribosomal protein L31-A Solution-based Exp.2 Ribosomal Protein 
     
M(ox)GVPYAIVK P17076 60S ribosomal protein L8-A Solution-based Exp.2 Ribosomal Protein 
M(ox)RYVYAHFPINVNIVEK P05738 
60S ribosomal protein L9-A;60S 
ribosomal protein L9-B Solution-based Exp.1B Ribosomal Protein 
SLVDNM(ox)ITGVTK P05738 
60S ribosomal protein L9-A;60S 
ribosomal protein L9-B Solution-based Exp.1B Ribosomal Protein 
SLVDNM(ox)ITGVTK P05738 
60S ribosomal protein L9-A;60S 
ribosomal protein L9-B Solution-based Exp.2 Ribosomal Protein 
IIRM(ox)PLVESVK P16861 
6-phosphofructokinase subunit 
alpha Solution-based Exp.2 ATP 
DLLQTM(ox)FPVDFIHEGK Q00955 
Acetyl-CoA carboxylase;Biotin 
carboxylase Solution-based Exp.2 
ATP, Biotin, Mn, 
Metal ion 
TTTDHISM(ox)AGPWLK P19414 Aconitate hydratase, mitochondrial Solution-based Exp.2 
4Fe-4S, Fe, Fe-S, 
Metal ion, ATP* 
EITALAPSSMK P60010 Actin Solution-based Exp.1B ATP 
M(ox)AIFDELLQM(ox)PETK P47143 Adenosine kinase Solution-based Exp.2 ATP, Mg 
IADISLAAFGRK P39954 Adenosylhomocysteinase Gel-based Exp. 2 NAD 
LNLILDDGGDLTTLVHEK P39954 Adenosylhomocysteinase Gel-based Exp. 2 NAD 
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 TGPFEVGVHVLPK P39954 Adenosylhomocysteinase Gel-based Exp. 2 NAD 
VPAINVNDSVTK P39954 Adenosylhomocysteinase Gel-based Exp. 2 NAD 
VPAINVNDSVTK P39954 Adenosylhomocysteinase Gel-based Exp. 2 NAD 
VQSEYLGIPEEGPFK P39954 Adenosylhomocysteinase Gel-based Exp. 2 NAD 
(ac)SSSESIRM(ox)VLIGPPGAGK P07170 Adenylate kinase 1 Solution-based Exp.1B ATP 
(ac)SSSESIRMVLIGPPGAGK P07170 Adenylate kinase 1 Solution-based Exp.1B ATP 
GTQAPNLQERFHAAHLATGDM(ox)L
RSQIAK P07170 Adenylate kinase 1 Solution-based Exp.1B ATP 
 
    
DGM(ox)DFADAM(ox)AQSTK P17555 Adenylyl cyclase-associated protein Solution-based Exp.2 Actin 
NPELRQSSTVSSTGSK P17555 Adenylyl cyclase-associated protein Gel-based Exp. 2 Actin 
ESNFLIDFLM(ox)GGVSAAVAK P18239 ADP,ATP carrier protein 2 Solution-based Exp.2 ATP, ADP 
LLIQNQDEM(ox)LK P18239 ADP,ATP carrier protein 2 Solution-based Exp.2 ATP, ADP 
AM(ox)GYRVLGIDGGEGK P00330 Alcohol dehydrogenase 1 Gel-based Exp. 2 NAD, Metal, Zinc 
AM(ox)GYRVLGIDGGEGK P00330 Alcohol dehydrogenase 1 Gel-based Exp. 2 NAD, Metal, Zinc 
AM(ox)GYRVLGIDGGEGK P00330 Alcohol dehydrogenase 1 Solution-based Exp.2 NAD, Metal, Zinc 
ANELLINVK P00330 Alcohol dehydrogenase 1 Gel-based Exp. 2 NAD, Metal, Zinc 
ANELLINVK P00330 Alcohol dehydrogenase 1 Gel-based Exp. 2 NAD, Metal, Zinc 
DIVGAVLK P00330 Alcohol dehydrogenase 1 Gel-based Exp. 2 NAD, Metal, Zinc 
DIVGAVLK P00330 Alcohol dehydrogenase 1 Gel-based Exp. 2 NAD, Metal, Zinc 
GQIVGRYVVDTSK P00330 Alcohol dehydrogenase 1 Gel-based Exp. 2 NAD, Metal, Zinc 
LPLVGGHEGAGVVVGM(ox)GENVK P00330 Alcohol dehydrogenase 1 Gel-based Exp. 2 NAD, Metal, Zinc 
VVGLSTLPEIYEK P00330 Alcohol dehydrogenase 1 Gel-based Exp. 2 NAD, Metal, Zinc 
LPLVGGHEGAGVVVGM(ox)GENVK P00330 
Alcohol dehydrogenase 1;Alcohol 
dehydrogenase 2 Solution-based Exp.2 NAD, Metal, Zinc 
LPLVGGHEGAGVVVGMGENVK P00330 
Alcohol dehydrogenase 1;Alcohol 
dehydrogenase 2 Solution-based Exp.2 NAD, Metal, Zinc 
SLQDIIAILGM(ox)DELSEQDK P00830 ATP synthase subunit beta, Solution-based Exp.2 ATP 
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 mitochondrial 
AELINNLGTIAK P15108 
ATP-dependent molecular 
chaperone HSC82 Gel-based Exp. 2 ATP 
AELINNLGTIAK P15108 
ATP-dependent molecular 
chaperone HSC82 Gel-based Exp. 2 ATP 
GVVDSEDLPLNLSREM(ox)LQQNK P15108 
ATP-dependent molecular 
chaperone HSC82 Gel-based Exp. 2 ATP 
GVVDSEDLPLNLSREM(ox)LQQNK P15108 
ATP-dependent molecular 
chaperone HSC82 Gel-based Exp. 2 ATP 
LGVHEDTQNRAALAK P15108 
ATP-dependent molecular 
chaperone HSC82 Gel-based Exp. 2 ATP 
LGVHEDTQNRAALAK P15108 
ATP-dependent molecular 
chaperone HSC82 Gel-based Exp. 2 ATP 
VLEIRDSGIGM(ox)TK P15108 
ATP-dependent molecular 
chaperone HSC82 Gel-based Exp. 2 ATP 
VLEIRDSGIGM(ox)TK P15108 
ATP-dependent molecular 
chaperone HSC82 Gel-based Exp. 2 ATP 
GVVDSEDLPLNLSREM(ox)LQQNK P15108 
ATP-dependent molecular 
chaperone HSP82;ATP-dependent m Solution-based Exp.2 ATP 
GVVDSEDLPLNLSREMLQQNK P15108 
ATP-dependent molecular 
chaperone HSP82;ATP-dependent m Solution-based Exp.2 ATP 
LLDAPAAIRTGQFGWSANM(ox)ERIM(
ox)K P15108 
ATP-dependent molecular 
chaperone HSP82;ATP-dependent m Solution-based Exp.2 ATP 
VLEIRDSGIGMTK P15108 
ATP-dependent molecular 
chaperone HSP82;ATP-dependent m Solution-based Exp.2 ATP 
APQALM(ox)LAPTRELALQIQK P10081 ATP-dependent RNA helicase eIF4A Solution-based Exp.1B ATP 
FTVSAIYSDLPQQERDTIM(ox)K P10081 ATP-dependent RNA helicase eIF4A Solution-based Exp.2 ATP 
GVAINFVTNEDVGAM(ox)RELEK P10081 ATP-dependent RNA helicase eIF4A Solution-based Exp.2 ATP 
M(ox)FILDEADEM(ox)LSSGFK P10081 ATP-dependent RNA helicase eIF4A Solution-based Exp.2 ATP 
SPTPQ(de)EILQ(de)RFQ(de)KQ(de) Q06337 
Chromatin modification-related 
protein EAF1 Gel-based Exp. 1 DNA 
LEDNM(ox)NLEAK REV__P46677 CON__P0C1U8 Solution-based Exp.2 N/A 
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 MVDLGIQPPPISTPNLSLPPVILSRFGSD
PSK P43616 Cys-Gly metallodipeptidase DUG1 Solution-based Exp.2 
Mn, Metal ion, 
Zinc 
AM(ox)QFNTIGVSDGISM(ox)GTK P39522 
Dihydroxy-acid dehydratase, 
mitochondrial Solution-based Exp.2 4Fe-4S 
YLYENNM(ox)LHGNTM(ox)TVTGDTL
AERAK P39522 
Dihydroxy-acid dehydratase, 
mitochondrial Solution-based Exp.1B 4Fe-4S 
YVM(ox)ADLINVGGTQSVIK P39522 
Dihydroxy-acid dehydratase, 
mitochondrial Solution-based Exp.2 4Fe-4S 
SVPTACNSYGGM(ox)YK P39976 
D-lactate dehydrogenase 
[cytochrome] 3 Solution-based Exp.2 FAD, Flavoprotein 
IGGIGTVPVGRVETGVIKPGM(ox)VVTF
APAGVTTEVK P02994 Elongation factor 1-alpha Gel-based Exp. 2 GTP, ATP (EF-Tu) 
IGGIGTVPVGRVETGVIKPGM(ox)VVTF
APAGVTTEVK P02994 Elongation factor 1-alpha Gel-based Exp. 2 GTP, ATP (EF-Tu) 
SVEM(ox)HHEQLEQGVPGDNVGFNV
K P02994 Elongation factor 1-alpha Gel-based Exp. 2 GTP, ATP (EF-Tu) 
WDESRFQEIVK P02994 Elongation factor 1-alpha Gel-based Exp. 2 GTP, ATP (EF-Tu) 
WDESRFQEIVK P02994 Elongation factor 1-alpha Gel-based Exp. 2 GTP, ATP (EF-Tu) 
WDESRFQEIVK P02994 Elongation factor 1-alpha Gel-based Exp. 2 GTP, ATP (EF-Tu) 
YAWVLDK P02994 Elongation factor 1-alpha Gel-based Exp. 2 GTP, ATP (EF-Tu) 
YAWVLDK P02994 Elongation factor 1-alpha Gel-based Exp. 2 GTP, ATP (EF-Tu) 
YQVTVIDAPGHRDFIK P02994 Elongation factor 1-alpha Gel-based Exp. 2 GTP, ATP (EF-Tu) 
AIEM(ox)EGLTWGAHQFIPIGFGIK P32471 Elongation factor 1-beta Solution-based Exp.2 GTP 
SIVTLDVKPWDDETNLEEM(ox)VANV
K P32471 Elongation factor 1-beta Solution-based Exp.2 GTP 
VSLDDLQQSIEEDEDHVQSTDIAAM(o
x)QK P32471 Elongation factor 1-beta Solution-based Exp.2 GTP 
ADLMLYVSK P32324 Elongation factor 2 Solution-based Exp.2 GTP, ATP* (EF-G) 
M(ox)M(ox)DRLWGDSFFNPK P32324 Elongation factor 2 Solution-based Exp.2 GTP, ATP* (EF-G) 
STAISLYSEM(ox)SDEDVK P32324 Elongation factor 2 Solution-based Exp.2 GTP, ATP* (EF-G) 
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 VAFTVDQMRSLMDK P32324 Elongation factor 2 Solution-based Exp.2 GTP, ATP* (EF-G) 
AYEELSNTDLEFKFPEPGYLEGVK P16521 Elongation factor 3A Gel-based Exp. 2 ATP, GTP 
EALASGQFRPLTRK P16521 Elongation factor 3A Gel-based Exp. 2 ATP, GTP 
GNFTEFVK P16521 Elongation factor 3A Gel-based Exp. 2 ATP, GTP 
LVEDPQVIAPFLGK P16521 Elongation factor 3A Gel-based Exp. 2 ATP, GTP 
NLTEEVWAVK P16521 Elongation factor 3A Gel-based Exp. 2 ATP, GTP 
AADALLLK P00924 Enolase 1 Gel-based Exp. 2 Mg, Metal ion 
NVNDVIAPAFVK P00924 Enolase 1 Gel-based Exp. 2 Mg, Metal ion 
RYGASAGNVGDEGGVAPNIQTAEEAL
DLIVDAIK P00924 Enolase 1 Gel-based Exp. 2 Mg, Metal ion 
VNQIGTLSESIK P00924 Enolase 1 Gel-based Exp. 2 Mg, Metal ion 
GVFRSIVPSGASTGVHEALEM(ox)RDE
DK P00925 Enolase 2 Solution-based Exp.1B Mg, Metal 
GVFRSIVPSGASTGVHEALEM(ox)RDE
DK P00925 Enolase 2 Solution-based Exp.2 Mg, Metal 
GVFRSIVPSGASTGVHEALEMRDEDK P00925 Enolase 2 Solution-based Exp.1B Mg, Metal 
GVMNAVNNVNNVIAAAFVK P00925 Enolase 2 Solution-based Exp.2 Mg, Metal 
LGANAILGVSMAAARAAAAEK P00925 Enolase 2 Solution-based Exp.2 Mg, Metal 
NVPLYQHLADLSK P00925 Enolase 2 Gel-based Exp. 2 Mg, Metal 
NVPLYQHLADLSK P00925 Enolase 2 Gel-based Exp. 2 Mg, Metal 
TAGIQIVADDLTVTNPARIATAIEK P00925 Enolase 2 Gel-based Exp. 2 Mg, Metal 
TFAEAMRIGSEVYHNLK P00925 Enolase 2 Solution-based Exp.2 Mg, Metal 
WLTGVELADM(ox)YHSLM(ox)K P00925 Enolase 2 Solution-based Exp.2 Mg, Metal 
TDVVFM(ox)PVSGYSGANLK P05453 
Eukaryotic peptide chain release 
factor GTP-binding sub Solution-based Exp.2 GTP 
ATGQEM(ox)DVVSEEPLIEWLAANYK P12385 
Eukaryotic peptide chain release 
factor subunit 1 Solution-based Exp.2 GTP, TPA-1 
M(ox)DLTSFLNDDTFGSSWAEEDVDL
NK P34167 
Eukaryotic translation initiation 
factor 4B Solution-based Exp.2 RNA 
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 KLEDLSPSTHNM(ox)EVPVVK P23301 
Eukaryotic translation initiation 
factor 5A-1 Gel-based Exp. 1 RNA* 
LEDLSPSTHNM(ox)EVPVVK P23301 
Eukaryotic translation initiation 
factor 5A-1 Solution-based Exp.2 RNA* 
RNEYQLLDIDDGFLSLM(ox)NM(ox)DG
DTK P23301 
Eukaryotic translation initiation 
factor 5A-1 Solution-based Exp.1B RNA* 
RNEYQLLDIDDGFLSLM(ox)NM(ox)DG
DTK P23301 
Eukaryotic translation initiation 
factor 5A-1 Solution-based Exp.2 RNA* 
VHLVAIDIFTGK P23301 
Eukaryotic translation initiation 
factor 5A-1 Gel-based Exp. 1 RNA* 
APEGELGDSLQTAFDEGK P23301 
Eukaryotic translation initiation 
factor 5A-2 Gel-based Exp. 2 RNA* 
EM(ox)IQEVIVEEDLEPFEASK P19097 
Fatty acid synthase subunit alpha; 
Acyl carrier;3-oxoacy Solution-based Exp.2 
NAD, NADP, Mg, 
Metal ion, 
phosphopantethei
n 
FFHNGM(ox)IYNK P19097 
Fatty acid synthase subunit 
alpha;Acyl carrier;3-oxoacy Solution-based Exp.2 
NAD, NADP, Mg, 
Metal ion, 
phosphopantethei
n 
FM(ox)EYHISNTDETK P19097 
Fatty acid synthase subunit 
alpha;Acyl carrier;3-oxoacy Solution-based Exp.2 
NAD, NADP, Mg, 
Metal ion, 
phosphopantethei
n 
SPVM(ox)ADLNGGLQFVPELK P19097 
Fatty acid synthase subunit 
alpha;Acyl carrier;3-oxoacy Solution-based Exp.2 
NAD, NADP, Mg, 
Metal ion, 
phosphopantethei
n 
APSGLDQSRIPFSERK P07149 Fatty acid synthase subunit beta Gel-based Exp. 2 NAD, NADP 
LLQENDTTLVK P07149 Fatty acid synthase subunit beta Gel-based Exp. 2 NAD, NADP 
GLLSATQFTQPALTLM(ox)EK P07149 
Fatty acid synthase subunit beta;3-
hydroxypalmitoyl-[ac Solution-based Exp.2 NAD, NADP 
NYITARIM(ox)AK P07149 Fatty acid synthase subunit beta;3- Solution-based Exp.2 NAD, NADP 
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 hydroxypalmitoyl-[ac 
EDLYTKPEQVYNVYK P14540 Fructose-bisphosphate aldolase Gel-based Exp. 2 Metal, Zinc 
EHGEPLFSSHM(ox)LDLSEETDEENIST
CVK P14540 Fructose-bisphosphate aldolase Solution-based Exp.2 Metal, Zinc 
GISNEGQNASIK P14540 Fructose-bisphosphate aldolase Gel-based Exp. 2 Metal, Zinc 
FEVM(ox)LQGIK P54885 
Gamma-glutamyl phosphate 
reductase Solution-based Exp.2 NADP 
FLM(ox)DGTTYLPSNGGIVQRDYK Q12680 Glutamate synthase [NADH] Solution-based Exp.2 
3Fe-4S, FAD, 
FMN, 
Flavoprotein, Fe, 
Metal, NAD 
DWRGGRTASGNIIPSSTGAAK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Gel-based Exp. 2 NAD, ATP 
DWRGGRTASGNIIPSSTGAAK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Gel-based Exp. 2 NAD, ATP 
IATYQERDPANLPWGSLK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Gel-based Exp. 2 NAD, ATP 
LTGM(ox)AFRVPTVDVSVVDLTVK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Gel-based Exp. 2 NAD, ATP 
LTGM(ox)AFRVPTVDVSVVDLTVK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Gel-based Exp. 2 NAD, ATP 
VLPELQGK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Gel-based Exp. 2 NAD, ATP 
VLPELQGK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Gel-based Exp. 2 NAD, ATP 
VLPELQGK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Gel-based Exp. 2 NAD, ATP 
VVITAPSSSAPM(ox)FVVGVNHTK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Solution-based Exp.1B NAD, ATP 
VVITAPSSSAPM(ox)FVVGVNHTK P00360 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 Solution-based Exp.2 NAD, ATP 
VVITAPSSSAPMFVVGVNHTK P00360 Glyceraldehyde-3-phosphate Solution-based Exp.1B NAD, ATP 
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 dehydrogenase 1 
LVSWYDNEYGYSTRVVDLVEHVAK P00358 
Glyceraldehyde-3-phosphate 
dehydrogenase 2 Gel-based Exp. 2 NAD, ATP 
NVEVVALNDPFISNDYSAYM(ox)FK P00358 
Glyceraldehyde-3-phosphate 
dehydrogenase 2 Gel-based Exp. 2 NAD, ATP 
NVEVVALNDPFISNDYSAYM(ox)FK P00358 
Glyceraldehyde-3-phosphate 
dehydrogenase 2 Solution-based Exp.2 NAD, ATP 
VVITAPSSTAPMFVMGVNEEK P00358 
Glyceraldehyde-3-phosphate 
dehydrogenase 2 Solution-based Exp.1A NAD, ATP 
YDSTHGRYAGEVSHDDK P00358 
Glyceraldehyde-3-phosphate 
dehydrogenase 2 Gel-based Exp. 2 NAD, ATP 
YDSTHGRYAGEVSHDDK P00358 
Glyceraldehyde-3-phosphate 
dehydrogenase 2 Gel-based Exp. 2 NAD, ATP 
YDSTHGRYAGEVSHDDK P00358 
Glyceraldehyde-3-phosphate 
dehydrogenase 2 Gel-based Exp. 2 NAD, ATP 
VINDAFGIEEGLM(ox)TTVHSM(ox)TA
TQK P00358 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.2 NAD, ATP 
VINDAFGIEEGLMTTVHSMTATQK P00358 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.1B NAD, ATP 
KVVITAPSSTAPM(ox)FVM(ox)GVNEE
K P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Gel-based Exp. 1 NAD, ATP 
KVVITAPSSTAPM(ox)FVM(ox)GVNEE
K P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.1B NAD, ATP 
KVVITAPSSTAPMFVMGVNEEK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.1B NAD, ATP 
VVITAPSSTAPM(ox)FVM(ox)GVNEEK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Gel-based Exp. 1 NAD, ATP 
VVITAPSSTAPM(ox)FVM(ox)GVNEEK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.1B NAD, ATP 
VVITAPSSTAPM(ox)FVM(ox)GVNEEK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.2 NAD, ATP 
VVITAPSSTAPM(ox)FVMGVNEEK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.1B NAD, ATP 
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 VVITAPSSTAPMFVMGVNEEK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.1B NAD, ATP 
LTGM(ox)AFRVPTVDVSVVDLTVK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.2 NAD, ATP 
LTGMAFRVPTVDVSVVDLTVK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 2;Glyceraldehy Solution-based Exp.1B NAD, ATP 
GVLGYTEDAVVSSDFLGDSHSSIFDAS
AGIQLSPK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 3 Gel-based Exp. 2 NAD, ATP 
IATYQERDPANLPWGSSNVDIAIDSTG
VFK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 3 Gel-based Exp. 2 NAD, ATP 
IATYQERDPANLPWGSSNVDIAIDSTG
VFK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 3 Gel-based Exp. 2 NAD, ATP 
VINDAFGIEEGLM(ox)TTVHSLTATQK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 3 Gel-based Exp. 2 NAD, ATP 
VINDAFGIEEGLM(ox)TTVHSLTATQK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 3 Solution-based Exp.1B NAD, ATP 
VINDAFGIEEGLM(ox)TTVHSLTATQK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 3 Solution-based Exp.2 NAD, ATP 
VINDAFGIEEGLMTTVHSLTATQK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 3 Solution-based Exp.1A NAD, ATP 
VINDAFGIEEGLMTTVHSLTATQK P00359 
Glyceraldehyde-3-phosphate 
dehydrogenase 3 Solution-based Exp.1B NAD, ATP 
IDGYSGPELGELM(ox)EK P38088 
Glycine--tRNA ligase 1, 
mitochondrial Solution-based Exp.2 ATP 
VESHLLNM(ox)SQDDLASK P38088 
Glycine--tRNA ligase 1, 
mitochondrial Solution-based Exp.2 ATP 
HQVDLSGSGTNNM(ox)GSNGAPK P51996 GTP-binding protein YPT32/YPT11 Solution-based Exp.2 GTP 
AM(ox)YTLSAQDEVFSLAFSPNRYWLA
AATATGIK P38011 
Guanine nucleotide-binding protein 
subunit beta-like pr Solution-based Exp.1B GTP 
DGEIM(ox)LWNLAAK P38011 
Guanine nucleotide-binding protein 
subunit beta-like pr Solution-based Exp.2 GTP 
SDVM(ox)SVDIDKK P38011 
Guanine nucleotide-binding protein 
subunit beta-like pr Solution-based Exp.1B GTP 
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 YAIDM(ox)TEQARQGK P31539 Heat shock protein 104 Solution-based Exp.2 ATP 
NVAAGCNPM(ox)DLRRGSQVAVEK P19882 
Heat shock protein 60, 
mitochondrial Solution-based Exp.2 ATP 
HVFSATQLAAM(ox)FIDK P32589 Heat shock protein homolog SSE1 Solution-based Exp.2 ATP 
DAGTIAGLNVLRIINEPTAAAIAYGLD
K P10591 Heat shock protein SSA1 Gel-based Exp. 2 ATP 
EPNRSINPDEAVAYGAAVQAAILTGD
ESSK P10591 Heat shock protein SSA1 Gel-based Exp. 2 ATP 
LIPRNSTIPTK P10591 Heat shock protein SSA1 Gel-based Exp. 2 ATP 
LVTDYFNGK P10591 Heat shock protein SSA1 Gel-based Exp. 2 ATP 
NQLESIAYSLK P10591 Heat shock protein SSA1 Gel-based Exp. 2 ATP 
VNDAVVTVPAYFNDSQRQATK P10591 Heat shock protein SSA1 Gel-based Exp. 2 ATP 
NQAAM(ox)NPANTVFDAK P10592 Heat shock protein SSA2 Solution-based Exp.2 ATP 
RLIGRNFNDPEVQGDM(ox)K P10592 Heat shock protein SSA2 Solution-based Exp.2 ATP 
DLLLLDVAPLSLGVGM(ox)QGDM(ox)
FGIVVPRNTTVPTIK P11484 Heat shock protein SSB1 Solution-based Exp.2 ATP 
ENTLLGEFDLK P11484 Heat shock protein SSB1 Gel-based Exp. 2 ATP 
SQIDEVVLVGGSTRIPK P11484 Heat shock protein SSB1 Gel-based Exp. 2 ATP 
SSNITISNAVGRLSSEEIEK P11484 Heat shock protein SSB1 Gel-based Exp. 2 ATP 
M(ox)VNQAEEFK P40150 
Heat shock protein SSB1;Heat shock 
protein SSB2 Solution-based Exp.2 ATP 
DAGLSTSDISEVLLVGGMSRMPK P0CS90 
Heat shock protein SSC1, 
mitochondrial Solution-based Exp.1B ATP 
ESEPM(ox)EVDEDDSK P15705 Heat shock protein STI1 Solution-based Exp.2 
ATPase inhibitor, 
HSP90, HSP 70 
binding 
LM(ox)SFPEAIADCNK P15705 Heat shock protein STI1 Solution-based Exp.2 
ATPase inhibitor, 
HSP90, HSP 70 
binding 
ELM(ox)QQIENFEK P04807 Hexokinase-2 Solution-based Exp.2 ATP 
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 SAEDASEFVGVGSIAAGGRYDNLVNM
(ox)FSEASGK P07263 
Histidine--tRNA ligase, 
mitochondrial Solution-based Exp.2 ATP 
GENVDPEIATYNEM(ox)VEDLFEQLAK P06101 Hsp90 co-chaperone Cdc37 Solution-based Exp.2 Hsp90, kinases 
ALGIM(ox)ALLDEGETDWK P00817 Inorganic pyrophosphatase Solution-based Exp.1B 
Mg, Metal, 
Diphosphate 
ALGIM(ox)ALLDEGETDWK P00817 Inorganic pyrophosphatase Solution-based Exp.2 
Mg, Metal, 
Diphosphate 
ALGIMALLDEGETDWK P00817 Inorganic pyrophosphatase Solution-based Exp.1B 
Mg, Metal, 
Diphosphate 
ENNIFNM(ox)VVEIPRWTNAK P00817 Inorganic pyrophosphatase Solution-based Exp.1B 
Mg, Metal, 
Diphosphate 
M(ox)SNIDFQYDDSVK P09436 
Isoleucine--tRNA ligase, 
cytoplasmic Solution-based Exp.2 ATP 
ELDTIRNM(ox)EIWK P06168 
Ketol-acid reductoisomerase, 
mitochondrial Solution-based Exp.2 
NAD, Mg, metal 
ion 
STGNFM(ox)TLEQTVEK P26637 Leucine--tRNA ligase, cytoplasmic Solution-based Exp.2 ATP 
AAAEGVANLHLDEATGEM(ox)VSK P15180 Lysine--tRNA ligase, cytoplasmic Solution-based Exp.2 ATP 
LVGELEDTCINPTFIFGHPQM(ox)M(ox)
SPLAK P15180 Lysine--tRNA ligase, cytoplasmic Solution-based Exp.2 ATP 
RYLDLIM(ox)NK P15180 Lysine--tRNA ligase, cytoplasmic Solution-based Exp.2 ATP 
DNQTSADAVEDGQNTGAM(ox)SHAFI
K Q08601 Metacaspase-1 Solution-based Exp.2 N/A 
VSVGDLRYM(ox)LTGLGEK P53141 Myosin light chain 1 Solution-based Exp.2 Ca, metal ion 
M(ox)SDSPADGLDLALK Q07551 
NADPH-dependent alpha-keto 
amide reductase Solution-based Exp.2 NADP 
NTWGSQLVDQIM(ox)DQVVTK P53184 Nicotinamidase Solution-based Exp.2 
nicotinamide, 
metal, Zinc 
NTWGSQLVDQIMDQVVTK P53184 Nicotinamidase Solution-based Exp.2 
nicotinamide, 
metal, Zinc 
VEEAVLQSQGK P40010 Nuclear GTP-binding protein NUG1 Gel-based Exp. 2 GTP 
SSM(ox)QIDNAPTPHNTPASVLNPSYL
K P25293 Nucleosome assembly protein Solution-based Exp.2 DNA 
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 GFGYAGSPFHRVIPDFM(ox)LQGGDFT
AGNGTGGK P14832 Peptidyl-prolyl cis-trans isomerase Solution-based Exp.2 CsA 
MPQTVEWSK P38013 Peroxiredoxin type-2 Solution-based Exp.2 N/A 
GLINDPDM(ox)NNSFQINK P14843 
Phospho-2-dehydro-3-
deoxyheptonate aldolase, 
phenylalan Solution-based Exp.2 PEP 
AQLPAGSNGLM(ox)IDYSHGNSNK P32449 
Phospho-2-dehydro-3-
deoxyheptonate aldolase, tyrosine-i Solution-based Exp.2 PEP 
ALENPTRPFLAILGGAK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
ALLDEVVK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
ALLDEVVK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
EGIPAGWQGLDNGPESRK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
ELQSLLGK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
GVEVVLPVDFIIADAFSADANTK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
IQLIDNLLDK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
ISHVSTGGGASLELLEGK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
ITSNQRIVAALPTIK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
LFAATVAK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
LSVQDLDLK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
SSAAGNTVIIGGGDTATVAK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
VLENTEIGDSIFDK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
YSLAPVAK P00560 Phosphoglycerate kinase Gel-based Exp. 2 ATP 
FNTYRRSFDVPPPPIDASSPFSQK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
GQQEAARAGELLK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
GQQEAARAGELLK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
HLEGISDADIAK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
HLEGISDADIAK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
LSRAIQTANIALEK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
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 LSRAIQTANIALEK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
LSRAIQTANIALEK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
LVLVRHGQSEWNEK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
NLFTGWVDVK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
TVM(ox)IAAHGN(de)SLRGLVK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 1 NA, ATP 
TVM(ox)IAAHGNSLRGLVK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 1 NA, ATP 
TVM(ox)IAAHGNSLRGLVK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
TVM(ox)IAAHGNSLRGLVK P00950 Phosphoglycerate mutase 1 Solution-based Exp.1A NA, ATP 
TVM(ox)IAAHGNSLRGLVK P00950 Phosphoglycerate mutase 1 Solution-based Exp.1B NA, ATP 
TVM(ox)IAAHGNSLRGLVK P00950 Phosphoglycerate mutase 1 Solution-based Exp.2 NA, ATP 
TVMIAAHGNSLRGLVK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 1 NA, ATP 
TVMIAAHGNSLRGLVK P00950 Phosphoglycerate mutase 1 Solution-based Exp.1A NA, ATP 
TVMIAAHGNSLRGLVK P00950 Phosphoglycerate mutase 1 Solution-based Exp.1B NA, ATP 
VYPDVLYTSK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
VYPDVLYTSK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
VYPDVLYTSK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
YVDPNVLPETESLALVIDRLLPYWQDV
IAK P00950 Phosphoglycerate mutase 1 Gel-based Exp. 2 NA, ATP 
FGPIVSASLEK P04147 
Polyadenylate-binding protein, 
cytoplasmic and nuclear Gel-based Exp. 2 RNA 
GQNCLDIDGIMDNPRK P36048 Pre-mRNA-splicing factor SNU114 Solution-based Exp.2 GTP 
VSLLTPDIGAVYSGM(ox)GPDYRVLVD
K P23639 Proteasome component Y7 Solution-based Exp.2 
ATP dependent 
proteolytic 
Activity 
HLQILQM(ox)PEK P16550 
Protein APA1;5,5-P-1,P-4-
tetraphosphate phosphorylase;A Solution-based Exp.2 ATP 
EQFPLFAIHDM(ox)TEDLK P17967 Protein disulfide-isomerase Solution-based Exp.2 N/A 
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 SENRTVSQGEM(ox)TSVHEPSTEEM(ox)
AK P46949 Protein FYV8 Solution-based Exp.2 N/A 
GLNNTSVGEEK Q04409 Putative glucokinase-2 Gel-based Exp. 1 ATP 
AIGVQNAYFPM(ox)FVSSRVLEK P38708 
Putative proline--tRNA ligase 
YHR020W Solution-based Exp.2 ATP 
M(ox)FNLSVENPLGSDHPK P38708 
Putative proline--tRNA ligase 
YHR020W Solution-based Exp.2 ATP 
DYETHRVATTGEWDK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
DYETHRVATTGEWDK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
GSIDEQHPRYGGVYVGTLSKPEVK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
GSIDEQHPRYGGVYVGTLSKPEVK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
GSIDEQHPRYGGVYVGTLSKPEVK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
GYKPVAVPARTPANAAVPASTPLK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
GYKPVAVPARTPANAAVPASTPLK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
IRNATFPGVQM(ox)K P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 1 
TPP, Mg, Metal 
ion 
IRNATFPGVQM(ox)K P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
IRNATFPGVQM(ox)K P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
KLIDLTQFPAFVTPM(ox)GK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
LIDLTQFPAFVTPM(ox)GK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
LLQTPIDM(ox)SLKPNDAESEK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
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 LLQTPIDM(ox)SLKPNDAESEK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
LLQTPIDM(ox)SLKPNDAESEK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
LLTTIADAAK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
LLTTIADAAK P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
NIVEFHSDHM(ox)K P06169 Pyruvate decarboxylase isozyme 1 Gel-based Exp. 2 
TPP, Mg, Metal 
ion 
YGM(ox)GTAASRSSAM(ox)TEYFK P16387 
Pyruvate dehydrogenase E1 
component subunit alpha, mito Solution-based Exp.2 
Pyruvate, TPP, 
ATP* 
AGLNIVRM(ox)NFSHGSYEYHK P00549 Pyruvate kinase 1 Gel-based Exp. 2 ATP 
GVNLPGTDVDLPALSEK P00549 Pyruvate kinase 1 Gel-based Exp. 2 ATP 
GVNLPGTDVDLPALSEK P00549 Pyruvate kinase 1 Gel-based Exp. 2 ATP 
GVNLPGTDVDLPALSEK P00549 Pyruvate kinase 1 Gel-based Exp. 2 ATP 
IENQQGVNNFDEILK P00549 Pyruvate kinase 1 Gel-based Exp. 2 ATP 
IM(ox)YVDYK P00549 Pyruvate kinase 1 Gel-based Exp. 2 ATP 
KGDTYVSIQGFK P00549 Pyruvate kinase 1 Gel-based Exp. 2 ATP 
VTDGVM(ox)VARGDLGIEIPAPEVLAV
QK P00549 Pyruvate kinase 1 Gel-based Exp. 2 ATP 
VTDGVM(ox)VARGDLGIEIPAPEVLAV
QK P00549 Pyruvate kinase 1 Gel-based Exp. 2 ATP 
VTDGVM(ox)VARGDLGIEIPAPEVLAV
QK P00549 Pyruvate kinase 1 Solution-based Exp.2 ATP 
TM(ox)EEDEEVLYK P41920 
Ran-specific GTPase-activating 
protein 1 Solution-based Exp.2 GTP 
YYNAVNPFEFM(ox)EDVATAGK P49723 
Ribonucleoside-diphosphate 
reductase small chain 2 Solution-based Exp.2 
cytidine 5'-
diphosphate 
DLEDIGAGDQGIMFGYATDETPEGLPL
TILLAHK P10659 S-adenosylmethionine synthase 1 Solution-based Exp.1B ATP 
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 NFDLRPGVLVK P10659 S-adenosylmethionine synthetase 1 Gel-based Exp. 2 ATP 
M(ox)LDINQFIEDK P07284 Serine--tRNA ligase, cytoplasmic Solution-based Exp.2 ATP 
IEQFVITEPEK P07284 Seryl-tRNA synthetase, cytoplasmic Gel-based Exp. 2 ATP 
TVPEQSRDADVDASQGASAGGLPDLG
SLLGGGLGGLM(ox)NNPQLM(ox)QAA
QK Q12118 
Small glutamine-rich 
tetratricopeptide repeat-containin Solution-based Exp.2 
Hsp70, regulates 
ATPase activity 
IGLINVRVPLPFNVAK P39692 
Sulfite reductase [NADPH] 
flavoprotein component Gel-based Exp. 2 
NADP, FAD, 
FMN, 
Flavoprotein 
IEEIGGLIKKVNTSVK P32854 Syntaxin PEP12 Gel-based Exp. 2 N/A 
VEM(ox)IGDEYFSFLDNCK P39077 T-complex protein 1 subunit gamma Solution-based Exp.2 ATP 
GIDPM(ox)SLDVFAK P39079 T-complex protein 1 subunit zeta Solution-based Exp.2 ATP 
HSSTM(ox)NNFHIRSK Q06163 Telomerase reverse transcriptase Solution-based Exp.2 
DNA, Mg, Metal 
ion 
LQETNPEEVPK P35691 
Translationally-controlled tumor 
protein homolog Gel-based Exp. 2 N/A 
M(ox)QSDTQEANDIVTLANLQYNGST
PADAFETK Q12273 
Transposon Ty1-PR2 Gag-Pol 
polyprotein;Capsid protein;T Solution-based Exp.2 
ATP, DNA, Mg, 
Metal, RNA, Zinc 
M(ox)QTSNVLILGLK P22515 Ubiquitin-activating enzyme E1 1 Solution-based Exp.2 ATP 
APQAAGVIHNDLM(ox)NTFILAQVM(
ox)K P38219 
Uncharacterized GTP-binding 
protein OLA1 Solution-based Exp.2 ATP 
FFPSM(ox)ISPDWEPSIIPSNK P53929 Uncharacterized protein YNL108C Solution-based Exp.2 N/A 
THSTYAFESNTNSVAASQMRNALNK P32861 
UTP--glucose-1-phosphate 
uridylyltransferase Solution-based Exp.1B 
UTP, Mg, Metal 
ion 
ATGQM(ox)TERETM(ox)ETEVIK P21576 
Vacuolar protein sorting-associated 
protein 1 Solution-based Exp.2 GTP 
GSQAM(ox)VM(ox)VEEK P21576 
Vacuolar protein sorting-associated 
protein 1 Solution-based Exp.2 GTP 
EAVDM(ox)EFGTGAVK P07806 Valine--tRNA ligase, mitochondrial Solution-based Exp.2 ATP 
GIYPPINVLPSLSRLM(ox)K P16140 V-type proton ATPase subunit B Solution-based Exp.2 ATP 
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 ALERDVDLIESM(ox)K P22203 V-type proton ATPase subunit E Solution-based Exp.2 ATPase activity 
TADLYAAM(ox)GLSK P32527 Zuotin Solution-based Exp.2 
DNA, ATPase 
activity 
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